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Abstract 
 
Malaria is a life-threatening infectious disease caused by a parasitic protozoan belonging to 
the genus Plasmodium. Resistance has started to emerge for the currently recommended 
artemisinin combination therapies used to treat malaria. There is a great need for new anti-
malarial drugs, but traditional drug discovery timelines take approximately 10-17 years. Drug 
repositioning offers a very effective alternative to de novo drug design and could minimise 
the long timescales involved in the process of bringing a drug to the market. Work at the 
University of Salford identified the previously widely-used anti-amoebic drug emetine 
dihydrochloride as a potent inhibitor of Plasmodium falciparum K1 strain parasites (IC50: 47 
+ 2.17 nM). Emetine is not currently in use due to its emetic and cardiotoxic effects. 
 
The cryo-EM structure (3J7A) depicting the emetine binding site on the 40S subunit of the 
80S P. falciparum ribosome has recently been published as a potential target binding site for 
emetine, enabling rational design of safer synthetic analogues. This study focuses on using 
molecular modelling tools to predict activities of the two isomers of dehydroemetine, a 
synthetic analogue of emetine developed in the 1960s by Roche. Studies conducted in the 
mid-20
th
 century found dehydroemetine to be less toxic than emetine; however, its use as an 
anti-amoebic was replaced due to the introduction of the safer drug metronidazole, although 
dehydroemetine still remains as a WHO recommended drug for use in amoebiasis in 
metronidazole treatment failure. Using MOE and Autodock vina docking software, the 
activities of two isomers of dehydroemetine; (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine were predicted. Docking studies predicted a better binding conformation 
for (-)-R,S-dehydroemetine compared to (-)-S,S-dehydroisoemetine. The two diastereomers of 
dehydroemetine were synthesised and tested against the multi-drug resistant K1 strain of 
Plasmodium falciparum. It was found that of the two diastereomers, (-)-R,S-dehydroemetine 
(IC50: 69.58 + 2.62 nM) shared almost similar potency with emetine (47 + 2.17 nM), whereas 
(-)-S,S-dehydroisoemetine (IC50: 1.85 + 0.2 µM) was much less active as predicted through 
modelling studies. Stage specificity studies of both compounds showed more activity against 
the trophozoite erythrocytic stages of the parasite. The IC50 speed assays carried out to verify 
onset of antimalarial activity in emetine and the dehydroemetine diastereomers, found that 
although the compounds started activity within 24 hours, the IC50 values were achieved only 
at 48 hours. Cell cytotoxicity assays showed both compounds to be potent against HepG2 
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hepatic cancer cell lines seeded at 5000 cells/well with low selectivity indices (SI = ~3 and 
~1 for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine). To achieve further dose 
reduction to minimise toxicity, CalcuSyn-based drug interactivity assays were optimised and 
validated on known synergistic antimalarial drug combinations (atovaquone/proguanil). Drug 
interaction analysis performed using the validated CalcuSyn method found the antimalarial 
drug atovaquone to be synergistic with (-)-R,S-dehydroemetine at IC50, IC75 and IC90 values 
(Combination indices (CI): 0.88-0.89). Proguanil displayed moderate synergy (CI: 0.67), 
additivity (CI: 1.04) and antagonism (CI: 1.6) with (-)-R,S-dehydroemetine at IC50, IC75 and 
IC90 combinatory doses, respectively. Combination studies with artemether (CI: 1.6) and 
doxycycline (CI: 1.5) were found to be antagonistic. Emetine and (-)-R,S-dehydroemetine 
were found to display gametocidal activity against both male and female gametes with no 
cross-resistance observed on 3D7A, Dd2 and W2 strains.  
 
Further experiments were conducted to investigate the possibility of a multimodal mechanism 
of action for emetine and its analogues. ATP proliferation experiments on parasite-infected 
erythrocytes showed emetine and (-)-R,S-dehydroemetine caused a reduction in cellular ATP 
concentrations. Emetine and (-)-R,S-dehydroemetine also resulted in the disruption of the 
parasite mitochondrial membrane potential in infected erythrocytes in a manner similar to the 
slow-acting antimalarial atovaquone. The results support multimodal mechanisms of action in 
addition to inhibition of protein translation. 
 
Experiments were also conducted to determine the cellular basis of cardiotoxicity previously 
reported in emetine and dehydroemetine therapy for amoebiasis. hERG K
+ 
channel blocking 
assays showed that emetine and (-)-R,S-dehydroemetine did not result in inhibition 
(Selectivity indices > 285), indicating a differential mechanism of action for cardiotoxicity. 
To explore this further, experiments were done to evaluate the effect of emetine and (-)-R,S-
dehydroemetine on calcium regulatory mechanisms on sheep ventricular myocytes. Both 
emetine and (-)-R,S-dehydroemetine displayed potentiation of ryanodine receptors, lowering 
the threshold for generation of calcium waves with consequent increased susceptibility for 
arrhythmias. (-)-R,S-dehydroemetine however, also displayed negative inotropic effects in 
comparison to emetine, thus making the compound potentially less arrhythmogenic and 
supporting early clinical observations reported in the 1960s during anti-amoebic therapy. 
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Chapter 1 Introduction 
 
Malaria is a life-threatening infectious disease characterised by a febrile illness and caused by 
a parasitic protozoan belonging to the genus Plasmodium. It is transmitted through the bites 
of infected female Anopheles mosquitoes. Malaria is a preventable and curable disease. As 
per the WHO fact sheet, the mortality rate from malaria has fallen by 47% globally and 54% 
in WHO African region since 2000, but the disease still plays a major role in global health 
issues. Every minute a child dies from malaria in Africa. As per WHO report 2015, the global 
incidence of malaria was 198 million cases in 2013 with an estimated 584,000 deaths mostly 
among the African children (Rodriguez-Morales et al., 2015) and in 2017, the number of 
malaria cases increased to 219 million with an estimated 435,000 deaths (WHO, 2018). 
Malaria is mostly prevalent in tropical and sub-tropical regions and presents a huge burden on 
economic development of malaria endemic countries by having an impact on population 
growth, absenteeism, workforce productivity, medical costs and mortality (Sachs and 
Malaney, 2002). 
 
1.1  History of malaria and discovery of the parasite: 
 
Historically, malaria has been around for a long time and was described in China about 5000 
years ago (Cui et al., 2015). Ancient Greeks were familiar with the disease since 500 BC. 
Hippocrates is known to have described the disease and its symptoms as early as 46 BC and 
Columella (AD 116) characterised it as a disease caused by germs breeding around swamps 
(Jamieson and Toovey, 2006). The English word for malaria was ‘Ague’ and has been 
mentioned in eight of William Shakespeare’s plays (Reiter, 2000). Malaria was known to be 
indiscriminate in choosing its casualties. Famous victims include Hadrian, Vespasian, Titus, 
St. Augustine and Alexander the Great (Jamieson and Toovey, 2006). The term malaria 
comes from the Italian ‘mala aria’ which means ‘bad air’, a reference to the presence of a 
peculiar sulphurous odour produced by anaerobic bacterial flora in brackish mud along river 
estuaries where the disease was more prevalent, reflecting the ecology and distribution of the 
mosquito vectors (Reiter, 2000). 
 
Since the first to the nineteenth century, the ‘miasmic theory’ dominated Europe as the cause 
of malaria. It was not until 1880, that a French Army doctor, Charles Louis Alphonse 
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Laveran observed the presence of parasites in the red blood cells of malaria-infected people 
while working in the military hospital in Constantine, Algeria. Laveran found pigmented 
bodies in peripheral blood films and observed exflagellation of the parasite. He proposed that 
malaria was caused by an organism, a protozoan he named Haemamoeba malariae (Ferri, 
2009). His discovery was initially met with scepticism but was gradually accepted as further 
confirmatory researches were published by other scientists. He was awarded the Breant Prize 
by the Academy of Sciences in 1889 for his discovery and later a Nobel Prize in 1907 for his 
work on protozoans causing diseases (Alphonse, 2009). In 1877, Patrick Manson, considered 
by many as the father of tropical medicine, discovered the role of mosquitoes in transmission 
of filarial parasites and drawing inference from this, Albert Freeman Africanus King, in 1883 
suggested the possibility of malaria also being transmitted by mosquitoes (Cook and Webb, 
2000). In 1881, Carlos Jan Finlay provided evidence of the role of mosquitoes in transmission 
of diseases in humans (Tan and Sung, 2008). Manson himself believed that malaria was 
transmitted by mosquitoes and formulated a hypothesis which he later called ‘Mosquito-
Malaria theory’ (Capanna, 2006). 
 
In 1892, a British physician Sir Ronald Ross commenced a study on malaria (Chernin, 1988). 
Ross met Manson in London in 1894, which proved to be a turning point in solving the life 
cycle of the malaria parasite, as Manson demonstrated the presence of parasitic bodies 
described by Laveran in the blood films of malaria infected patients and provided Ross with 
the knowledge he desperately sought (Ferri, 2009). While working in India, Ross conducted 
experiments to prove the hypothesis of the role of mosquitoes in transmission of malaria. He 
initially used the Culex mosquitoes and his research bore no results. Disheartened by the lack 
of results, Ross lost interest in it only to be encouraged by Manson to not give up. Ross later 
conducted research on other species of mosquitoes found in highly malarious areas and 
discovered single large cells in the stomach walls of the mosquitoes fed on malaria-infected 
patients. These cells increased in diameters with each passing day thus demonstrating growth. 
Ross was able to show that the parasite reproduced sexually in the stomach of the mosquito. 
He continued his research on transmission of malaria in birds and noted the passage of 
parasites from stomach to salivary glands of the infected mosquito, from where it then passed 
into the bloodstream of the healthy bird when bitten by such mosquitoes. In 1902, Ross 
earned the Nobel Prize in medicine for demonstrating the life cycle of the malaria parasite 
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and establishing the mosquito species Anopheles as the vector carrier of malaria (Chernin, 
1988).  
 
1.2  Geography and Incidence: 
 
Malaria was widely prevalent in Medieval Europe until the breeding habits of the mosquito 
vectors were disrupted by land reclamation, building of well-lit and ventilated houses, and 
improved drainage (Jamieson and Toovey, 2006). Today, malaria is mainly a disease of 
tropical and sub-tropical regions. Implementation of Malaria Control Programmes and 
increased financing has seen a huge reduction in the malaria incidence and mortality since 
2010 (Mita and Jombart, 2015). The figures 1.2.1 and 1.2.2 respectively show the trend in the 
estimated cases and deaths due to malaria since 2000. The past few years have seen little 
progress in the fight against malaria (WHO, 2018). 
 
 
 
Figure 1.2.1 Estimated number of malaria cases (WHO, 2018) 
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Figure 1.2.2 Estimated number of malaria deaths (Source: WHO 2018) 
 
Climate plays an important role in the life cycle of malaria parasites as rainfall, humidity and 
ambient temperatures determine the survival of the mosquito vector. Warm tropical and sub-
tropical temperatures are ideal for the parasite to complete the growth cycle. At temperatures 
15 °C or 59 °F for Plasmodium vivax, 20 °C or 68 °F for Plasmodium falciparum the growth 
cycle is not completed and thus the transmission of malaria is difficult (Ecology of malaria, 
2015). The ecological conditions required for the more efficient mosquito vectors of malaria 
to thrive, determine the intensity of the disease and its distribution (Gallup and Sachs, 2001). 
There is a compelling correlation between malaria and poverty. Human societies have 
prospered least in areas where malaria has prospered most (Rodriguez-Morales et al., 2015). 
Cases and deaths from malaria started to increase globally since 1990 and reached a peak in 
2003 with more than 350 million cases and more than 1 million deaths (WHO, 2005). A 
decrease in child mortality rates has been observed in the sub-Saharan region since 2004, 
while the malaria mortality rate has been on a steady decline since 1990 in regions outside of 
Africa (Murray et al., 2014). Artemisinin-based combination therapies (ACT) have played a 
major role in decreasing the global burden of malaria but the emergence and potential spread 
of strains of malaria parasites resistant to artemisinin in Southeast Asia and variations in 
sensitivities to artemisinin partner drugs is a major cause for concern (Cui et al., 2015). 
Figure 1.2.3 shows the global distribution of malaria in 2000 and 2016. 
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Figure 1.2.3 Map of countries endemic for malaria from 2000 to 2016 (WHO, 2016) 
 
1.3  Malaria parasite, mosquito vector and Life-cycle: 
 
Malaria in humans is caused by a protozoan parasite belonging to one of the following four 
Plasmodium species: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and 
Plasmodium malariae (Franco-Paredes and Santos-Preciado, 2006). Plasmodium knowlesi is 
a zoonotic parasite and is known to cause infections in humans.  
 
The malaria parasite is transmitted to humans through bites of female Anopheles mosquitoes. 
The ability to transfer malaria parasite differs among the various species of Anopheles. Some 
female Anopheles species have an inclination towards human blood for their meals 
(anthropophilic) whereas some others prefer animals (zoophilic). Some have indoor biting 
habits (endophagic) whereas the others have outdoor (exophagic). All the other factors being 
equal, the better vectors for malaria transmission are the species with anthropophilic, 
endophagic habits as they tend to have more frequent contacts with humans. A field study 
observed that Plasmodium falciparum alters the behavioural patterns of the mosquito vector 
host Anopheles gambiae and increases the frequency of multiple feeding, thereby facilitating 
a more rapid spread and increase in the transmission in humans (Koella et al. (1998). There 
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are many countries which have eliminated malaria but the Anopheles mosquito is still present 
in these countries, and presents a potential for reintroduction of malaria through cases in 
returning travellers or immigrants (imported malaria), if such cases are not treated promptly 
(Odolini et al., 2012). 
 
The malaria parasite requires two hosts to complete the life cycle; humans and the female 
Anopheles mosquito. In the human host the parasite presents different antigens throughout the 
several life stages which are useful targets for vaccine development (Florens et al., 2002). 
The mosquito transmits the disease from one human to another but itself does not suffer from 
the presence of parasites. 
 
1.3.1 Life cycle of Plasmodium parasites:  
 
 Plasmodium parasites in the form of sporozoites are introduced into the 
bloodstream of human hosts by bites of infected female Anopheles mosquitoes. 
These sporozoites reach the liver and over the period of 7 to 10 days the 
sporozoites multiply asexually producing no symptoms (pre-erythrocytic stage). 
 The parasites, in the form of merozoites are released in the bloodstream where 
they infect the red blood cells (erythrocytes) and multiply further. The 
erythrocytes burst releasing the merozoites which invade more erythrocytes thus 
repeating the cycle and causing fever each time there is the release of merozoites 
from the erythrocytes (erythrocytic stage).  
 Some of these merozoites leave the asexual cycle and develop into the sexual 
forms called gametocytes.  
 These gametocytes enter the mosquito during a blood meal when it bites an 
infected human and develops into mature sex cells called gametes. 
 Ookinetes are formed on fertilization of the female gamete. The ookinetes actively 
move through the midgut wall of the mosquito and develop into an oocyst inside 
which several thousands of sporozoites are formed. These sporozoites are released 
into the body cavity when the oocyst burst. 
 The sporozoites then travel to the mosquito’s salivary gland and the cycle is 
completed when the infected mosquito bites a human (Soulard et al., 2015). 
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Figure 1.3.1 Life-cycle of malaria parasite. 
Sexual and asexual stages of malaria parasite life cycle. Adapted from Centres of Disease Control and 
Prevention, 2016. 
 
P. vivax and P. ovale have stages in their asexual life cycle in humans (hypnozoites) wherein 
they remain in a dormant state in liver and can reactivate later. They can invade the blood 
stream causing relapses. Vertical transmission through the mother (congenital malaria), 
shared needles, organ transplantation or transfusion are rare modes of malaria transmission 
from person to person without the involvement of the mosquito vector (Zoller et al., 2009). 
Figure 1.3.1.1 shows the life cycle of the Plasmodium parasite. 
 
1.3.2 Signs and symptoms of malaria: 
 
Incubation period of Malaria is between 9 to 30 days depending on the Plasmodium species 
and the patient usually presents with non-specific flu-like syndrome with fever, malaise, 
headache, myalgias, nausea, vomiting, sometimes diarrhoea or jaundice. Diagnosis or 
exclusion of malaria should be confirmed by microscopic examination of blood films 
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(Bartoloni and Zammarchi, 2012). There are three stages in the classical malaria paroxysm 
lasting for 6 to 10 hours and usually beginning in afternoon or evening:  
 
Cold stage- The patient feels cold and may shiver. The phase usually lasts up to 10 – 30 
minutes and the temperature begins to gradually rise usually to 39°C to 41°C 
Hot stage- The shivering stops, and the temperature may rise further to hyperpyrexial levels. 
The skin is hot and dry, the face appears flushed, and patient may suffer from vomiting, 
diarrhoea, retro-orbital headache, altered consciousness. Convulsions might occur in children. 
The phase lasts for 2 to 6 hours (Bartoloni and Zammarchi, 2012). 
Sweating stage- The phase is characterised by profuse sweating and rapid fall in temperature. 
The patient feels better but is usually tired and the stage lasts for 2 to 3 hours. 
Fever is usually synchronised with schizogony and occurs every alternate day (Tertian) in P. 
vivax, P. ovale or P. falciparum malaria and every third day (Quartan) in P. malariae malaria 
(Ferri, 2009). 
 
P. falciparum is the only species causing severe malaria leading to death by causing acidosis, 
respiratory distress, severe anaemia, acute renal failure, haemoglobinuria, severe anaemia or 
shock (Algid malaria), encephalopathy and coma due to cerebral malaria (Bartoloni and 
Zammarchi, 2012) (Krungkrai et al., 2010). This occurs due to the ability of the P. falciparum 
parasites to sequester in brain and various other organs (Greenwood et al., 2008). 
 
1.4 Malaria prevention, control and treatment: 
 
1.4.1 Malaria vaccines: 
 
Vaccines have been instrumental in reducing the burden of infectious diseases. Vaccines 
could be attenuated microbes, killed microbes or protein subunits. Repeated exposure to 
malaria infection gives strain-specific protective acquired immunity people which helps to 
reduce inflammatory response to the parasite (Artavanis-Tsakonas et al., 2003) (Heppner, 
2013). This immunity is ineffective against a different strain (Wang et al., 2009) (Artzy-
Randrup et al., 2010). Efforts to develop an effective vaccine against malaria started over six 
decades ago; however, there is still no licensed vaccine against malaria. Nonetheless, the 
development of a vaccine against malaria has provided a leading edge for assessing many 
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new vaccine technologies such as novel adjuvants, vectored prime-boost regimes and the 
concept community vaccination to prevent transmission of malaria. It has been over 60 years 
but chemotherapy and insecticides still remain the main tools in the fight against malaria 
(White, 2004) (Na‐Bangchang and Karbwang, 2009). It has proven difficult to develop and 
administer attenuated whole parasite vaccine. Comparable efficacy has not been observed in 
subunit vaccines. Malaria vaccines can be classified into three distinct categories: 
i. Pre-erythrocytic vaccines: 
Sporozoites and hepatic stages of the parasite are the targets for pre-erythrocytic vaccines. 
They aim to destroy infected liver cells and prevent the emergence of merozoites into the 
bloodstream (Duffy et al., 2012). The main challenge is the short time frame of two hours 
within which sporozoites have to reach the liver once injected by the mosquito bite (Mac-
Daniel et al., 2014). The pre-erythrocytic stage vaccine candidate RTS/S/AS01 is the most 
promising to date and has entered the Phase III trial (Tinto et al., 2015) (von Seidlein and 
Bejon, 2013). The large Phase III trial of RTS,S/ AS01 involving more than 15,000 children 
over 11 sites in sub-Saharan Africa has had only some successes (Barry and Arnott, 2014). It 
is still considered effective in averting a substantial number of malaria cases with the 
European Medicines Agency recommending the use of vaccine in young children in Africa in 
July 2015 (Takashima et al., 2016).   
This vaccine is based on a region of the circumsporozoite protein, fused to the surface antigen 
of the hepatitis B virus and combined with AS01B (liposome-based adjuvant) to target the 
sporozoite stage. RTS,S was found to be moderately efficacious in sub-Saharan Africa with 
efficacy being 36.3% in children and 25.9% in infants following fourth booster at 20 months, 
well below the efficacy target set at 75% by WHO (Kurtovic et al., 2019) (Tinto et al, 2015). 
The vaccine will undergo pilot implementation in Kenya, Malawi and Ghana to evaluate 
safety and reduction in childhood mortality amid reports of rapidly declining protection after 
vaccination (Ghana, 2017).  
ii. Erythrocytic vaccines or blood-stage vaccines 
Asexual reproduction of the parasite in RBCs is the target for erythrocytic vaccines which 
aim to significantly reduce the number of merozoites and reduce the parasite density. This 
also reduces the density of gametocytes besides preventing the clinical symptoms (Barry and 
10 
 
Arnott, 2014). The P. falciparum erythrocyte membrane protein (PfEMP1) which mediates 
adhesion of parasite cells to host cells is another target. Most blood-stage vaccines are still 
undergoing Phase I or II trials (Takashima et al., 2016). 
iii. Transmission blocking vaccine (TBV)  
 
Transmission blocking subunit vaccines which target blood-stage merozoites, or gametocytes 
have also been studied (von Seidlein and Bejon, 2013). Antigens expressed during parasite 
stages in the mosquito host are the target for transmission blocking vaccines (Barry and 
Arnott, 2014) (Birkett et al., 2013). Vaccine induced antibodies along with Plasmodium 
gametes are taken up by the mosquito during the blood meal resulting in interference with 
parasite’s development thereby preventing parasite transmission from mosquito to the human 
host. The Pfs25 protein expressed on the surface of zygotes and ookinetes is one of the 
targets and Phase I human trial have been conducted with little success using a recombinant 
Pfs25H/Montanide ISA51 formulation (Jones et al., 2015, Shimp et al., 2013). Detoxified 
form of Pseudomonas aeruginosa exo-protein A (EPA) has been developed as an adjuvant 
for Pfs25 but its safety and immunogenicity in humans remains to be evaluated (Shimp et al., 
2013). 
 
Vaccines targeting early pre-erythrocytic stages have shown most success. The currently 
available vaccines usually target a single stage of parasite’s life cycle. Viral vector vaccines 
target the intracellular liver-stage of the parasite through cellular immunity and a protein 
adjuvant vaccine targets the sporozoites through antibodies. But these have only been 
partially effective in humans. A multi-component vaccine targeting more than one stage of 
the parasite is required to be more effective against malaria (Hill, 2011). Vaccine candidates 
with attenuated whole-parasite are highly protective but there are difficulties with 
manufacturing and administration of these vaccines.  
 
In the absence of any known correlates for immunity, expensive clinical trials in humans 
remain the only way to evaluate a vaccine’s efficacy. Poor immunogenicity in the blood-stage 
candidates and unlikelihood of any candidate vaccine which targets only a single antigen to 
provide complete protection has left development of a multistage, multicomponent vaccine to 
be the only feasible option to achieve success, the possibility of which seems unlikely in near 
future (Guerin et al., 2002) (Heppner, 2013) (von Seidlein and Bejon, 2013) (Hill, 2011).  
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1.4.2 Mosquito control methods: 
 
Draining of swampland, standing water resources, layering of potholes and puddles were 
done in mid-20
th
 century to eliminate the Anopheles vector by targeting its breeding sites. 
Insecticide treated bed nets (ITNs) and indoor residual spraying (IRS) are currently the two 
major strategies for vector control (N'Guessan et al., 2007). Distribution of pyrethroid 
insecticide treated bed nets has been part of many vector control programmes since 1980s as 
most Anopheles mosquito bites usually occur at night and thus bed nets help to reduce the 
disease. Pyrethroid insecticides most in use were the ones which killed rather than deflected 
the mosquitoes and remained active for six months. Long lasting insecticide treated bed nets 
(LLIN) which remain effective for almost five years have been developed recently. 
 
Mosquitoes which rest up on the walls are the targets for indoor residual spraying (IRS) and a 
much broader range of insecticide can be used for this purpose. A significant effect has been 
observed on the disease prevalence due to sustained IRS but the spread of insecticide 
resistance has emerged as a major challenge for vector control (Nkya et al., 2014). Evolved 
resistance to one pyrethroid usually gives protection against the whole family. 
 
Some mosquitoes are poor vectors for transmitting malaria as they either lack the essential 
factor for Plasmodium or they attack the parasite. Another method is to genetically engineer 
mosquitoes in such a way as to reduce or hamper their capacity to transmit malaria. It was in 
2000, that the Anopheles mosquitoes were successfully genetically transformed for the first 
time (Grossman et al., 2001). 
 
1.4.3 DDT and the Malaria Eradication Programme: 
 
The first samples of DDT (2,2-bis-(p-chlorophenyl)-1,1,l-trichloroethane) were synthesised 
by Othmar Zeidler in 1874 in the University of Strassburg in the laboratory of Professor 
Adolf von Baeyer but were left on the shelves for nearly 65 years. DDT was synthesised in 
1939 by Paul Müller, in the laboratory of a Swiss dyestuff manufacturer, as an insecticide and 
this discovery won him the Nobel Prize in 1948 (Metcalf, 1973). DDTs insecticidal 
properties appeared to be a blessing in disguise in the post-World War II era as it was a cheap 
synthetic chemical which was apparently safe for humans and persisted long enough on 
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houses sprayed with DDT to kill mosquitoes even months after application. DDT was first 
used against malaria by the US Army during World War II as it required only semestrial or 
annual applications (Najera et al., 2011). 
 
Discovery of DDT in 1939 played an important in the fight against malaria (Sadasivaiah et 
al., 2007). In 1955, the Global Health Assembly announced eradication of malaria, as the 
parasite does not have an animal reservoir and effective measures to interfere with the 
transmission or achieve radical cure existed. Haemoglobin provides amino acids to the 
parasites and haeme is its toxic by-product. Haeme is biocrystallised to haemozoin (malaria 
pigment) to detoxify it. Chloroquine acts by accumulating in parasite’s food vacuole and 
interfering with sequestration of haeme (Djimdé et al., 2001) (Hyde, 2007). Malaria 
eradication programme employed a two-pronged attack against the mosquito and the parasite 
by using DDT and chloroquine (Dondorp et al., 2010) (Jensen and Mehlhorn, 2009). It 
involved DDT indoor residual house spraying and mass drug administration programmes 
with chloroquine and pyrimethamine (Talisuna et al., 2004). This resulted in Europe being 
free from malaria in 1975 and disease localising in sub-tropical and tropical regions. 
 
37 countries with a population of 728 million were pronounced malaria free by 1972. 
Another 90 countries were either under complete or partial control as per WHO in 1972 
(Metcalf, 1973). But the resistance to DDT soon emerged in house flies and by 1960s, the 
mosquitoes resistant to DDT effectively interfered with the worldwide eradication of malaria 
(Ramirez et al., 2009). It was soon evident that DDT was an environmental micro-pollutant 
and accumulated in the food chain due to its low vapour pressure (1.5 x 10
-7
 mm at 20
o
), its 
high fat solubility, low water solubility and its stability to photo-oxidation (Metcalf, 1973). 
Use of DDT as an insecticide was eventually banned (Butler et al., 2010). 
 
Due to mosquito vector resistance to DDT, objection of locals to the entry of spray men in 
their household, increase in exophilic mosquitoes which do not stay indoors long enough to 
pick up the lethal dose and lack of stable and organisational infrastructure of the vector 
control programmes, it was realised that in a large number of countries eradication of malaria 
was an unrealistic goals (Talisuna et al., 2004).  
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The success of the eradication programme was hence short-lived as environmental concerns 
were raised due to bioaccumulation of DDT in humans and wildlife, the development of 
insecticide resistance and development of chloroquine resistance. Resistance to chloroquine 
is due to multiple mutations on pfcrt gene which encodes the digestive vacuole membrane 
transporter protein (PfCRT) which progressively diminishes the level of chloroquine inside 
the food vacuole (White, 2004). Resistance to chloroquine first emerged in Thailand-
Cambodia border (1957), South America (1959), and in Africa (1974) leading to the 
abandonment of the malaria eradication programme in 1972 (Greenwood et al., 2008). This 
lead to resurgence of the disease and efforts were then directed towards treatment and control 
of malaria (Carter and Mendis, 2002). 
 
Realising the limitations of the eradication programme, WHO announced the ‘Roll Back 
Malaria’ programme in 1998 with an intention to approach malaria by strengthening health 
services to make effective prevention and treatment services accessible to all who need it. 
The programme aimed build on past experiences and halve the mortality rate by 2010 and 
again by 2015 by using existing tools against malaria more effectively (Nabarro, 1999). 
 
1.5 Malaria chemotherapy: 
 
Humankind has suffered since early ages without any specific treatment for malaria until the 
seventeenth century when a Peruvian tree bark was brought back by the Spanish colonisers 
from which quinine was later extracted. Medication for malaria (antimalarial drugs) are given 
either to treat a suspected or confirmed infection, or as prophylaxis to individuals with no 
immunity travelling to areas endemic to malaria, or as intermittent preventive treatment to 
certain groups in malaria endemic regions (Franco-Paredes and Santos-Preciado, 2006).  
 
Certain antimalarials such as hydroxychloroquine and chloroquine have been repositioned for 
use in other diseases such as lupus-associated arthritis and rheumatoid arthritis (Shippey et 
al., 2018). Benefits for giving combination treatment for malaria are not just increased 
compliance and decreased side-effects but it also reduces the risk of development of drug 
resistance (Blasco et al., 2017). It is recommended that confirmation of presence of malaria 
parasites is done prior to the starting of antimalarial therapy by detection of parasites through 
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microscopy or through rapid diagnostic tests (RPT) (Moody, 2002). The antimalarials differ 
in their mechanism of action based on their chemical structure. 
 
1.5.1 Quinine: 
 
A fascinating story exists on the discovery of quinine. It was believed that the Spanish 
realised about the curative power of Peruvian tree when the wife of Spanish viceroy of Peru, 
Countess of Chinchón, fell ill with an intermittent fever around 1630 and the prefect of Loxa, 
a city in Ecuador, brought a bark of a locally found tree as a cure which restored the Countess 
back to health. It was therefore called ‘Countess’s powder’ by local people and was brought 
to Europe by the Countess and her husband as a treatment for malaria. Unfortunately, the 
legend is not true as the Countess died in 1625 before her husband moved to Peru. The Count 
remarried but his second wife had robust good health and died of an epidemic illness in 1641 
on her way to Madrid. Nonetheless, for the new binomial system when the bark was sent to 
Carl Linnaeus in Sweden in the next century for naming, he had heard of the story of the 
Countess and named the genus of the tree ‘Cinchona’ after her (Butler et al., 2010). It is still 
known as the cinchona bark.  
 
The Peru tree bark was actually introduced in Europe by Spanish priests when they brought it 
to Rome in 1632. It became known as the ‘Jesuits bark’ and the interest of Cardinal Juan de 
Lugo facilitated its widespread use in Europe. Due to its connection with the Roman Catholic 
Church, Protestant England was a bit wary of the use of the bark but when it cured King 
Charles II tertian fever, it began to be more widely accepted and was included in the London 
Pharmacopoeia in 1677 as Cortex peruanus. The British and the Dutch introduced it in India 
and in 1765 James Lind in Calcutta proved that full doses of the drug are required to achieve 
best results. The crude bark was used for 200 years for preparing powders and infusions. It 
was only in 1820, the two basic alkaloids ‘quinine and cinchonine’ were isolated by the 
French chemists Pierre Pelletier and Joseph Caventou (Kyle and Shampe, 1974). Following 
the isolation of two other alkaloids ‘quinidine and cinchonidine’, factories were set up in 
many parts of the world for the production of cinchona bark alkaloids. 
 
The production was insufficient to meet the demand and attempts were made to cultivate 
cinchona plantations in other parts of the world. In 1864, the Dutch started cinchona 
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cultivation in Java with the help of botanist Justus Hasskarl and the British established 
cultivations in Ceylon and Nilgiri hills in India, but these seedlings had low yield in quinine. 
It was the British collector Charles Ledger who sold the high quality seeds, which he 
obtained with huge difficulty from Bolivia, to the Dutch and within 50 years the Dutch 
plantations in Java were producing 97% of the world’s quinine (Kitchen et al., 2006). 
 
Quinine and its derivatives are still often used in acute cases of malaria and in areas where 
high levels of resistance is observed against other antimalarials (Achan et al., 2011). It is also 
used as post-exposure treatment in individuals who have travelled to malaria endemic regions 
(Tan et al., 2011). It is an alkaloid which acts on the blood schizont stages and has weak 
gametocidal properties. It accumulates in the food vacuoles and causes aggregation of haeme 
which is cytotoxic in nature. It does this by preventing the crystallisation of haeme into 
haemozoin, a process known as haemozoin-biocrystallisation (Hempelmann, 2007) (Fong 
and Wright, 2013).  
 
Quinine could be given orally, intramuscularly or intravenously and WHO recommends in 
cases sensitive to quinine, it could be given 20 mg/kg initially followed by 8 mg/kg three 
times a day for 5 to 7 days in combination with doxycycline, clindamycin or tetracycline 
(Lalloo et al., 2016). Quinine stimulates insulin secretion and can result in hypoglycaemia. 
Hence, it is imperative to observe blood glucose levels every 4 to 6 hours in patients 
receiving quinine (Gribble et al., 2000). ‘Cinchonism’ is a syndrome characterised by 
tinnitus, nausea, vomiting, rashes, vertigo and abdominal pain. It can occur during quinine 
therapy. Neurological effects such as delirium, confusion or coma could also be seen as 
quinine also affects the excitability of motor neuron end plates. Respiratory and renal failure 
could also result during quinine therapy (Kuhlmann and Fleckenstein, 2017). 
 
Commonly related compounds are also used as antimalarials. Warburg’s tincture, with 
quinine as its main ingredient was developed for use as an antimalarial in 1834 by Carl 
Warburg (Maclean, 1875). Quinidine, a diastereoisomer with similar properties to quinine, 
and ‘quinimax’, a slightly more effective combination of quinine, quinidine, cinchonine and 
cinchonidine are also presently used (Sharma et al., 2015). Figure 1.5.1 shows the chemical 
structures quinine and its analogues. 
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Figure 1.5.1 Chemical structure of quinine and its analogues (Na‐Bangchang and Karbwang, 2009) (Butler et 
al., 2010) 
 
1.5.2 Alternatives to quinine: mepacrine and chloroquine: 
 
The Germans developed a synthetic alternative ‘mepacrine’ as they were unable to obtain 
quinine for the German soldiers during the world wars (Bruce-Chwatt, 1964). Mepacrine is a 
version of quinine with an acridine ring system rather than quinoline. Mepacrine was also 
manufactured in the USA, which was given to American soldiers during the Second World 
War as prophylaxis. When Japan entered the world war, the supply of quinine from Java was 
cut off and the Japanese realised the potential of malaria as a killer. They spread the 
propaganda against mepacrine using Japanese–American broadcaster known as ‘Tokyo Rose’ 
(a name given by Americans to a number of English speaking Japanese broadcasters) that 
intake of the drug causes skin to become yellowish, which was true, and also causes sterility, 
which was incorrect. Thus the American soldiers stopped using mepacrine and fell victim to 
malaria.  
 
America responded by developing a chemical variant of sontoquine, another anti-malarial 
drug developed by Germans and obtained by Americans in North Africa from prisoners of 
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war. This chemical variant was more effective than mepacrine and sontoquine against malaria 
parasite, with apparently no adverse side effects and was easy to manufacture. Chloroquine 
was thus born and it played an important role in the world war against Japan (Butler et al., 
2010). 
 
Chloroquine, a quinolone-containing drug was highly successful against malaria and its mode 
of action was accumulation in the acidic food vacuoles of intra-erythrocytic trophozoites by a 
weak base mechanism. It prevents the degradation of haeme to haemozoin occurring in the 
food vacuoles by increasing the internal pH. Haeme which is toxic to the malaria parasite 
results in its killing (Slater, 1993). It is also believed that production of nucleic acids are 
affected in parasites due to formation of chloroquine-haeme or chloroquine-DNA complexes 
(Surolia and Padmanaban, 1991). Chloroquine has schizonticidal and gametocidal properties 
against P. vivax, P. malariae, and P. ovale (Williams et al., 2003). WHO recommends an 
initial dose of 10 mg/kg followed by 5 mg/kg after 6 to 8 hours and then 5 mg/kg for the next 
2 days. Chloroquine can also be given in a single dose of 5 mg/kg/week as a prophylactic 
treatment for individuals travelling to areas affected by P. vivax and chloroquine sensitive P. 
falciparum strains (Organization, 1995). 
 
The effectiveness of chloroquine has decreased due to the emergence of resistance but it is 
still used in sub-Saharan regions, mainly in combination with other antimalarials (Winstanley 
et al., 2004). It is one of the safest drugs available compared to other antimalarials although it 
can cause itching and could be a provocation factor for psoriasis (Olsen, 1981). It does not 
have teratogenic or abortifacient properties and can be safely administered during pregnancy 
(Wolfe and Cordero, 1985).  
 
1.5.3 Amodiaquine:  
 
It is a 4-aminoquinolone, similar to chloroquine (Figure 1.5.1) in mechanism of action and 
structure, causes less side-effects and is recommended by WHO as a combination therapy 
with artesunate in areas with chloroquine resistance. It is usually given 25 mg/kg for 3 days 
(WHO, 2015). 
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1.5.4 Mefloquine: 
 
Mefloquine and halofantrine, the two aryl amino alcohols discovered in Walter Reed Army 
Institute of Research (WRA) were granted FDA approval by 1989 and 1992, respectively 
(Croft, 2007). Reports of neuropsychiatric disturbances and cardiotoxicity, emergence of 
resistance due to its similarity to quinolones and high costs limited their use especially in 
Africa (Na‐Bangchang and Karbwang, 2009) (Ridley, 2002). Mefloquine is structurally 
similar to chloroquine and has schizonticidal activity (Thompson et al., 2007). It damages the 
food vacuoles by formation of haeme complexes which are toxic to the parasite. 
Recommended dose is 15 – 25 mg/kg and can be given for the treatment of acute infection or 
for prophylaxis. It is used in resistant P. falciparum strains. Side-effects include vomiting, 
diarrhoea and oesophagitis. It can also cause sleep disturbances, anxiety disorders, delirium, 
bradycardia and sinus arrhythmia. Mefloquine can be safely administered in all trimesters in 
pregnancy (Schlagenhauf et al., 2012). 
 
1.5.5 Primaquine: 
 
Another potent class of antimalarials was discovered during the 30 years between the World 
Wars I and II. In 1925, pamaquine or plasmochin, an 8-aminoquinoline was found to be 
effective against the gametocytes of the malaria parasites when it was used along with 
quinine and could prevent the relapse of Plasmodium vivax infection. But it was not effective 
as a blood schizontocide and its high toxicity led to pamaquine being abandoned for its 
therapeutic use. In 1946, a safer synthetic 8 aminoquinoline SN-13,272 was developed in 
United States by Elderfield and co-workers, which was named Primaquine. Due to its high 
efficacy and low toxicity as a gametocytocide, primaquine was employed primarily as a 
transmission blocking antimalarial and also as a tissue schizontocide (Vale et al., 2009). 
Primaquine can cause haemolysis in humans with glucose-6 phosphate dehydrogenase 
(G6PD) deficiency, a genetic condition more commonly found in African men.  
 
Primaquine, an 8-aminoquinolone, acts by blocking the oxidative metabolism in malaria 
parasite. It can cure both acute infections and relapsing ones as well (Baird and Hoffman, 
2004). It is effective on the erythrocytic stages in asexual cycle, gametocytes and also on 
hypnozoites of P. vivax and P. ovale. Recommended dose is 0.15 mg/kg for 14 days in cases 
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of relapse in P. vivax and P. ovale and 0.75 mg/kg single dose for gametocidal effect. It can 
cause nausea, vomiting, anaemia, abdominal pain and granulocytopenia (Martins et al., 
2015). 
 
1.5.6 Anti-folate antimalarials: 
 
Anti-folates, originally developed as the treatment for cancer due to their action on rapidly 
dividing cells, helped stall the resurgence of malaria. In 1945 during the Second World War, 
proguanil was found to be effective against malaria (Nzila, 2006). This lead to the 
development of drugs such as pyrimethamine and cycloguanil which target dihydrofolate 
reductase (DHFR) enzyme, and sulpha drugs (supladoxine, sulfalene, dulfone and dapsone) 
which target dihydropteroate synthetase (DHPS) enzyme in the folate synthesis pathway. The 
combination of DHFR inhibitors and DHPS inhibitors was found to be synergistic and more 
effective than its respective monotherapy (Gregson and Plowe, 2005). These drugs results in 
reduced folate co-factors which impairs DNA synthesis in rapidly multiplying parasites 
during the erythrocytic cycle (Hyde, 2005) (Hyde, 2007). The combination therapy replaced 
chloroquine therapy as the first line of treatment in late 1980s until the resistance began to 
emerge (Miller and Su, 2011) (Koram et al., 2005) (Ratcliff et al., 2007).  
 
1.5.7 Pyrimethamine: 
 
Pyrimethamine (Figure 1.5.2) is a dihydrofolate reductase inhibitor which affects the DNA 
replication, cell division and reproduction by preventing the formation of purines and 
pyrimidines (Sienkiewicz et al., 2008). It is used in combination with a sulphonamide in 
chloroquine-resistant strains (Chin et al., 1966). DHFR inhibitor drugs are used in other 
diseases as well, such as methotrexate in cancer and trimethoprim in bacterial infections. 
 
1.5.8 Proguanil: 
 
Proguanil, a synthetic derivative of pyrimidine, developed in 1945 is a biguanide which upon 
administration is converted to the active metabolite cycloguanil by the dihydrofolate 
reductase enzyme in P. falciparum, P. vivax and P. ovale (Gelband et al., 2004). It is active in 
the primary tissue stages and has a weak schizonticidal activity. Recommended dose is 3 
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mg/kg per day. It can also be given with atovaquone and chloroquine as prophylaxis 
(Overbosch et al., 2001). Figure 1.5.2 shows the chemical structures of proguanil, cycloguanil 
and pyrimethamine. 
 
 
                                          
 
Figure 1.5.2 Chemical structures of pyrimethamine, the prodrug proguanil and its active metabolite cycloguanil 
(Sienkiewicz et al., 2008) (Gelband et al., 2004). 
 
Combination of sulphadoxine and pyrimethamine (SP) came to be used as an alternative 
antimalarial due to widespread chloroquine resistance. The parasite soon developed 
resistance to this combination resulting in lowering the drug binding affinity to the parasite 
enzymes involved in the obligatory parasite-folate biosynthesis pathway. Mutations in the 
gene for parasite enzyme dihydrofolate reductase are responsible for pyrimethamine 
resistance and mutations in the gene for parasite enzyme dihydropteroate synthetase are 
attributed to sulphadoxine resistance (Mbugi et al., 2006). Triple mutation on dhfr gene and 
double mutation on dhps gene results in treatment failure (Gregson and Plowe, 2005) (White, 
2004). Pattern of emergence and spread of resistance to anti-folate drugs was similar to 
chloroquine resistance with emergence in South America and South-East Asia, 
independently, and then the spread to Africa (Plowe, 2009). 
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1.5.9 Sulfonamides: 
 
Sulfamethoxypyridazine and sulfadoxin are structural analogue of p-aminobenzoic acid 
(PABA) and acts on the folate synthesis pathway by inhibiting dihydropteroate synthetase 
enzyme. It competes with PABA and prevents the production of dihydrofolic acid (de Beer et 
al., 2006). Fansidar is available as a synergistic combination of sulfadoxin and 
pyrimethamine (Bojang et al., 1998).  
 
1.5.10 Atovaquone: 
 
Malarone is the synergistic combination of atovaquone with proguanil and is used against P. 
falciparum for treatment as well as for prophylaxis (Looareesuwan et al., 1999). Mepron is a 
liquid oral suspension of atovaquone (Baggish and Hill, 2002). 
 
1.5.11 Artemisinin: 
 
During the Vietnam War, a cultural revolution took place in China as they supported the 
North Vietnamese in the war against the United States. Malaria was a big problem in the war 
zone with a rise in chloroquine resistant Plasmodium falciparum cases. On-going research 
work on both sides led to the discovery of mefloquine in the US, and in China a secret 
nationwide program called the Project 523 was started in 1967 which recruited over 500 
scientists in ∼60 different laboratories and institutes. The project’s short term goal was to 
come up with an antimalarial for immediate use in the battlefield, with a long term goal of 
discovering new antimalarial drugs by screening synthetic chemicals and investigating the 
ancient recipes and practices of traditional Chinese medicine (Miller and Su, 2011). The 
turning point came when one of the research groups, headed by Professor Youyou Tu, 
discovered that extracts from Artemisia annua or the sweet wormwood, were very effective 
against inhibiting the parasite growth which led to further investigations. On 4
th
 October 
1971, the group isolated a non-toxic, neutral extract from the plant which was 100% effective 
again Plasmodium berghei in mice and Plasmodium cynomolgi in monkeys. Following this 
success, trials were carried out in patients infected with Plasmodium vivax and Plasmodium 
falciparum to determine clinical efficacy which showed reduced blood parasite levels and 
disappearance of symptoms as compared to patients on chloroquine. In 1972, a colourless, 
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crystalline substance with a molecular formula C15H22O5, molecular weight of 282 Da and a 
melting point of 156-157
°
C was isolated as the active ingredient of the extract. It was named 
‘quinhaosu’ in Chinese, known in the rest of the world as ‘artemisinin’ (Tu, 2011). But it was 
only in 1980s that the world noticed the efficacy of artemisinin against malaria. Professor 
Youyou Tu was awarded the 2015 Nobel Prize in Physiology or Medicine for her work in 
discovery of artemisinin (Su and Miller, 2015). 
 
Artemisinin is a sesquiterpene lactone with a peroxide-bridge linkage and is derived from the 
plant Artemisia annua. It has been used in Chinese herbal medicine as a treatment for fever 
for over 1000 years (Brown, 2010) predating the western world’s use of quinine. Ge Hong 
documented the use of artemisinin in his book Zhou Hou Bei Ji Fang (A handbook of 
prescriptions for emergencies) in 340 AD. Artemisinin was extracted by Ge Hong using a 
simple macerate (Yarnell, 2014). It was suggested by the first studies on mechanism of action 
of artemisinin that 1,2,4 trioxanes generate toxic reactive oxygen species (ROS) in presence 
of iron. There are two other models which have been suggested to explain the mechanism of 
action since the initial theory and these differ based on their dependency on iron and 
involvement of carbon centred radicals (Cui and Su, 2009). 
 
Currently there are four compounds in use; artemisinin, the parent compound and its more 
active derivatives, the water-soluble hemisuccinate: artesunate, oil-soluble ethers: arteether 
and artemether. All these compounds are readily metabolised to dihydroartemisinin, which is 
the biologically active metabolite. Figure 1.5.3 shows the chemical structures artemisinin and 
its analogues. 
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Figure 1.5.3 Chemical structures of artemisinin and analogues (Tu, 2011) (Brown, 2010). 
i. Artemsinin:  
 
It is used to treat acute infections and rapidly clears the parasites from the blood. 
Recommended dose is 20 mg/kg on the first day followed by 10 mg/kg for the next 5 days. 
Side effects usually observed are headaches, nausea, vomiting, dark coloured urine and 
occasional non-specific ST changes.  
ii. Artemether (methyl ether):  
 
It is a semi-synthetic derivative of artemisinin which is converted in the body to active 
metabolite dihydroartemisinin. It is used in combination therapy to treat resistant cases of P. 
falciparum. Recommended dose is 4 mg/kg for 3 days and 1.6 mg/kg for the next 4 days.  
iii. Artesunate:  
 
It is a hemisuccinate derivative of dihydroartemisinin and is used in combination therapy in a 
5 or 7 day course usually with mefloquine. Recommended dose is 4 mg/kg for the first 3 days 
and 2 mg/kg afterwards. No adverse side-effects have been observed. 
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iv. Arteether (ethyl ether):  
 
It is a semi-synthetic derivative of artemisinin and converts to the active metabolite 
dihydroartemisinin in the body. It is administered intramuscularly and recommended dose is 
150 mg/kg/day for 3 days.  
v. Dihydroartemisinin:  
 
It is the active metabolite, and has gametocidal and schizonticidal activity. Recommended 
dose is 4 mg/kg on first day and then 2 mg/kg for the next 6 days. No adverse side-effects 
have been observed. 
 
1.5.12 Halofantrine: 
 
Halofantrine is structurally related to quinine (Figure 1.5.1) and was developed in 1960s by 
Walter Reed Army Institute of Research (Croft, 2007). It belongs to the class of phenanthrene 
compounds and acts by damaging the parasite membranes by forming cytotoxic complexes 
with ferritoporphyrin XI. Its use is limited due to the high costs and the potential of 
cardiotoxicity due to prolongation of QT interval. Recommended dose is 8 mg/kg. 
Lumefantrine, which is related to halofantrine is used in combination therapy with other 
antimalarials (Byakika-Kibwika et al., 2011). 
 
1.5.13 Doxycycline: 
 
Doxycycline is an oxytetracycline derivative and is one of the most widely used drugs in 
malaria (Tan et al., 2011). It inhibits protein synthesis by binding to the 30S ribosomal unit. It 
can be used in combination with quinine to treat acute cases of P. falciparum resistant strains 
and for chemoprophylaxis in chloroquine resistant cases. Recommended dose is 100 mg per 
day for 7 days in combination with a fast acting antimalarial for acute infections (Tan et al., 
2011). Tetracycline in doses of 250 mg can be used in combination with other antimalarials 
for treatment of infection. These drugs can cause enamel hypoplasia and depression of bone 
growth. Hence it is not used in pregnant or lactating women and children under 8 years of 
age. It is also not used in patients suffering from liver dysfunction. 
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1.5.14 Clindamycin:  
 
Clindamycin is a lincomycin derivative and has a slow action. It can be used in combination 
with quinine at 300 mg four times a day for 5 days (Obonyo and Juma, 2012). It can cause 
nausea, vomiting and abdominal pain. 
 
1.6 Combination therapies: 
 
Drugs can be used in combinations and have been found to be effective in inflammation, 
cancer and type 2 diabetes (Feala et al., 2010) (Yin et al., 2014). Simultaneous use of two 
drugs could produce synergistic or antagonistic effects (Yeh et al., 2009). An enhanced effect 
could sometimes be elicited from the combination of two or more drugs with similar activity. 
Synergy is when this enhanced effect produced by drugs in combination is greater that their 
individual potencies. It allows for dose reduction and possibly reduction in adverse reactions 
as well (Tallarida, 2011).  
 
Synergy between codeine and paracetamol leads to an increased analgesic effect (Mattia and 
Coluzzi, 2015). Anti-bacterial resistance could be overcome by synergistic effect of 
clauvulanic acid with amoxicillin (Matsuura et al., 1980). Administration of combination 
therapy is a successful way for combating antimalarial resistance. Two or more schizonticidal 
drugs having different biochemical targets with a mechanism of action independent of each 
other are given in a combination therapy (Agarwal et al., 2017). High throughput screening 
for synergistic drugs have a low hit rate (<10%) (Borisy et al., 2003) (Roy, 2018). The 
expense of combination therapy is however, 10 times more than using the drugs in mono-
therapy. The combinations could be artemisinin-based or non-artemisinin based. They could 
be given as two separate drugs or could be administered as a single tablet which has both 
drugs in a fixed-ratio co-formulated into one tablet. Chloroquine is the drug of choice for P. 
vivax except in the regions with high prevalence of chloroquine resistance. ACTs are the 
recommended treatment for uncomplicated P. falciparum cases. In pregnant women, ACTs 
such as artesunate plus clindamycin for 7 days or quinine with clindamycin for 7 days is 
recommended by WHO guidelines. Dapsone, primaquine and tetracyclines should be avoided 
in lactating women and young children (Phillips-Howard and Wood, 1996).  A minimum of 
24 hours of parenteral treatment with intramuscular or intravenous artesunate or quinine as a 
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possible alternative should be administered in severe cases of P. falciparum malaria. It should 
be followed by ACT such a clindamycin or doxycycline with artesunate. Quinine could be 
used as an alternative in the absence of artesunate. 
 
New anti-malarial drug policies (ADMPs) were adopted by many countries in view of the 
widespread resistance of malaria parasite to commonly available drugs. The most preferred is 
the artemsinin-based combination therapies (ACTs) due to their enhanced efficacy and their 
potential to reduce the rate of emergence and spread of resistance. WHO Expert Consultative 
Group in 2001 recommended four ACTs: artemether-lumefantrine (Coartem), artesunate-
mefloquine, artesunate-amodiaquine and artesunate-sulfadoxine/pyrimethamine. Progression 
to severe disease and malaria mortality rate can be controlled by treating early cases of 
uncomplicated malaria by ACTs due to their rapid parasite clearance time (Mutabingwa, 
2005). 
 
1.6.1 Non-artemisinin-based combination therapies: 
 
Fansidar (Sulphadoxine-pyrimethamine): It is a fixed dose combination with both drugs 
acting on the folate pathway (Salako et al., 1990). It is not recommended to use fansidar 
alone for treatment of malaria caused by P. falciparum. 
 
Fansidar plus chloroquine: It is used only in few areas due to high levels of resistance. 
 
Fansidar plus amodiaquine: Clinical recovery is fast but ACTs are preferred. 
 
Fansidar plus mefloquine (Fansimef): Widespread resistance implies the drug is used only in 
few areas (Ellis-Pegler et al., 1988). 
 
Quinine plus doxycycline/tetracycline: In addition to side-effects such as ‘cinchonism’ and 
contraindication of tetracyclines in children and lactating women, the complicated 7 day 
regime of quinine 10 mg/kg every 8 hours and tetracyclines 4 mg/kg every 6 hours has made 
this combination a less popular option (Newton et al., 2005). 
 
27 
 
1.6.2 Artemisinin-based combination therapy (ACTs): 
 
Due to the multi-modal mechanism of action, transmission blocking properties and rapid 
clearance of parasites from blood, artemisinin is a useful drug and is recommended only in 
combination therapy to prevent emergence of resistance against it. Emergence of resistance to 
artemisinin has been reported but the data available is limited (Lim et al., 2009).  
 
Artesunate with amodiaquine (Coarsucam or ASAQ): It can cause neutropenia in certain 
cases but is recommended as one of the treatments for uncomplicated P. falciparum malaria. 
 
Artesunate and mefloquine (Artequin or ASMQ): Mefloquine has a long half-life and could 
result in a high-selection pressure on parasites thus facilitating resistance. WHO recommends 
this combination as one of the treatments for uncomplicated cases of P. falciparum malaria. 
 
Artemether and Lumefantrine (Coartem, Riamet, Amatem, Faverid, Lonart or AL): Side-
effects are very few and its availability in fixed-dose formulation gives it a good compliance 
rate. It is widely used to manage uncomplicated P. falciparum malaria cases. 
 
Artesunate with sulphadoxin/pyrimethamine (Airplus or Amalar plus): It is one of the WHO 
recommended treatment for uncomplicated P. falciparum malaria, but the resistance to 
sulphadoxin/pyrimethamine limits its use (Adam et al., 2006). 
 
Dihydroartemisinin-piperaquine (Duo-Cotecxin or Artekin): It has shown high efficacy in the 
treatment of uncomplicated P. falciparum malaria. 
 
Pyronaridine and artesunate (Pyramax): The only ACT approved by the European Medicines 
Agency (EMA) for its quality, safety and efficacy in the treatment of both P. falciparum and 
P. vivax, it was developed by Medicines for Malaria Venture (MMV) and Shin Poong 
Pharmaceutical (Roth et al., 2018). 
 
Artesunate with chlorproguanil-dapsone (CDA): It is efficacious but can cause haemolysis in 
patients suffering from glucose-6-phosphate dehydrogenase (G6PD) deficiency (Premji et al., 
2009). 
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Fast elimination of malaria through source eradication (FEMSE) is a protocol found to 
drastically reduce the number cases of malaria (Feng et al., 2016). Three doses of artequick 
(fixed-dosed combination of artemisinin (80 mg), piperaquine (400 mg) and primaquine (4 
mg)) are given with a month between each dose and primaquine is administered with the first 
dose as per the protocol. 
 
1.7 Development of resistance: 
 
Due to the absence of a currently available or under development therapy to provide total 
protection against malaria, the emergence and spread of antimalarial resistance is a serious 
threat to public health. The rate of development of new drugs or therapies for malaria lags far 
behind the rate of emergence of resistance (Ashley et al., 2014). Careful usage of the 
available drugs is a necessity to control the development of resistance as the development of 
new drugs or therapies is expensive and the population in need of these drugs live in some of 
the poorest regions of the world (Vestergaard and Ringwald, 2007). Sound primary care 
structure with necessary supplies and adequately trained staff are imperative for effective 
prevention and control (Alonso et al., 2011). This is a major concern as most malaria endemic 
countries have inadequate fundamental health care structure (Ricci, 2012). Resistance to 
antimalarials is not uncommon. Besides drug resistance, treatment failure could be due to a 
number of issues such as non-compliance, interaction with other co-administered drugs, 
improper diagnosis, poor quality of the drugs, incorrect dosage and improper absorption. 
These factors could also lead to the emergence of drug resistance (Klein, 2013).  
 
Initial reports of chloroquine resistance started emerging almost 6 decades ago and by late 
1980s resistance to sulphadoxine-pyrimethamine and mefloquine were also reported in Thai-
Cambodia and Thai-Myanmar. Resistance to chloroquine emerged in 1957 in Thailand 
(Hanboonkunupakarn and White, 2016) and was attributed to development of an efflux 
mechanism by the parasite to remove chloroquine, leading to inefficient levels of drug to 
cause an effective inhibition of haeme polymerisation. The resistance could be reduced by 
addition of compounds which stop the efflux (Henry et al., 2006). A similar mechanism is 
responsible for the development of resistance to amodiaquine, mefloquine, halofantrine and 
quinine (Cui et al., 2015). Resistance to anti-folates, sulphadoxin and pyrimethamine is 
attributed to two gene mutations in the folate synthesis pathway (Heinberg and Kirkman, 
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2015). Resistance to atovaquone is believed to be due to a cytochrome-b single-point gene 
mutation (Peters et al., 2002). Resistance in the parasite could develop due to spontaneous 
single-point or multiple mutations reducing the drug sensitivity and providing an 
evolutionary benefit to the parasite. Some parasites with resistant alleles survive even if the 
mutation proves fatal for most of the parasites in a population. Selection of these resistant 
parasites over a long period of time establishes the resistance firmly (Plowe, 2009). Table 
1.7.1 shows the year on introduction of the antimalarial and the year that the resistance was 
first reported. 
 
Table 1.7.1 The year of introduction of the anti-malarial drug and the year resistance was first reported 
(Wongsrichanalai et al., 2002) 
 
Antimalarial drug Introduced Resistance first reported Difference in years 
Quinine 1632 1910 278 
Chloroquine 1945 1957 12 
Proguanil 1948 1949 1 
Sulfadoxin-Pyrimethamine 1967 1967 0 
Mefloquine 1977 1982 5 
Atovaquone 1996 1996 0 
 
 
1.8 Spread of resistance: 
 
Various factors from economics to parasite and vector biology, and human behaviour to 
pharmacokinetics of drugs could lead to the spread of resistance (Olasehinde et al., 2015). 
Resistance could emerge due to a number of reasons which lead to the survival of the parasite 
in the presence of an antimalarial. This could happen when the host’s immune system is 
compromised or in cases of non-compliance with treatment. Drugs with longer half-live can 
cause periods where the drug concentration is low leading to development of resistance. 
Cross-resistance could emerge for antimalarials with similar chemical structures such as 
amodiaquine and chloroquine (Croft et al., 2012). 
 
Countless lives have been saved by the use of artemisinins but resistance has started to 
emerge in Thailand-Cambodia border which is the historical epicentre for the emergence of 
multidrug resistance. Resistance has also been observed at the Myanmar-Thailand, China–
Myanmar borders and a province of Vietnam (Dondorp et al., 2010) (Ioset and Kaur, 2009). 
30 
 
It is believed the resistant population of parasites were able to emerge here and establish due 
to poor compliance with treatment, use of sub-lethal doses and low malaria transmission 
leading to ideal conditions for high drug pressure in this area which resulted in emergence of 
resistance to chloroquine (1957), sulfadoxine/pyrimethamine (1982) and mefloquine (1990s) 
(Alker et al., 2007) (Dondorp et al., 2010) (Krungkrai et al., 2010) (Plowe, 2009). 
Development of resistance to artemisinin was perceived to be difficult due to the rapid 
parasite clearance times and short half-life but recently slower parasite clearance in the 
presence of adequate drug concentrations and re-emergence of parasites after 28 days of 
treatment have been observed (Krungkrai et al., 2010) (Noedl et al., 2008). Artemisinin-
resistant parasites could be identified by using specific region of the kelch gene (K13) as a 
genetic marker. Artemisinin resistant P. falciparum parasites have been identified using the 
K13 marker in Myanmar, just 25 km from the Indian border (Tun et al., 2015). It is vital to 
prevent the spread of resistance to high transmission areas such as the Indian border which 
has historically served as the gateway to the global spread of antimalarial drug resistance 
(Bhattarao et al., 2007) (Miller and Su, 2011) (Obonyo and Juma, 2012). 
 
The need for anti-malarial therapy could be decreased and spread of resistance could be 
countered by preventing the transmission of parasites with resistant alleles and by preventing 
the transmission of malaria infections. Chemoprophylaxis to travellers, mosquito repellents, 
insecticide treated bed-nets, indoor residual spraying, swamp draining and other 
environmental methods are effective in preventing the transmission of parasites (Dondorp et 
al., 2017). Development of a malaria vaccine could result in enormous public health benefits 
as it could not only limit the transmission of gametocytes but also the onset of malaria 
infection. Antimalarial chemotherapy could be given in addition to the vaccine to limit the 
emergence of vaccine resistance (Lorenz et al., 2014). Currently there are no drugs in the 
pipeline to replace artemisinins hence strategies such as identification of all cases of 
artemisinin resistance, use of artemisinin-based combination therapy, impregnated bed nets 
and mosquito control methods, education of local communities on risk of using counterfeit 
drugs and reduction of drug pressure in affected areas have been employed to contain the 
spread of artemisinin resistance (Ioset and Kaur, 2009) (WHO, 2010). Figure 1.8.1 shows the 
geographical distribution of drug resistant P. falciparum. 
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Figure 1.8.1 Geographic distribution of antimalarial drug resistant P. falciparum.  
Blue and yellow circles represent the resistance to chloroquine and sulphadoxine-pyrimethamine respectively. 
The black circular dash area represents artemisinin resistance, spreading over Southeast Asia, from Vietnam to 
Myanmar in 2014. Source: (Krungkrai and Krungkrai, 2016) 
 
1.9 Malaria today: 
 
Pyrethroids remains an important component of control programmes for indoor residual 
spraying (IRS). Insecticide treated bed nets (ITN) and long-lasting insecticide treated bed 
nets (LLITN), with a 3-year lifespan, have been instrumental in malaria prevention in recent 
years. Careful monitoring and insecticide rotation for IRS are vital as there is already 
resistance to pyrethroids in the field (WHO, 2013).    
 
Avoidance of pharmacokinetic mismatch of current combinations is imperative (Kremsner 
and Krishna, 2004) (Nandakumar et al., 2006) (Ramharter et al., 2003). Combination of a 
fast-acting compound with a slow-acting compound was though to provide dissimilar killing 
profile of each drug in the combination and reduce the chances of recrudescent infections. 
However, in such a combination the longer plasma half-life partner is left exposed towards 
the end of the treatment regime and its sub-lethal concentrations may lead to the selection of 
drug resistant mutants (Na‐Bangchang and Karbwang, 2009) (Dondorp et al., 2010) (Koram 
et al., 2005) (Walsh et al., 2007). Antimalarial drug discovery has been a challenging 
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endeavour as longevity of second-generation compounds is a formidable concern due to 
resistance against the parent molecules.  
 
1.10 Drug discovery: 
 
Although there is no genetic inheritance or mutation in the process of drug discovery, it still 
draws many parallels with the selection processes of evolution. With a high rate of attrition, 
through a meticulous selection process only a handful of medicines, from countless potential 
candidate molecules become successful (Warren, 2011). Many new drugs are developed by 
modifying the earlier designs and are referred to as first, second or third generation products. 
 
A number of natural products have potent anti-inflammatory, anti-infective, anti-oxidative 
and anti-carcinogenic properties and have served as a source for effective synthetic and 
semisynthetic lead compounds (Ramana et al., 2014). Since historical times, medicinal plants 
or minerals were the main source of therapeutic drugs (Takenaka, 2001). Serendipity of the 
medicinal chemist in the nineteenth century marked the first notable period in drug discovery 
(Pina et al., 2010). Active principles of the natural products were isolated using purification 
methods developed in the nineteenth century and many of these agents were used in the 
treatment of diseases (Li, 2013). Serendipitous discovery of natural product remedies include 
the treatment of congestive heart failure with digitalis (foxglove), treatment of dysentery with 
Ipecacuanha (cephaelis plant bark or root), treatment of fever with willow tree bark and the 
treatment of malaria with quinine (cinchona bark) (Permin et al., 2016).  Essential 
foundations of chemical theory were laid by late-19
th
 century. Theory on structure of 
aromatic organic compounds was formulated by August Kekule in 1865 which led to the 
development of dye chemistry. Paul Ehrlich, while working on dyes with selective affinity to 
biological tissues (1872 and 1874) postulated the existence of chemoreceptors which 
eventually resulted in the birth of chemotherapy in the 20
th
 century (Drews, 2000). 
 
19
th
 century saw drug discovery move from usage of dried and ground preparations to the 
isolation and purification of active components. ‘Mauve’ created by William Henry Perkin in 
an attempt to synthesise quinine lead to the creation of first synthetic textile dye (Schlitzer, 
2007). Paul Ehrlich (1890) stained the malaria parasite with methylene blue which has had a 
huge impact on drug discovery. The ability of chemical dyes to selectively stain certain 
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biological tissues lead to the development of the drug receptor concept. This connection 
between drug structure and biological activity lead to the birth of medicinal chemistry 
(Drews, 2000).  
 
Major classes of molecular drugs used for treating almost 87% human diseases belong to 
natural products isolated from natural sources such as vertebrates, invertebrates, plants or 
micro-organisms (Pina et al., 2010). Morphine was isolated from opium extracts by F. W. 
Serturner in 1815, papaverin was discovered in 1848 but it was only in 1917 its 
antispasmodic properties came to light, and coal-tar, an industrial by-product with many 
aromatic or aliphatic compounds became an important tool for medicinal chemistry. 
Discovery of penicillin from the mould Penicillium by Alexander Fleming in 1929 
revolutionised the treatment of bacterial infections and led to the development of many other 
antibiotics (Drews, 2000) (Rubin, 2007). Natural products lead to discovery of several 
immunosuppressive agents (cyclosporins and rapamycin), anti-cancer agents (paclitaxel and 
camptothecin) and cholesterol-lowering agents (lovastatin and mevastatin) (Pina et al., 2010).  
 
1928 to 1962 was considered the golden era of drug discovery. Fritz Mietzsch and Josef 
Klarer synthesised prontosil, a sulfonamide derivative (1935). Prontosil was also found to 
demonstrate 100 % cure rates against P. falciparum (Gregson and Plowe, 2005). 1950/1960s 
saw interest in sulpha compounds emerge as potential antimalarials. Treatments for malaria, 
tuberculosis, hypotension, diabetes and many other diseases became available. Biological 
activity was first tested in-vivo in animal models and then compounds were subsequently 
purified and synthesised followed by lead optimisation through structural modification (Pina 
et al., 2009). P. relictum in canaries (1926-1935), P. gallinaceum in either chicks, ducklings 
or turkeys (1935-1948) and the rodent P. berghei model, first isolated from the thicket rat 
(central Africa, 1948), were the animal models used in malaria (Cellier-Holzem et al., 2010) 
(Frevert et al., 2008). The rodent P. berghei model is still in use today. In vitro culture 
methods eventually replaced the need to conduct the preliminary investigations through in 
vivo methods. This transition for malaria was made possible by Trager and Jensen in 1976, by 
isolating P. falciparum parasites from Aotus trivirgatus monkey and successfully culturing 
them in human blood (Trager and Jensen, 1976). In 1980s, in-depth understanding of disease 
aetiology, cellular processes and molecular biology made a rational approach to drug design 
norm which was supplemented by the advent of genomic revolution (Chatterjee and Yeung, 
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2012) (Jana and Paliwal, 2007) (Wells, 2010). For malaria, the sequencing of the P. 
falciparum genome (Gardner et al., 2002) renewed hope in finding a new effective 
antimalarial as no orthologues were discovered for 60 % of the parasite proteins (Guiguemde 
et al., 2012).   
 
New drug structures found in the early twentieth century led to an era of antibiotics 
discovery. The field of drug discovery saw rapid advances towards the end of last century 
with the development of techniques such as computer-based drug design, combinatorial 
chemistry, automated high-throughput screening and recombinant DNA technology which 
made it possible to develop new drug target candidates and marked the onset of ‘Omics’ 
revolution (Pina et al., 2010). In the last two decades, drug discovery has gradually shifted 
from a physiology-based to target-based approach. Physiology based approach relies on 
physiological effects of drugs in disease-relevant models. The weakness of this method lies in 
the lack of complete understanding of relationship between the mechanism of action of the 
drug, its biological effect and low-throughput screening (Sams-Dodd, 2005). Phenotypic 
screens and target-based screens have sequentially ruled over the drug development stages 
(Kotz, 2012). The ratio of success rate of a new drug to pass the approval stage to the 
investment required for research and development is very low (Figure 1.10.1).  
 
 
Figure 1.10.1 The drug development to market timelines for de novo drug discovery.  
De novo drug discovery can take 10-17 years with very low probability of success. ADMET, absorption, 
distribution, metabolism, excretion and toxicity information may already be available for the repositioned drug 
candidate (Somerville, 2015). 
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1.10.1 Target-based drug discovery  
 
The target, ideally specific to the disease causing organism is usually identified to avoid the 
chances of adverse effects (Chatterjee and Yeung, 2012). After the identification of the target 
and genetic validation through knock-out studies, high-throughput screening is conducted via 
in vitro chemical assays using ‘druggable’ small molecules, which obey the rule of 5 (more 
than 5 H-bond donors, 10 H-bond acceptors, the molecular weight greater than 500, and the 
calculated Log P (CLog P) greater than 5 are more likely to result in poor absorption or 
permeation) (Frearson et al., 2007) (Blaazer et al., 2015) (Benet et al., 2016). Structural 
optimisation is done to increase pharmacokinetic properties of the hit compounds. X ray 
crystallography and computational 3D modelling can also be used to aid in the process 
(Gilbert, 2013). After determining the selectivity of hit compounds in cellular assays and 
evaluating the toxicity profile, the hit compound is only validated when it shows efficacy in 
the clinical settings (Gilbert, 2013). This approach has led to development of many successful 
drug therapies such as imatinib and gefitinib against cancer (Swinney, 2013). Cysteine 
proteases, protein farnesyl transferases, dihydrofolate reductase and phospholipid 
biosynthesis are few of the many putative targets which have emerged for the development of 
new antimalarials (Fidock et al., 2008) (Gelb, 2007) (Jana and Paliwal, 2007) (Nwaka et al., 
2004) (Winstanley, 2000). Problems with this approach is that target based drugs have 
limited impact on disease treatment (Sams-Dodd, 2005). Unfortunately, in vitro/ in vivo 
disconnect is observed more frequently than desired and leads to disappointing results during 
clinical validation for many novel targets, mostly due to lack of cellular context which is used 
for identification of hit compounds. This ultimately causes problems with cellular 
penetration, sequestration in lipid compartments, non-specific binding, undesirable kinetic 
properties or alterations in molecule in the active site of the enzyme (Chatterjee and Yeung, 
2012) (Gilbert, 2013). Lactate dehydrogenase (LDH), thioredoxin reductase (TrxR) and the 
fatty acid biosynthesis enzyme (FabI) were used as targets for enzyme inhibition in malaria 
but failed when tested for whole-parasite activity. FabI was eventually found to be 
dispensable in the intraerythrocytic cycle whereas LDH and TrxR were found not druggable 
despite intensive lead optimisation (Guiguemde et al., 2012).   
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1.10.2 Validated antimalarial drug targets  
 
Our existing knowledge of parasite biology has led to the realisation that novel modes of 
metabolism, cell division, signalling and communication pathways are commonly used by the 
parasite causing unexpected adverse effects leading to poor attrition rates (Reaume, 2011) 
(Jana and Paliwal, 2007). The three validated targets namely the haemozoin pathway 
(chloroquine), the folate pathway (anti-folates; dihydrofolate reductase and dihydropteroate 
synthase inhibitors) and mitochondria’s cytochrome bcl complex (atovaquone) developed 
based on action of pre-existing antimalarials and not through modern fully rational, target-
based drug discovery framework, have dominated the antimalarial development pipeline 
(Chatterjee and Yeung, 2012) (Gilbert, 2013) (Na‐Bangchang and Karbwang, 2009). Figure 
1.10.2 shows the various targets for antimalarials in P. falciparum. Most new antimalarial 
compounds are generally the less toxic and efficacious second or third generation compounds 
(Gelb, 2007). The longevity of such second generation compounds is questionable due to the 
parasite’s pre-existing resistance capabilities (Canfield et al., 1995) (Wells, 2010).   
 
The reduction in development of novel first class drugs has questioned the over-reliance of 
drug discovery on the target-based strategy and genetic approach to drug discovery (Kotz, 
2012). Conserved homology dictates the rarity of selective compounds in reality (Chatterjee 
and Yeung, 2012). The other important issue affecting the malaria drug market is the half a 
billion people needing treatment in a year that cannot afford to pay for it leading to a 
negligible profit margin, making it unattractive for large pharmaceutical companies to invest 
in antimalarial drug development (Craft, 2008) (Muthyala, 2011) (Winstanley, 2000).  
 
The Medicine for Malaria venture (1999) and the Bill and Melinda Gates foundation, the 
non-profit public, private and philanthropic partnerships have fortunately revitalised efforts to 
develop new antimalarials (Fidock et al., 2004). This has led to formation of academic and 
industrial partnership programs focussing on novel antimalarials to sustain the drug discovery 
pipeline for antimalarials (Gelb, 2007) (Gilbert, 2013). High failure rate of candidates with 
only 7% becoming a drug further hampers the long de novo drug development process. Faster 
development processes are thus imperative to avoid an imminent void in the malaria drug 
market currently under threat of spread of artemisinin resistance (Craft, 2008) (Gelb, 2007).   
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Figure 1.10.2 Various antimalarials with their targets in P. falciparum. Source: (Greenwood et al., 2008) 
 
1.10.3 Phenotypic drug screening/ high-throughput Screening (HTS) 
 
Phenotypic screening exploits diverse chemical libraries developed over nearly 100 years of 
medicinal chemistry and involves high throughput in vitro whole-cell screening followed by 
compound purification according to potency. It is a top-down development process with 
retrospective identification of drug targets and mechanisms of action (Gilbert, 2013).  
The main purpose of high-throughput screening (HTS) is to screen a large number of 
biological modulators and effectors against selected and specific targets and has become a 
standard in the pharmaceutical industry (Szymanski et al., 2012). In one HTS, nearly 1.7 
million compounds were screened, with ~6,000 small molecules identified as having potent 
antimalarial activity (<1.25 μM) (Plouffe et al., 2008). Another screen of nearly two million 
compounds in GlaxoSmithKline’s chemical library identified 13,533 hits with activity against 
P. falciparum at 2 μM concentration (Gamo et al., 2010). 275 primary hits with sub-
micromolar activity against P. falciparum were identified from a screen of ~ 12,000 pure 
natural products (Rottmann et al., 2010).  
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1.10.4 Phenotypic screening for malaria  
 
Whole-parasite high-throughput screening techniques such as hypoxanthine incorporation 
assay, ELISA and SYBR green-based methods to evaluate compounds against the erythrocyte 
stages have made phenotypic screening for malaria a possibility. This addresses the 
aforementioned issues of permeability and cellular efflux by screening the compounds 
against whole parasites. Mammalian cell lines are used to determine selectivity and toxicity 
(Wells, 2011). Improvements in compound activity through structural alterations are limited 
due to lack of prior knowledge of the target (Gilbert, 2013). Nonetheless, regulatory approval 
of drugs does not require prior knowledge of targets and historically it has been observed the 
most successful antimalarials have multiple targets, with difficult to elucidate pathways 
(Chatterjee and Yeung, 2012) (Medina-Franco et al., 2013).  
 
1.11 Compounds from natural sources in malaria: 
 
Tetracycline discovered in 1940’s is a natural product-derived compound with antimalarial 
activity. Several classes of compounds such as alkaloids, terpenes, flavonoids, quinones, 
xanthones, coumarins, peptides, phenols and lignans have been identified as having 
antimalarial properties (Wells, 2011).  
 
By 1950s, 8-aminoquinoline, 4-aminoquinoline and folic acid synthesis inhibitors replaced 
quinine in the treatment of malaria and it was widely believed malaria would soon be 
eradicated from the world (Mojab, 2012). Emergence of drug resistance and insecticide 
resistance quashed any hopes of eradicating the disease (Churcher et al., 2017). Drug 
resistance to artemisinin has reached Thai-Cambodia border and the world is in dire need of a 
new effective anti-malarial (Phyo et al., 2012). Natural products have played an important 
role in shaping the treatment for malaria (Wells, 2011). Quinine which is derived from 
Cinchona (White, 1985) and artemisinin which is derived from Chinese herb Artemisia 
annua (Warhurst, 1985) have proven to be the two strongest antimalarials till date. Dichroea 
febrifuga, another species used in Chinese herbal medicine has been found to be effective 
against malaria (Phillipson et al., 1987). Simaroubaceae is another species traditionally used 
in Asia, Africa and America against malaria (Bertani et al., 2006). 
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Another species with activity against the malaria parasite is Bignoniaceae, whose active 
ingredient lapachol and its derivative lapinone led to the development of atovaquone 
(Carvalho et al., 1988) (Fawaz and Fieser, 1950). Cryptolepine from Cryptolepis 
sanguinolenta is marketed in Ghana as PHYTO-LARIA (Lisgarten et al., 2002) (Wright et 
al., 1996). Gedunin from Azadirachta indica, has been used in India (Willcox et al., 2004) 
and is available as capsules (IRACARP) in Nigeria (Anyaehie, 2009).  
 
Natural source based antimalarials such as quinine (effective despite being in use for nearly 
400 years) and artemisinin are in stark contrast when compared with development of 
resistance in targeted anti-folate class of drugs which emerged within 5 years of use (Achan 
et al., 2011) (Craft, 2008). Artemisinin is believed to act through multiple targets with reports 
suggesting involvement of reduction of the endoperoxide bridge through generation of free 
radicals (Meshnick, 2002), activation on the mitochondrial electron transport chain leading to 
generation of reactive oxygen species (Mercer et al., 2011), interference with haemoglobin 
and haeme pathway (Klonis et al., 2011) (Zhang and Gerhard, 2009), and the interaction with 
the calcium pump PfATP6 (ortholog of endoplasmic reticulum pump SERCA) (Valderramos 
et al., 2010).  
  
1.12 Molecular Modelling: 
 
Drugs are either provided through discovery or through design in medicinal chemistry. 
Mapping of the human genome has led to molecular biological revolution and exponential 
growth in potential therapeutic targets. Intelligent molecular mimicry and structural analyses 
of binding domains of the biological targets with the agonist or antagonist co-crystallised 
with it provides a significant understanding of the receptor-ligand interactions (Krogsgaard-
Larsen et al., 2010). Growth in protein databank (RCSB), better docking algorithms, large 
scale quantum calculations, computational models to predict pharmacophore and prediction 
absorption/distribution/metabolism/excretion (ADME) - toxicity coupled with advancement 
in computer power has led to the incorporation of molecular modelling in the process of drug 
discovery. It involves a large bio-molecular target which binds with a small molecule leading 
to the activation or inhibition of the target. It is helpful for lead generation and lead 
optimisation. Deleting (knocking-out) a reaction in the metabolic network in silico and 
comparison of reconstructed metabolic network models can help determine essential enzymes 
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(Fatumo et al., 2009). Structure-based designs require a three dimensional target structure and 
graphic tools to observe the ligand interactions in the binding site with insight into the 
molecular energetics of the binding process. Ligand-based designs are based on the analysis 
of structure/activity data of compounds observed on assays measuring the target’s biological 
function (Wilson and Lill, 2011). Ability to accurately predict a ligand’s potency to bind with 
the intended target is invaluable in the drug-discovery process. Molecular docking is used to 
dock ligands to the active site of the target and scoring functions are used to analyse the 
resulting receptor-ligand interactions to provide a quantitative measure of fit quality 
(Rajamani and Good, 2007). Computer-aided drug design could be ligand-based or structure-
based (Osakwe and Rizvi, 2016) (Mortier et al., 2018) (Vyas et al., 2012).  
 
Benefits of predicting inter-molecular interactions are immense. In the process of rational 
drug design or elucidation of biochemical processes, the knowledge of the binding 
conformation of the target with a small molecule ligand is important for structure-based drug 
design (Kitchen et al., 2004). The analogy of ‘lock and key’ is often used for the ligand fitting 
in the binding pocket of the target, similar to a key which fits in a lock (Du et al., 2016) 
(Tripathi and Bankaitis, 2017) (Kuntz et al., 1994). Due to the flexible nature of the proteins 
and the ligand, a ‘hand in glove’ analogy is a better fit (Jorgensen, 1991). The conformational 
adjustment of protein and the ligand leading to overall binding is known as ‘induced-fit’ 
(Bucher et al., 2011) (Wei et al., 2004). The purpose of simulation is to identify a 
conformational pose between the ligand and the target protein such that the system has the 
minimum ‘free energy’ (Meng et al., 2011) (Gray, 2006). In docking two main approaches 
are popular: ‘Shape complementarity’ and ‘Simulation’. 
 
1.13 Mechanics of docking:  
 
Energetically acceptable poses of the ligand are usually identified by evaluation of force-field 
energy (Liu and Wang, 2015). Systematic, stochastic, molecular dynamics simulation and 
genetic algorithms are various strategies used to develop the search algorithm (Dastmalchi, 
2016). Most ligand poses generated during docking result in clashes with the protein and are 
rejected immediately (Osada, 2009) (Friesner et al., 2006). A force-field based scoring 
function, which assesses the energy of the pose in relation to the binding site, is then used to 
evaluate remaining poses and rank them based on how favourable a binding interaction they 
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represent (Murcko, 1995). A stable system has a negative or low energy. Knowledge-based 
approach is an alternative which utilizes the ligand-protein complexes data from large 
databases to predict the best fit of the pose for a given potential (Yang et al., 2006) (Roche et 
al., 2001). Examples of computer-aided drug design are dorzolamide, a carbonic anhydrase 
inhibitor approved in 1995 (Greer et al., 1994) (Gubernator and Böhm, 1998) and imatinib 
which inhibits tyrosine kinase as a treatment for Philadelphia-chromosome positive 
leukaemias (Capdeville et al., 2002).  
 
Molecular docking has the potential to efficiently predict non-covalent binding of 
macromolecules (protein-protein docking) or a macromolecule and a small molecule 
(receptor-ligand docking) using a computational procedure. The knowledge of bound 
conformation and the binding affinity is used to virtually screen libraries of drug-like 
molecules for lead generation and lead optimisation for further drug development. In this 
study, the molecular docking software, MOE (Molecular Operating Environment) and 
AutoDock Vina were used for molecular docking and virtual screening.  
 
1.14 Virtual Screening 
 
Until recently, drug discovery by empirical screening has dominated the search of new 
ligands for biological target structures. Virtual screening has now established its place in drug 
discovery (Shoichet, 2004). Despite recent advances in combinatorial chemistry, it is not 
possible for the chemists to synthesis all the possible compounds in the drug library. Virtual 
screening offers a solution by reducing the library to a manageable size which could be 
synthesised (Walters et al., 1998). Hit identification and lead optimisation frequently employs 
virtual screening to dock possible ligands into macromolecular structures and score their 
potential complementarity to the binding pocket (Kitchen et al., 2004). There are still many 
issues in the application of screening approaches, but HIV protease inhibitors are a good 
example where screening and structure-based design played an important role in the 
development of new drugs (Yadav et al., 2012). 
 
In silico assessment of large libraries of chemical structures either alone or in combination 
with high-throughput screening is being used regularly. Availability of computational 
screening approaches has increased with the increase in molecular databases of compounds 
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and target structures. Virtual screening acts as a fast-tract method. Large compound libraries 
containing bioactive molecules have already been screened for malaria and other diseases but 
very few have progressed beyond the hit identification stage (Baniecki et al., 2007) (Chong et 
al., 2006) (Jones et al., 2010) (Lucumi et al., 2010) (Major and Smith, 2011).  
 
1.15 Drug Repositioning: 
 
De novo drug discovery through target-based strategy has less than 10% success rate and can 
take 10-17 years. Novel drug discoveries to increase productivity of biopharmaceutical 
companies have not achieved the desired results. As such, repositioning the existing drugs 
towards new indications can help increase the productivity needed by the industry. ‘Drug 
repositioning’ or ‘repurposing’ is a strategy where abandoned or existing pharmacotherapies 
are used on novel indications identified through phenotypic screening (Boguski et al., 2009) 
(Medina-Franco et al., 2013). Drug repositioning offers a solution to the dilemma of reducing 
the research and development timelines without increasing the associated risks as the in vitro 
and in vivo screening, chemical optimization, toxicology, formulation development, side-
effects profiling, bulk manufacturing and clinical development have already been completed 
and so can potentially be bypassed thus eliminating the costs of substantial risks and several 
years from the development to market pathway (Ashburn and Thor, 2004).  
 
Many drugs have been successfully repositioned for use in various diseases, such as sildenafil 
(Viagra) originally developed to treat cardiovascular diseases is now used for erectile 
dysfunction (Fink et al., 2002), thalidomide  which was developed to treat morning sickness 
was found to be effective against Erythema nodosum leprosum and for the treatment of 
multiple myeloma (Walker et al., 2007). Buproprion (Wellbutrin) and Duloxetine (Cymbalta) 
developed for treating depression were found to be effective as a smoking cessation aid and 
for stress urinary incontinence, respectively (Boguski et al., 2009).  
 
Clinically/FDA approved drugs could serve as sources for drug repositioning (Andrews et al., 
2014) (Lotharius et al., 2014). Doxycycline, an antibiotic has been repositioned for use in 
malaria.  Medicines for Malaria Venture (MMV) supported the high-throughput screening of 
approximately 4 million compounds by Novartis, GlaxoSmithKline (GSK) and St. Jude 
Children’s Research Hospital in the late 2000s leading to identification of over 20,000 
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compounds with antimalarial activity which were deposited in the public domain 
(Guiguemde et al., 2012) (Fong et al., 2015). Drug repositioning could potentially have 
reduced risks of drug failure in addition to reduced cost and time due to the availability of 
pre-clinical toxicology data, pharmacokinetics and dose range in some instances (Baek et al., 
2015). Although legal issues could arise with regards to intellectual property of the drug. 
 
Derived from Psychotria ipecacuanha, emetine, a hydrochloride of an alkaloid in ipecac root, 
has been used to treat amoebiasis, cough, and as the name suggests, to induce emesis or 
vomiting (Lee, 2008). Methylation of cephaeline could also be used to prepare emetine (Jain 
et al., 2012). Emetine has been found to be active against leukemia (Möller et al., 2007) and 
dengue virus infection (Yin Low et al., 2009) amongst other diseases. Dehydroemetine, the 
synthetic derivative of emetine has been tested for activity in amoebiasis (Hilmy Salem and 
Abd-Rabbo, 1964), leishmaniasis and herpes zoster (Hernandez-Perez, 1980).  
 
1.16 Previous drug repositioning work conducted at the University of Salford: 
 
Drug repositioning studies were conducted in the University of Salford in a bid to identify 
compounds with activity against Plasmodium falciparum. Optimisation of reliable in vitro 
drug susceptibility assays was done and two FDA-approved libraries, LOPAC and ENZO 
(~700 compounds) were screened. Around 60 compounds were identified as potential hits, 
and emetine dihydrochloride hydrate, an anti-amoebic compound was found to be 
approximately 1000-fold more potent an inhibitor (IC50 = 47 + 2.17 nM) of the multidrug 
resistant Plasmodium falciparum, strain K1 compared to Entamoeba histolytica (26.8 + 1.27 
µM) (Bansal et al., 2004). Parasite reduction ratios (PRR), parasite clearance time (PCT) and 
drug interaction analysis with existing antimalarials were conducted in the second-phase 
characterisation of the compound. Emetine and atovaquone were found to have ideal 
pharmacokinetic matching and synergy (Matthews et al, 2013). 
 
1.17 Emetine and dehydroemetine: 
 
A natural alkaloid native to Brazil extracted from plant source Psychotria ipecacuanha (plant 
family Rubiaceae) also known as Cephaelis ipecacuanha has been used in the past for the 
treatment of amoebiasis. Mitochondrial and ribosomal protein synthesis is inhibited by 
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emetine and it has antiviral, anti-parasitic, contraceptive and anti-cancer properties. 40S 
ribosomal subunit of the eukaryotic 80S ribosome is the site of action of emetine (Jimenez et 
al., 1977). Poliovirus infected HeLa cells treated with emetine have been reported to show 
inhibition of viral RNA synthesis  (Akinboye and Bakare, 2011). Human cytomegalovirus, 
Zika virus and Ebola virus are also inhibited by emetine at nanomolar concentrations 
(Mukhopadhyay et al., 2016) (Yang et al., 2018). 
 
 
 
Figure 1.17.1  Emetine structure from pubchem showing R configuration at C-1
’ 
 
The (R) configuration at C-1´ and the presence of secondary nitrogen at 2´ position are 
important for emetine’s biological activity (Figure 1.17.1), as (S) configuration at C-1´ 
(isoemetine) or substitution of secondary amine results in the loss of activity. Symmetry at 
carbons 2 and 3 is lost with unsaturation at 2-3 position (dehydroemetine) but the biological 
activity is retained (Grollman, 1966). The cross-resistance of emetine-resistant mutants of 
Chinese hamster ovary cells to related compounds such as (-)-cryptopleurine 
(phenanthroquinolizidine-type alkaloids), (-)-tylocrebrine (phenanthroindolizidine type), and 
(-)-emetine, (-)-tubulosine, (-)-cephaeline, and (-)-dehydroemetine (benzoiosoquinoline 
alkaloids) was observed (Gupta and Siminovitch, 1977). The study concluded that the planar 
structure of the molecule with two aromatic rings made slightly electronegative by hydroxyl 
or methoxyl groups, the distance between two aromatic rings and the angle between 
nucleophilic element such as nitrogen and the rings are essential to maintain biological 
activity. 
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The important side-effects of emetine are vomiting and cardio-toxicity. Emetine’s cardio-
toxicity was immediately recognised since it was first advocated in 1912 by Sir Leonard 
Rogers. Boyd and Scherf in 1941, found widening of QRS complexes, PR interval 
prolongation, T wave changes and extra-systoles in the electrocardiograms of animals. In 
1944, Hardgrove and Smith found cardiographic changes especially in T waves of 53% of the 
study subjects (Turner, 1963). 
 
Reports of emergence of resistance to the artemisinins is a call to discover novel anti-malarial 
drugs and drug repositioning via screening existing FDA-approved drug libraries can offer a 
short term solution.  
 
Cytoplasmic ribosome, mitochondrial ribosome and non-photosynthetic plastid, the 
apicoplasts are responsible for protein synthesis in the Plasmodium parasite (Jackson et al., 
2011) (McFadden et al., 1996). Delayed death effect is observed in second generation drug 
exposure in parasites treated with macrolide antibiotics such as azithromycin which target the 
apicoplast ribosome (Dahl and Rosenthal, 2007). Cytosolic protein translation inhibition 
displays quick results due to its dominance in blood stages of the parasite (Waters et al., 
1989).  
 
The Pf80S ribosome is comprised of large (Pf60S) and small subunit (Pf40S) with a total of 
74 proteins as well as the 5S, 5.8S, 18S, and 28S rRNAs and a tRNA bound (Figure 1.10.4.1) 
at the E-site (Wong et al., 2014). 18S rRNA helices 23, 24, 45, and the C-terminus of uS11 
form the emetine binding pocket (Figure1.17.2). No changes are induced in the pocket due to 
binding of emetine. 
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Figure 1.17.2 tRNA (in pink) bound to the E-site of Pf80S ribosome reproduced through a molecular graphics 
software, PyMol. 
 
 
 
Figure 1.17.3 Emetine binding site with emetine (in white) in the binding pocket reproduced through a 
molecular graphics software, Discovery Studio (3J7A by Wong et al, 2014). 
 
Base-stacking interaction is formed between G973 of h23 and the benzo[a]quinolizine ring of 
emetine whereas a hydrophobic interaction is formed by its ethyl group with C1075 and 
C1076 of h24. The isoquinoline ring stacks against the C-terminal Leu151 of protein uS11 
and a hydrogen bond formed between the NH group of emetine’s isoquinoline ring and an 
oxygen atom on the backbone of U2061 of h45 stabilizes this interaction. Emetine possibly 
binds to the cytoplasmic host ribosomes in a way similar to that of Plasmodium as each of the 
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core binding elements in the emetine binding site in Pf80S appear to be conserved (Figure 
1.17.3) when compared with the equivalent region in the 4.8 Å human structure (Anger et al., 
2013) (Wong et al., 2014). This could be the reason behind observed cytotoxicity in humans. 
 
Mutations of Arg149 and Arg150 of protein uS11 in Chinese hamster ovary (CHO) cells lead 
to development of resistance to emetine (Madjar et al., 1982). The molecular basis of 
resistance could be explained by mutations of the C-terminal arginine residues of uS11 which 
disrupts the emetine binding pocket by destabilizing h23 and h45. In Plasmodium, a long coil 
with seven basic residues (residues 141–151; RKKSGRRGRRL) is formed by the C-terminus 
of uS11, leading to electrostatic interactions with the phosphate backbones of h45, h23 and 
h24, which is necessary for the stabilisation of the conformation of this coil with the 18S 
rRNA (Wong et al., 2014). Pactamycin, which binds to the bacterial 30S and acts by blocking 
mRNA/tRNA entry into the E-site during the translocation step of protein synthesis share the 
same binding pocket as emetine (Dinos et al., 2004) (Brodersen et al., 2000). Emetine thus 
possibly acts via the same mechanism as pactamycin. Figure 1.17.4 shows the comparison of 
emetine binding residues between human (S14) and Plasmodium (uS11) proteins. 
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Figure 1.17.4 Comparison of human and Plasmodium ribosomal emetine binding sequence.  
(A) human 80S ribosome small subunit 40S ribosome protein S14 (4UG0) and (B) P. falciparum 3J7A 
ribosomal 40S small subunit protein uS11 with residues (141–151; RKKSGRRGRRL) forming emetine binding 
site. Sequence adapted from Protein Data Bank. 
 
Pactamycin and its analogues with reduced cytotoxicity have been shown to be potent 
against P. falciparum (Otoguro et al., 2010) (Lu et al., 2011). Similarly, dehydroemetine, a 
synthetic derivative of emetine which differs from its parent compound by a double bond 
next to the ethyl group of benzo[a]quinolizine ring, has been found to maintain anti-parasitic 
properties but produces less toxic effects (Dempsey and Salem, 1966) (Chintana et al., 1986). 
Structural modification of emetine is unlikely to avoid binding to mammalian ribosome due 
to conserved nature of the binding site in humans. Reduced cytotoxicity observed in 
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dehydroemetine could possibly be due to its faster excretion from the body (Schwartz and 
Herrero, 1965). 
 
Dehydroemetine, a synthetic analogue of emetine hydrochloride has been claimed to have 
less cardio-toxic effect than emetine in a study to assess the effect of combination of 
chloroquine with emetine hydrochloride and dehydroemetine in the treatment of amoebic 
liver abscess (Scragg and Powell, 1968). It can thus serve as an interesting lead to test the 
compound for antimalarial activity. In this study, we have tested the two diastereomers of 
dehydroemetine, (-),-R,S-dehydroemetine and (-),-S,S-dehydroisoemetine for the activity 
against the multi-drug resistant strain K1 of P. falciparum. 
 
1.18 Future directions  
 
Identification of new antimalarials to circumvent the spread of resistance is of utmost 
importance. The faster pace of drug repositioning in treatment of diseases which often relies 
on serendipity, offers a valuable option especially in diseases like malaria. It could bridge the 
gap arising from treatment failure due to spread and emergence of resistance, and time and 
cost of future drug developments by identifying suitable candidates not only for novel 
therapy but also for combinatory regimes with existing antimalarials. This should run in 
parallel with existing target-based studies. Expedition of the drug discovery timeline is 
crucial and drug repositioning could be used as one of the methods for developing new 
antimalarials (Grimberg and Mehlotra, 2011, Lotharius et al., 2014). 
 
With these statements in mind, the main aims and objectives of this research are to:  
 
1. To use computational tools to locate the binding site and predict the activity of the two 
isomers of dehydroemetine. 
2. To investigate the antimalarial efficacy of the two isomers of dehydroemetine against the 
multidrug resistant P. falciparum K1 strain through IC50 level of inhibition and killing profile 
in order to develop an understanding of the mode of action. 
3. Evaluate the toxicity of the tested compounds on human cell lines.  
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4. To further characterise the action of the selected isomer of dehydroemetine by 
investigating its interaction with currently used antimalarial drugs to look for a synergistic 
partner, and to determine suitability and potential for combination therapy.   
5. To define the cellular basis for cardiotoxicity observed during emetine and dehydroemetine 
anti-amoebic therapy and propose possible remedies. 
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Chapter 2 General materials and methods 
 
All materials for the Plasmodium falciparum culture and experiments were prepared in a 
sterile fume hood after generous spraying with 70 % ethanol (ESCO class II Biological safety 
cabinet) and using pre-sterilised equipment in the pathogen laboratory (University of 
Salford). All biological waste was disinfected with 2% Virkon (Antec International, UK) 
which was prepared by adding 2 scoops of Virkon (Antec International, UK) to 1 litre of 
water, prior to autoclaving. All routine culture methods were consistent with those employed 
by (Read and Hyde, 1993)). Health and Safety risk assessment has been carried out according 
to COSHH protocols. 
 
Ethics Statement: 
For routine malaria culture, anonymised whole blood packs deemed unfit/outdated for 
clinical use were purchased from the NHS Blood Bank at Plymouth Grove, Manchester, UK. 
For experiments carried out in GlaxoSmithKline, Diseases of the Developing World 
Medicines Development Campus, Tres Cantos, Spain, the human biological samples were 
sourced ethically and their research use was in accord with the terms of the informed 
consents under an IRB/EC approved protocol. All procedures carried out at the University of 
Manchester accord with the Animals (Scientific Procedures) Act, UK, 1986 and Directive 
2010/63/EU of the European Parliament (Home Office, 1986). 
 
2.1 Preparation of complete media: 
 
500 ml RPMI 1640 media containing 1x (+) L-Glutamine (+) 25 mM Hepes (Gibco, Life 
Technologies, UK) was used for the culture and experiments. Complete media was prepared 
by adding 2.5 g Albumin bovine serum fraction V (Sigma, UK), 2.5 ml 1 mg/ml 
hypoxanthine (Sigma, UK) in phosphate buffered saline (PBS) (Fisher Chemical, UK), 2.5 ml 
40% glucose (Dextrose Anhydrous, Fisher Scientific, UK) in sterile water and 0.5 ml 50 
mg/ml gentamycin (Sigma, UK) in PBS to 20 ml of RPMI 1640 in a falcon tube which was 
subsequently added directly into the 500 ml bottle of RPMI 1640 medium using a 20 ml 
syringe after passing through a 0.22 µm filter. The complete media was stored at 2-8
o
C. 
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2.2 Preparation of washing media: 
 
For washing media a 500 ml bottle of pre-sterilised RPMI 1640 1x (+) L-Glutamine (+) 
25mM Hepes (Gibco, Life Technologies, UK) devoid of  additives was used and stored at 2-
8
o
C for up to 2 weeks. 
 
2.3 Preparation of human blood: 
 
O+ whole blood (obtained from the human blood bank) was washed immediately before use 
to remove the leucocytes. Blood was centrifuged in a falcon tube for 5 minutes at 3000 rpm 
and the supernatant two layers containing the plasma and buffy coat were removed. Equal 
volume of washing media (sterile RPMI) was added to the remaining layer composed of red 
blood cells. After mixing it well, RPMI with blood was centrifuged at 3000 rpm for 5 mins 
and the supernatant was removed. Washing step was repeated two more times to ensure the 
white blood cell layer does not exist. 
 
A final wash was done using 5 to 10 ml of the complete media and the top layer was 
discarded leaving a layer of RBCs with 100% haematocrit. RBCs were re-suspended in equal 
volume of complete media to obtain 50% haematocrit which was then stored at 2-8 ℃. RPMI 
and blood used in the process were maintained at similar temperature to prevent lyses of 
RBCs.  
 
2.4 Cryopreservation of Plasmodium falciparum: 
 
The strain used in the experiments was K1 multi-drug resistant P. falciparum strain which is 
resistant to chloroquine, pyrimethamine and sulphadoxin. Culture selected for cryo-
preservation was over 10% parasitaemia with more than 50% ring stage as larger parasites 
gets lysed in due course. The parasitized blood was centrifuged and brought to 50% 
haematocrit by re-suspending in complete media. 0.5 ml of this blood was taken in a sterile 
cryotube and 0.5 ml of 20 % dimethyl sulphoxide (sterile filtered DMSO, Sigma, UK) in 
Ringers solution (9 g NaCl, 0.42 g KCl and 0.25 g CaCl2/ Litre) was added. The cryotube 
was immediately placed in the liquid nitrogen to snap-freeze at -80
o
C. 
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2.5 Retrieval from liquid nitrogen: 
 
Parasitized blood was removed from the cryovial and placed in a microcentrifuge tube which 
was centrifuged in a minispin centrifuge (eppendorf, UK) at 13000 rpm for 90 seconds. 
DMSO supernatant was removed and 1 ml of 10% sorbitol (Fisher Scientific, UK), prepared 
in sterile phosphate buffer solution was added. After mixing gently, it was centrifuged again 
as mentioned above. Supernatant was discarded and the process was repeated with 1 ml of 
5% sorbitol in sterile phosphate buffer solution. Three washes were done by 1 ml of complete 
media and after removing the supernatant, it was re-suspended in complete media, bringing 
the haematocrit to 50%. This parasitized blood was then added to the culture flask containing 
10 ml of complete media and 0.5 ml of washed blood, maintaining the haematocrit for the 
culture at 5%. 
 
2.6 Routine Plasmodium falciparum culture and determination of parasitaemia: 
 
Existing P. falciparum culture was taken in the sterile hood without dislodging the parasites. 
Approximately 9 ml of medium was removed by using a serological pipette by tilting the 
flask. The waste medium was disposed in Virkon. Remaining parasite blood was mixed 
thoroughly. A drop was placed and smeared on a microscope slide to check the parasitaemia. 
After parasitaemia was estimated as mentioned (below), parasitized blood was diluted with 
fresh blood to give approximately 0.5 to 1% parasitaemia at 50% haematocrit. Culture was 
maintained in 10 ml or 30 ml culture flasks. 
 
1 ml of 50% haematocrit parasite blood was transferred to 10 ml culture flask and 9 ml of 
complete media was added to bring the haematocrit to 5%. For a 30 ml culture flask 3 ml of 
parasite blood was added to 27 ml of complete media bringing 5% haematocrit. The flask was 
gassed with a 5% CO2, 5% O2 and 90% N2 gas mixture (BOC Limited, UK) while creating 
small ripples on the surface of culture medium for about 15 seconds and then placed in the 
incubator at 37℃.  
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2.7 Estimating parasitemia through blood film: 
 
A drop of parasitized blood from the culture was taken on a microscope slide and a thin 
smear was prepared. After air drying the slide, it was fixed with 100% methanol. The slide 
was again left to air dry and then stained with Giemsa prepared by diluting Gurr’s Giemsa 
solution (BDH/VWR international limited, UK) in the ratio 1:10 in Sorensen buffer (BDH 
laboratory supplies, England). The slide was left in Giemsa stain for 20-30 minutes and then 
rinsed gently under tap water. It was left to air dry. The slide was viewed in Leica DM 500 
compound microscope at 100x magnification under oil immersion to determine the degree 
and stage of parasitaemia. 
 
 
 
Figure 2.7.1: Microscopic view of RBCs infected with Plasmodium falciparum in trophozoite stage. Parasites 
were stained with Giemsa. 
 
  
 
Figure 2.7.2: Microscopic view of RBCs infected with Plasmodium falciparum in ring stage. Parasites were 
stained with Giemsa. 
55 
 
Parasitaemia was calculated by counting the total number of RBCs in a field and total number 
of infected RBCs in that particular field. The step was repeated for 5 different fields selected 
randomly and average was taken. 
 
Parasitaemia was estimated using the following formula: 
 
                                              Average infected RBC x100 
          Parasitaemia =          ------------------------------------------------  
                                                          Average total RBCs   
 
2.8 Synchronization of P. falciparum culture: 
 
Different stages are observed in the asexual life cycle of malaria parasite: merozoites, ring-
stages, trophozoites and schizont stages. In natural hosts the parasite maintains synchronous 
development, but synchrony is lost quite rapidly in in-vitro cultures. Larger parasites in 
trophozoites and schizont stages are destroyed by sorbitol and so treatment with sorbitol is 
used to maintain tight synchrony. 1 ml of parasitized blood pellet was treated with 9 ml of 5% 
sorbitol (prepared in distilled water and filtered using 0.22 mm porosity millipore filter). 
After mixing gently, it was allowed to remain at room temperature for 5 minutes and 
centrifuged at 3000 rpm for 5 minutes. Supernatant was discarded, and complete media was 
used to wash the pellet 3 times after which an equal volume of complete media was added to 
the pellet to bring haematocrit at 50%. The freshly prepared RBCs were used to set up new 
culture. 
 
2.9 Drug treatment of P. falciparum K1 Strain: 
 
Drug stock solutions were prepared in DMSO unless otherwise stated for a particular 
compound. A serial dilution of the working solution was made using complete media. 
Parasite culture used for the experiment was diluted to approximately 0.5% to 1% for 72 
hours or 48 hours experiment, respectively. Haematocrit was maintained at 5%. 100 µl of 
drug solution in serial dilution was added in the black bottom 96 well plate (Nunc, Denmark). 
100 µl of the parasite blood was then added to these wells bringing the haematocrit to 2.5%. 
Control wells contained 100 µl of complete media and 100 µl of parasite blood. The plate 
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was kept in an airtight jar sterilised with 70% ethanol. It was gassed with 5% CO₂, 5% O₂ and 
90% N₂ gas mixture for 2½ minutes. The jar was closed and incubated for 48 or 72 hours at 
37℃.  
 
2.10 Staining sample with SYBR green for microtitre plate assay: 
 
SYBR green 1 (nucleic acid gel stain 10,000 x, Sigma, UK) staining solution (5 x SG in wash 
media or PBS) working solution was prepared by using following formula: 
 
 3.3 x (total volume of solution need for experiment in ml) 
                      ---------------------------------------   
                                        10000  
 
(150 µl of SYBR green 1 working solution was needed per well, so the total volume required 
is calculated by multiplying 150 µl by number of wells used in the experiment) 
 
Following the incubation period for the experiment, 150 µl of complete media was removed 
from each well and 150 µl SYBR green l working solution was added to these wells. Each 
well sample was mixed gently by pipetting up and down, the plate was covered with 
aluminium foil and left to incubate for 40 minutes. The experiment was read using a GENius 
plate reader (Tecan) with excitation and emission measured at 485 nm and 535 nm, 
respectively. 
 
2.11 Using the GENius Tecan plate reader: 
 
The computer and the plate reader were switched on. Plate reader software was selected. The 
correct plate (Nunc 96) was selected and the reading parameters were set to fluorescence with 
excitation and emission set as 485 nm and 535 nm, respectively. Plate was read from the top. 
 
2.12 Staining sample with SYBR green 1 for flow-cytometry: 
 
After the incubation period was over, 50 µl from the control and drug treated wells on a 96 
well plate used in drug efficacy experiments were transferred to a microcentrifuge tube. Both 
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infected and non-infected blood samples were washed once with PBS. After removing the 
supernatant, 1 ml of 5 x SYBR green 1 solution  (in PBS) was added to each sample 
(prepared by adding 5 µl of 10,000 x SG to 10 ml PBS). Incubation was done in the dark at 
room temperature for 20 minutes. 
 
2.13 Fixing the sample for flow-cytometry: 
 
After staining, the samples were centrifuged for 1 minute at 14,000 rpm and the supernatant 
was discarded. Samples were re-suspended in 250 µl of 0.37% formaldehyde fixation 
solution which was prepared by diluting 36.5% formaldehyde (Sigma, UK) with PBS to a 
final concentration of 0.37%. The samples were placed in the fridge and incubated at 4℃ for 
15 minutes. Samples were centrifuged as above and supernatant was discarded. 1 ml of PBS 
was used to wash the samples 3 times and analysis was done using the GENius plate reader 
(Tecan) or the FITC channel of the BD FACsVerse flow cytometer system. 
  
2.14 Using the BD FACs Verse flow-cytometer 
 
2.14.1 Setup and Performance QC 
 
BD FACs Verse flow-cytometer was turned on and left for 20 minutes for warming up. Green 
light indicated the machine was ready to use, amber- it was warming up, while red- signified 
problem. After assuring there was good connection between the computer and the machine 
(indicated by a green light on the software programme at the bottom left of the computer 
screen), cytometer setup and tracking (CST) with the CST Beads was performed by clicking 
‘Setup & QC’. To run performance QC, 2 drops of CST bead was added to 0.5 ml sheath 
fluid. Performance QC was selected from the drop down menu next to ‘task’ and the number 
entered was matched to that on the CST bead stock vial used. Tube containing diluted CST 
beads was put on the machine when prompted and instructions were followed. 
 
2.14.2 Running samples on the FACs machine 
 
New experiment was created, and each tube was read. The axis on the default graph was 
changed by right clicking and selecting a different axis label. ‘PMTV’ was used to alter axis 
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voltage. Gates were added by selecting the required shape from the toolbar (Figure 2.14.1). 
The number of events acquired was altered by right clicking on the tube, selecting properties 
and then acquisition. For this study, the required number of events required to read the 
samples was selected as 50,000. Once the samples were read, FACs daily clean was 
performed using 3 ml of de-ionised water and 2 ml of FACs clean in separate tubes.  
 
 
Figure 2.14.1 Flow-cytometer graph showing two populations of RBCs measured on the FITC-A channel. P1 is 
the population of non-infected RBCs and P2 is the population of Plasmodium falciparum infected RBCs.  
 
2.15 Optimisation for medium used to read the experiments: 
 
Optimisation was performed to determine the best medium for washing and diluting the 
samples for reading the experiments through plate-reader. Phosphate Buffer Solution (PBS) 
or RPMI 1640 containing HEPES and L-glutamine were evaluated. Complete medium RPMI 
1640 contains albumax which could interfere with the detection of signal due to its inherent 
fluorescence and hence was not considered for the optimisation experiment.  
 
Two sets (Set A and Set B) of three samples each of P. falciparum blood cultures were 
prepared by 2 fold serial dilution such that if parasitaemia was considered to be 100% in 
sample 1, parasitaemia would be 50% in sample 2 and 25% in sample 3, as shown in Table 
2.15.1. 
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2.15.1 Estimation of parasitaemia through microscopy: 
 
Slides were prepared from each sample and viewed under the light microscope as per the 
methods mentioned in Chapter 2, section 2.7. Parasitaemia in sample 1 was found to be 
1.72%, sample 2 was 0.81% and sample 3 was 0.39%. If percentage of parasitaemia was 
considered 100% in sample 1, based on calculating the parasitaemia through microscopy, 
parasitaemia in sample 2 was 47% and in sample 3 was 23%. 
 
 
 
 
Figure 2.15.1 Light microscopy view of red blood cells infected with P. falciparum trophozoites stained with 
Giemsa. 
 
2.15.2 Estimation of parasitaemia through plate-reader: 
 
All three samples in Set A were washed and diluted with PBS, whereas all three samples in 
Set B were washed and diluted with RPMI 1640. The samples were incubated for 40 minutes 
after staining with SYBR green. Post-incubation, the samples were read through plate-reader 
as per the methodology mentioned in Chapter 2. The experiments were read at Gain 60, Gain 
70 and Gain 80 to determine the best setting for reading the experiment. Percentage of 
parasitaemia was determined. It was observed in Set A (PBS as wash medium), if 
parasitaemia was considered to be 100% in sample 1, parasitaemia in samples 2 and 3 were 
found to be 50% and 29% respectively in Gain 60, 49% and 28% respectively in Gain 70 and 
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50% and 29% respectively in Gain 80. In Set B (RPMI 1640 as the wash medium), if 
parasitaemia was considered to be 100% in sample 1, parasitaemia in samples 2 and 3 were 
found to be 54% and 0% respectively in Gain 60, 57% and 0% respectively in Gain 70 and 
54% and 0% respectively in Gain 80. Results are shown below in Table 2.15.1 
 
Table 2.15.1 Determination of percentage of parasitaemia 
 
P. falciparum 
culture 
Percentage of 
parasitaemia 
through 
microscopy 
% Parasitemia in Set A % Parasitemia in Set B 
Gain 60 Gain 70 Gain 80 Gain 60 Gain 70 Gain 80 
                
Sample 1 
(1.72%) 100 100 100 100 100 100 100 
Sample 2 
(0.81%) 47 50 49 50 54 57 54 
Sample 3 
(0.39%) 23 29 28 29 0 0 0 
 
The serial dilution of infected blood starting at 1.72 % to 0.39% parasitaemia was analysed using the SYBR 
Green MicroPlate assay at Gain 60, 70 and 80. Comparisons were made between parasite infected blood 
samples diluted in either PBS (Set A) or RPMI 1640 (Set B). 
 
No difference was observed Gain 60, Gain 70 and Gain 80 measuring the parasitaemia in 
both sets. It was observed, whilst there was not much difference between PBS and RPMI 
1640 in measuring parasitaemia at higher percentages, but the plate-reader was unable to 
detect signals in samples washed with RPMI 1640 at parasitaemia lower than 0.25%.  
 
PBS was found to be a good medium to wash and dilute the culture samples for the purpose 
of reading the experiments through plate-reader. 
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2.16 Calculation of IC50 values: 
 
Values obtained from all dose response data sets were transferred into Microsoft excel from 
respective software programmes. The infected blood controls were set at 100% and 
percentage parasitaemia was calculated for drug treated samples relative to the infected 
control. For IC50, Graphpad prism 5.0 was used to further process the data. The largest value 
in the data set was set to correspond to 100% and the smallest value to 0% by normalising the 
data. IC50 values were calculated using nonlinear regression (Graphpad prism 5.0) by using 
log-transformed drug concentrations plotted against the dose response. The log(inhibitor) vs. 
normalised response-variable slope option was used for IC50 calculation. 
 
2.17 Synthesis of dehydroemetine: 
 
The synthesis process was outsourced to Chiroblock GMBH, Germany. Isomers of 
dehydroemetine were synthesised by differential substitution on the four aryl oxygen as per 
the established literature (Scheme 1, Brossi 1967, Patent No. 3,311633 [16]). Derivatives 
were validated using NMR, HPLC and FTIR. In the 1950’s and 1960’s, the chemistry of 2-
dehydroemetine 13 was published, mostly in German, in a number of patents and applications 
by chemists at Hoffmann-La Roche. However, in most cases no conventional analytics, like 
1
H-NMR spectra or MS, were presented. Therefore, it was decided to reproduce the synthesis 
with slight modifications to get the authentic specimen of 2-dehydroemetine 13 claimed in 
the patents (Figure 2.17.1). 
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Figure 2.17.1 Schematic representation of the steps involved in the synthesis of 2-dehydroemetine (13) and its 
diastereomer (14). 
 
The two compounds synthesised were (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine. The methodology for synthesis of is mentioned in Appendix I. 
 
 
  Figure 2.17.2: Chemical structure of (-)-R,S-dehydroemetine 
 
 
(S)-2-((R)-6,7-Dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-
ylmethyl)-3-ethyl-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-
pyrido[2,1-a]isoquinoline * dihydrobromide 
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Figure 2.17.3: Chemical structure of (-)-S,S-dehydroisoemetine 
 
2.18 Drug interaction analysis for (-)-R,S-dehydroemetine: 
 
Preparation of the primary stock solutions was done as mentioned above. For experimental 
set up a dose range of 0.125–8 x the IC50 was made by a two-fold serial dilution for each 
compound tested. The compounds were co-administered at each level and the parasites were 
treated at ring stage in a 96 well plate. They were incubated for 72 hours at 37ºC. For drug 
susceptibility, the plates were read using SYBR green plate reader method. CalcuSyn 
software (Biosoft) was used for analysing the data. The methodology for the experiment is 
explained in detail in Chapter 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(S)-2-((S)-6,7-Dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-
ylmethyl)-3-ethyl-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-
pyrido[2,1-a]isoquinoline * dihydrobromide 
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Chapter 3 Molecular modelling of emetine and dehydroemetine 
 
3.1 Introduction: 
 
Drug discovery depends on testing compounds on cultured cells or animals in a trial and error 
method to determine if a compound could be a potential treatment (Ginsburg and McCarthy, 
2001) (Boran and Iyengar, 2010). In contrast to this, knowledge of a biological target could 
also be used to identify or invent new drugs. This process is called rational drug design 
(Stocks, 2013) (Takenaka, 2001). This requires a biological target molecule whose 
modulation or mutation is associated with the disease process and has the capacity to interact 
with a small molecule (druggability) which would result in the modulation of the target 
biomolecule (Yuan et al., 2013). It is more appropriate to call it a process for ‘ligand design’ 
as once a compound is identified to have a good binding affinity to a target, its half-life in the 
body, absorption and excretion profile, and side-effects determine if the ligand could be 
optimised as a drug to be safely and efficaciously used for treatment (White et al., 2004) 
(Tollenaere, 1996). In-vitro experiments to determine the ADMET profiles together with 
computational modelling techniques are frequently used to determine the physiochemical 
properties of a ligand in drug design in a bid to minimize high attrition rates in the drug 
delivery pipelines (Merz Jr et al., 2010) (Waring et al., 2015) (Yu and Adedoyin, 2003). 
 
Computer-aided drug design could be ligand-based or structure-based (Merz Jr et al., 2010). 
Knowledge of molecules which bind to a particular target could help design a pharmacophore 
model which specifies certain characteristics a small molecule must have structurally, in 
order to bind to the target molecule in ligand-based drug design (Güner, 2000). On the other 
hand, structure-based drug design relies on NMR spectroscopy, X-ray crystallographic or a 
homology model three dimensional structure of a biological target molecule and screens a 
database of small molecules to selectively identify the ones which bind with high affinity and 
form a stable complex (Li et al., 1996) (Hillisch et al., 2004). Few examples of drugs 
discovered via computer-aided drug design are dorzolamide, a carbonic anhydrase inhibitor 
approved in 1995 (Greer et al., 1994) (Talele et al., 2010) (Song et al., 2009), imatinib which 
inhibits tyrosine kinase as a treatment for Philadelphia-chromosome positive leukemias 
(Capdeville et al., 2002) and raltegravir, which is an HIV integrase inhibitor (Mouscadet and 
Tchertanov, 2009). 
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Drug design could be aided by use of docking for rapid identification of a potential hit by 
scanning through large databases of compounds (Ekins et al., 2007). The potential lead could 
be optimised to design analogues which are more potent and selective (Rees et al., 2004). The 
orientation in which two molecules bind or interact with each other to make a stable complex 
could be predicted by docking (Lengauer and Rarey, 1996). Scoring functions could be used 
to analyse the orientation of the molecules with respect to each other and help in the 
prediction of binding affinity or the strength of association (Warren et al., 2006). Benefits of 
predicting inter-molecular interactions are immense. In the process of rational drug design, 
elucidation of biochemical processes and knowledge of the binding conformation of the 
target with a small molecule ligand in the binding site is important for structure-based drug 
design (Anderson, 2003). 
 
The analogy of a ‘hand in glove’ is a better fit than the century old ‘lock and key’ analogy by 
Fisher and Ehrlich (Dunker et al., 1998). In docking, the main approaches are ‘shape 
complementarity’ or ‘simulation’. The fast and robust shape complementarity methods could 
scan thousands of ligands in a very short span of time but are unable to accurately model the 
dynamic changes in the conformations of proteins or ligand (Grünberg et al., 2004) (Mukesh 
and Rakesh, 2011) (Forli et al., 2016). The method considers that a dockable or 
complementary set of features, such as molecular surfaces, are present between the protein 
and ligands and utilizes these features to predict if a ligand would bind to the active site of a 
protein (Goldman and Wipke, 2000) (Grant et al., 1996). ‘Simulation’ is a computationally 
expensive method to calculate the interaction energies between the ligand and the protein 
separated by some distance (Feig et al., 2004). Ligand flexibility is incorporated in this 
method and the ligand undergoes a number of moves to bind into the active site of the protein 
(Joseph‐McCarthy et al., 2003). Every move follows calculation of the total energy of the 
system as every move result in an energetic cost to the system (Tripathi and Misra, 2017) 
(Alonso et al., 2006)..  
 
For docking, a protein structure is used and ligand database could be used to retrieve ligands 
for docking (Irwin and Shoichet, 2005) (Nealon et al., 2017) (Wolber and Langer, 2005). A 
docking program relies on the search algorithm and scoring function (Perola et al., 2004) 
(Ferreira et al., 2015). It is not possible for search algorithms to exhaustively explore all the 
possible conformations of the protein relative to the ligand and so most docking programs 
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consider the ligand as flexible and the protein as a rigid structure (Sousa et al., 2006) 
(Claussen et al., 2001). Proteins being highly flexible large molecules, makes it challenging 
to model its conformation (Ciemny et al., 2018). Ignoring the flexibility of the receptor does 
lead to poor docking results in some instances (Cerqueira et al., 2009). A scoring function, 
which assesses the energy of the pose in relation to the binding site, is used to evaluate ligand 
poses and rank them based on how favourable a binding interaction they represent. A stable 
system has the minimum energy (Halperin et al., 2002).  
 
In this study, various docking approaches were used to replicate the predicted binding pose of 
emetine (Wong, et al, 2014) and model synthetic dehydroemetine diastereomers in the 
binding pocket. Alangiaceae, Icacinaceae, and Rubiaceae are the three plant families in 
which emetine and its analogues occur. Native to Brazil, Psychotria ipecacuanha also known 
as Cephaelis ipecacuanha, belonging to the family Rubiaceae is the major source. Emetine, 
the main active ingredient in ipecac syrup, has been widely used as an anti-parasitic drug and 
in phytomedicine in the past. Emetine exhibits antiviral, anti-parasitic, anticancer and 
contraceptive activities due to its ability to inhibit both ribosomal and mitochondrial protein 
synthesis. It is also known to cause the up-regulation and down-regulation of certain genes 
and to interfere with the synthesis and activities of DNA and RNA (Akinboye and Bakare, 
2011). Emetine and its derivatives have been tested in laboratories and have shown potent 
activity on prostate cancer, ovarian cancer, pancreatic cancer and a few other cancer cell lines 
(Akinboye et al., 2016) (Sun et al., 2015) (Han et al., 2014) (Uzor, 2016). Various small 
clinical trials were conducted to evaluate the potency and side-effects of emetine.  
 
Dehydroemetine, was first synthesised in Switzerland by Roche as an effective but less toxic 
derivative of emetine (1967). It is a synthetic emetine analogue and is a WHO recommended 
drug for use in metronidazole therapy failure in amoebiasis and giardiasis (Appendix II). It is 
irritant if taken orally but is less toxic than its parent compound emetine. It is assumed that 
like emetine, dehydroemetine also exerts its effects by inhibiting protein translation (Hellgren 
et al., 2014). It has been investigated for use in cutaneous amoebiasis (Magańa‐García and 
Arista‐Viveros, 1993), amoebic dysentery (Knight, 1980) (Rubidge et al., 1970), amoebic 
liver abscess (Nigam et al., 1985) (Peters et al., 1979), herpes zoster (Hernandez-Perez, 1980) 
(Glaser, 1983) and leishmania infection (Al-Khateeb et al., 1977) (Fouarge et al., 1989). 
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Emetine has been identified as a potent antimalarial and this chapter focuses on modelling the 
two diastereomers of dehydroemetine on the emetine binding site on the published cryo-EM 
structure (3J7A). 
 
3.2 Methods: 
 
3.2.1 Generation of emetine, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine 
structures: 
 
The cryo-EM structure of P. falciparum 80S ribosome bound to emetine dihydrochloride was 
obtained from the Protein Data Bank (PDB code 3J7A) (Wong et al., 2014) to predict the 
bound position of emetine and its synthetic analogues. Emetine structure was extracted from 
3J7A and analysed. The emetine conformer was also generated from the software package 
Molecular Operating Environment (MOE). Subsequently, MOE was used to construct the 
emetine derivatives (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine (MOE, 2016). 
Crystallographic water molecules were removed, and hydrogens were assigned. PyRx, 
Autodock vina and MOE-Dock were used to perform docking of ligands to the Pf40S 
subunit. The cryo-EM ligand location was used to define the binding site region. Internal 
flexibility was allowed for ligands but not the ribosome and poses were scored automatically 
by the software’s scoring system. 
 
3.2.2 Autodock vina for docking: 
 
Autodock tools is a software used to prepare the receptor (ribosome) and ligands for docking. 
Significant improvement in the accuracy of the binding mode predictions of autodock vina 
and about two orders of magnitude speed-up has been observed in comparison with the 
molecular docking software AutoDock 4. Autodock vina calculates the grid maps 
automatically and the results are clustered in a way that is transparent to the user (Trott and 
Olson, 2010). Autodock vina tutorials were followed to perform docking (Trott and Olson, 
2010). Ribosome receptor was protonated with polar hydrogens and saved as .pdbqt file. 
Similarly, the ligand was also prepared and saved as .pdbqt file by adding polar hydrogens, 
selecting the number of rotatable bonds and assigning torsion value. For the search space, 
grid was centred on the ligand. Configuration text file was prepared with the grid parameters. 
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The receptor, ligand and configuration files were saved in the autodock vina path and the 
programme was run using command prompt. The vina output results were viewed using 
PyMol and Discovery Studio.  
 
 
 
 
Figure 3.2.1: Methodology for performing receptor-ligand docking through Autodock vina. 
 
3.3 Results: 
 
3.3.1 Structure analysis of 3J7A cryo-EM structure of emetine bound to 40S subunit 
of 80S ribosome: 
 
The availability of a high resolution cryo-EM structure of Plasmodium falciparum 80S 
ribosome bound to emetine (Wong et al., 2014) has given rise to the possibility of structure 
based changes to further modify the drug. This study aims to use molecular modelling as a 
tool for lead optimisation of synthetic analogues of emetine dihydrochloride to identify 
molecules with similar potency as emetine but potentially reduced side effects. The study 
began by analysing the bound position of emetine in 3J7A cryo-EM structure. 
  
The Cryo-EM structure of P. falciparum 80S ribosome 3J7A has a resolution of 3.2A. The 
pdb structure file does not mention the overall anisotropic B-factor value. B-factor of less 
Download 
•Download PDB file from protein data bank 
•Remove water molecules and ligand. Save ligand as pdb (Discovery Studio) 
•Download SDF of ligand from Pubchem and convert to pdb through PyMol 
Preparation 
•Autodock tools to prepare the protein and ligand for docking.  
•Add polar hydrogen and save as .pdbqt 
•Prepare grid centred on the ligand 
•Open ligand through ADT, choose torsion, rotatable bonds and save as .pdbqt 
Docking 
•Command prompt to run Autodock vina 
•View the results through PyMol 
•Binding site and residues viewed through Discovery Studio 
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than 60 is usually indicative of good temperature stability but the b-factor map of the 
ribosome structure in MOE displayed poor resolution as shown in Figure 3.3.1 – Figure 3.3.3. 
 
 
 
Figure 3.3.1 B-factor map of 40S subunit of 80S ribosome in 3J7A cryo-EM structure. B-factor value > 60 (red 
map) is indicative of poor temperature stability. 
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Figure 3.3.2 B-factor map of the binding pocket on 40S subunit of 80S ribosome in 3J7A cryo-EM structure. 
Emetine is seen in the pocket in a U-shaped conformation. B-factor value > 60 (red map) is indicative of poor 
temperature stability. 
 
  
 
Figure 3.3.3: Settings in MOE depicting the colour code for B-factor map. 
B-factor value > 60 (red map) is indicative of poor temperature stability. 
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3.3.2 Structure of emetine in 3J7A cryo-EM model of emetime bound P. falciparum 
80S ribosome: 
 
Chemical degradation experiments were conducted in the past to elucidate the chemical 
structure and stereochemistry of emetine. Structure activity relationship studies showed 
(Grollman, 1966) that C-1´ must have the R configuration and the 2´ position must be a 
secondary amine for emetine to be biologically active. The S configuration at C-1´ as seen in 
‘isoemetine’ makes the compound inactive. 
 
Emetine was extracted from the cryo-EM structure through Discovery Studio and the 
structure was analysed for its stereochemistry using Molecular Operating Environment 
(MOE). It was found that the emetine in the cryo-EM structure in 3J7A (Wong et al., 2014) 
has incorrect chirality (Figure 3.3.2.3). For comparison, emetine structure was downloaded 
from pubchem (Figure 3.3.2.2) and referenced with the published emetine structure (Figure 
3.3.2.1) (S Akinboye and Bakare, 2011). It was found that in 3J7A (Wong et al., 2014), not 
only the important chiral centre at C-1´ had S configuration instead of R configuration but the 
other 2 chiral centres in the cryo-EM emetine structure are also incorrect as shown Figure 
3.3.4 – Figure 3.3.10.  
   
 
Figure 3.3.4: Emetine structure adapted from (Akinboye and Bakare, 2011) showing R configuration at C-1
’ 
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Figure 3.3.5: Pubchem (database of chemical molecules) emetine structure showing R configuration at C-1
’ 
 
 
   
 
Figure 3.3.6: Emetine structure in 3J7A pdb structure file published by Wong et al, 2014 showing S 
configuration at C-1
’
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Figure 3.3.7: Emetine structure in 3J7A pdb structure file in the electron density map published by Wong et al, 
2014 showing R configuration at C-1
’
 
 
 
 
Figure 3.3.8 S-configuration at the C1 chiral centre of emetine in 3J7A cryo-EM model (highlighted on the 
toolbox on the left). Natural emetine has a R-configuration. 
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Figure 3.3.9 R-configuration at the second chiral centre of emetine in 3J7A cryo-EM model (highlighted on the 
toolbox on the left). Natural emetine has a S-configuration. 
 
 
 
Figure 3.3.10 R-configuration at the third chiral centre of emetine in 3J7A cryo-EM model (highlighted on the 
toolbox on the left). Natural emetine has a S-configuration. 
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3.3.3 Docking of emetine and dehydroemetine 
 
Dehydroemetine, a synthetic analogue of emetine hydrochloride has been claimed to have 
less cardio-toxic effects than emetine. Dehydroemetine can exist in R and S isomeric forms, 
which are diastereomers of each other. Being an analogue of emetine, it is likely that 
dehydroemetine also binds to the emetine binding site on 40S subunit of the 80S ribosome. 
To test the hypothesis, docking was performed on the 80S ribosome (3J7A) with emetine, (-)-
R,S-dehydroemetine and (-)-S,S-dehydroisoemetine. 
 
The PDB file of P. falciparum 80S ribosome bound to emetine dihydrochloride (3J7A) was 
downloaded from protein databank and the program Discovery Studio was used to remove 
any solvents in the structure. The structure was saved in the .pdb format. The ribosome was 
then separated from the bound ligand emetine. Both the receptor and the ligand were saved 
separately as .pdb files. The 3D drug structure of emetine was also downloaded from the 
Pubchem database due to the incorrect chirality of emetine molecule in 3J7A. Structures of (-
)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine were drawn using MOE software 
(Figure 3.3.11). The receptor was treated as rigid and the ligands as flexible molecules. 
 
 
Figure 3.3.11: From left to right, 3D structures of emetine dihydrochloride, (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine drawn using MOE software. 
 
Various docking programs were used to perform the docking of emetine, (-)-R,S-
dehydroemetine and (-)-S,S-dehydroisoemetine. 
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3.3.4 PyRx for molecular modelling: 
 
A virtual screening software for computational drug discovery known as PyRx was used to 
perform receptor-ligand (Dallakyan and Olson, 2015). PyRx has a plugin for autodock vina 
which enables it to perform the docking. It provides support to the users and guides them 
through every step of this process - from data preparation to job submission and analysis of 
the results. In this study the free version of PyRx was used. 
 
The pdb structures of the ribosome receptor and emetine molecule were uploaded on PyRx 
and the search grid was selected around the emetine binding site (Figure 3.3.12. and Figure 
3.3.13). Docking was performed through the autodock vina plugin to check if the emetine 
binding site could be replicated through PyRx. Many docking runs were performed but PyRx 
was unable to replicate the binding conformation of emetine as predicted in 3J7A.  
 
 
 
Figure 3.3.12: Emetine bound 3J7A pdb structure of 80S ribosome as observed in PyRx. Emetine is depicted in 
sky blue colour in the binding pocket. 
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Figure 3.3.13: Grid map with grid parameters around the emetine binding site. 
 
The binding site predicted by PyRx did not overlap with the 3J7A published binding site 
Figure 3.3.14. So, it was decided to not go ahead with PyRx for the docking of 
dehydroemetine. 
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Figure 3.3.14: Difference in the binding site predicted by PyRx and published literature.  
(A). The molecule in blue is the binding site predicted by Wong et al, 2014. As seen in the above images, PyRx 
was unable to accurately locate the emetine binding site. No superimposition of the binding poses from PyRx 
with the published pose in 3J7A (B). 
 
3.3.5 Receptor-ligand docking: 
 
The PDB file (3J7A) of 40S subunit of 80S Ribosome of P. falciparum bound to emetine was 
downloaded from the Protein databank. The file was opened in Discovery studio and the 
solvent water molecules were removed. The structure was saved in .pdb format. The 
A 
B 
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ribosome was then separated from the bound ligand (emetine) and both the ribosome and 
emetine molecule were saved in .pdb format (Figure 3.3.15 – Figure 3.3.17)  
 
 
                       
Figure 3.3.15: Emetine bound 40S subunit of 80S ribosome. The black outlined circle focuses on the binding 
pocket. Emetine is visualised in the binding site. 
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Figure 3.3.16: Focused view of emetine binding site on 40S subunit of 80S ribosome published in the cryo-EM 
structure 3J7A. 
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Figure 3.3.17 View of 3J7A 40S subunit of 80S ribosome after the removal of the bound ligand, emetine. Black 
outlined circle focuses on the binding pocket. Emetine is absent from the binding site.  
 
3D structures of emetine dihydrochloride hydrate was downloaded from pubchem. Structure 
of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine were drawn using MOE. Autodock 
tools was used to prepare the receptor and ligand molecules, and docking was performed for 
all ligand molecules following the steps outlined in methodology. 
 
Polar hydrogens were added to the ribosome and parameters were specified to prepare the 
grid and configuration file, respectively. Multiple unbound magnesium atoms were observed, 
and the software was directed to go ahead and add the hydrogens. In a bid to replicate the 
binding conformation in 3J7A, emetine from cryo-EM structure, emetine from pubchem, and 
(-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine were docked on the 40S subunit of the 
80S ribosome using the same grid parameters keeping the x, y and z dimension of the grid 
box at 30 units. Figure 3.3.18 – Figure 3.3.20, depict the process in step by step manner.   
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Autodock vina was unable to reproduce the binding pose published by Wong et al, 2014. The 
docking results for the two emetine structures (cryo-EM and pubchem) were similar. 
Autodock vina output result for emetine and the binding site residues are also shown in 
Figure 3.3.21 and Figure 3.3.22. 
 
 
 
Figure 3.3.18 Autodock vina prompt to indicate presence of unbound magnesium ions prior to receptor 
preparation for docking. 40S subunit of 80S ribosome is visualised in the background in the working space 
window of Autodock Tools software. 
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Figure 3.3.19: Specifications of the grid map selected on 3J7A through Autodock tools. The x, y and z 
dimensions were set at 30ºA. 40S subunit of 80S ribosome is visualised in the working space window of 
Autodock Tools software. 
 
     
     
Figure 3.3.20: Specifications of the configuration text file for performing docking through Autodock vina. It 
specifies the grid dimensions and identifies the receptor and ligand input files for docking  
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Figure 3.3.21 Autodock vina results showing the top 9 binding poses for emetine obtained from pubchem on 
40S subunit of 80S ribosome structure obtained from protein data bank (3J7A). 
         
 
     
 
Figure 3.3.22: Binding site residues for emetine obtained from pubchem on 40S subunit of 80S ribosome 
structure obtained from protein data bank (3J7A). 
 
 
 
85 
 
Docking was first performed with grid space of 30ºA. Since autodock vina was unable to 
reproduce the published binding pose, the grid space was reduced to 20ºA and then further 
again to 15ºA to limit the number of conformations away from the binding pocket residues. 
Reducing the grid dimensions to 15ºA, autodock vina was able to produce a bent U-shaped 
conformation for emetine and dehydroemetine but it was not completely superimposable on 
the conformation predicted in 3J7A (Wong et al, 2014). Figures 3.3.23 – 3.3.30 show the 
various conformations observed by limiting the grid space for emetine from 3J7A cryo-EM 
model, emetine structure from pubchem, (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine. 
 
   
Figure 3.3.23 Superimposition of autodock vina top pose for emetine (cyan) from cryo-EM model 3J7A with x, 
y and z grid dimensions set at 30ºA with the published U-shaped pose of emetine (green) (A). Discovery studio 
was used to view the binding site residues (B). 
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Figure 3.3.24 (A) Superimposition of autodock vina top pose for emetine from cryo-EM model 3J7A (cyan) 
with x, y and z grid dimensions set at 20ºA with the published U-shaped pose of emetine (green). (B) Autodock 
vina top pose for emetine from cryo-EM model 3J7A with x, y and z grid dimensions set at 15ºA.  
 
 
 
 
Figure 3.3.25 Superimposition of autodock vina top pose for emetine obtained from pubchem (cyan) with x, y 
and z grid dimensions set at 30ºA with the published U-shaped pose of emetine (green). (A) Discovery studio 
was used to view the binding site residues (B). 
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Figure 3.3.26 (A) Superimposition of autodock vina top pose for emetine obtained from pubchem (cyan) with x, 
y and z grid dimensions set at 20ºA with the published U-shaped pose of emetine (green). (B) Autodock vina 
top pose for emetine obtained from pubchem with x, y and z grid dimensions set at 15ºA. 
 
 
 
    
 
Figure 3.3.27 Superimposition of autodock vina top pose for (-)-R,S-dehydroemetine (cyan) with x, y and z grid 
dimensions set at 30ºA with the published U-shaped pose of emetine (green) (A). Discovery studio was used to 
view the binding site residues (B). 
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Figure 3.3.28 (A) Superimposition of autodock vina top pose for (-)-R,S-dehydroemetine (cyan) with x, y and z 
grid dimensions set at 20ºA with the published U-shaped pose of emetine (green). (B) Autodock vina top pose 
for (-)-R,S-dehydroemetine with x, y and z grid dimensions set at 15ºA. 
 
 
 
 
 
Figure 3.3.29 Superimposition of autodock vina top pose for (-)-S,S-dehydroisoemetine (cyan) with x, y and z 
grid dimensions set at 30ºA with the published U-shaped pose of emetine (green) (A). Discovery studio was 
used to view the binding site residues (B). 
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Figure 3.3.30 (A) Superimposition of autodock vina top pose for (-)-S,S-dehydroisoemetine (cyan) with x, y 
and z grid dimensions set at 20ºA with the published U-shaped pose of emetine (green). (B) Autodock vina top 
pose for S dehydremetine with x, y and z grid dimensions set at 15ºA. 
 
The top poses obtained of emetine from 3J7A and emetine from pubchem, with the grid 
dimension 30ºA were superimposed on each other (Figure 3.3.31). They were found to 
completely superimpose indicating the two structures were treated similarly even though they 
differed in chirality but neither pose was similar to the published pose in 3J7A. 
 
 
 
Figure 3.3.31 Superimposition of top poses obtained for emetine from 3J7A (pink) and emetine from pubchem 
(blue), with the grid dimension 30ºA. The two molecules differ in chirality. 
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3.3.6 Docking through MOE: 
 
Due to incorrect chirality, non-natural enantiomer of emetine, (1S,2R,3S,11bR)-emetine was 
not used to perform docking through MOE. Emetine, i.e. the (1R,2S,3R,11bS) structure, was 
docked into the identified Pf40S binding site using MOE-Dock (Chemical Computing Group, 
2016.). Docking was repeated with MOE and none of the resulting poses of the two emetine 
structures matched that of the published literature (Figure 3.3.33 and Figure 3.3.34).  
 
 
 
Figure 3.3.32 View of emetine binding site amino acid residues, in 3J7A cryo-EM structure of 40S subunit of 
80S ribosome, as observed through MOE software. 
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Figure 3.3.33 View of docked emetine and the binding site amino acid residues after performing docking 
through MOE software. 
 
On closer inspection, it was observed that a magnesium ion close to the binding pocket was 
affecting the docking results, probably by pulling the ligand towards it. The magnesium ion 
was thus deleted from the ribosome receptor structure and docking was performed again with 
both Autodock vina and MOE. Figure 3.3.35 and Figure 3.3.36 depict the position of 
magnesium ion close to the binding pocket. 
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Figure 3.3.34: View of magnesium ion within 13.5ºA of the binding pocket. Emetine is shown in green. 
Structure visualised through MOE software. 
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Figure 3.3.35: View of magnesium ion in the binding pocket. 
Magnesium ion exerting a pull towards the ligand. Molecule in green is emetine from cryo-EM structure and the 
molecule in pink is emetine obtained from Pubchem. Structure visualised through MOE software. 
 
After the removal of magnesium ion docking was performed once again with autodock vina 
and MOE. Autodock vina was still unable to reproduce the binding pose for Emetine. MOE, 
on the other hand, was able to reproduce the binding pose with good superimposition to that 
predicted by published literature. The docked emetine geometry mapped well into the 
electron density envelope (shown at a contour level 0.1542e/A^3 (3.50rmsd) in Figure 3.3.37 
A; the bound pose broadly follows the twisted U-shape conformation of the observed electron 
density, resembling some aspects of the previously modelled non-natural emetine enantiomer 
geometry (Figure 3.3.37 B).  
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Figure 3.3.36 (A) Overlay of docked pose of emetine (green) with its enantiomer present in the cryo-EM 
structure (maroon); observed electron density envelope is also shown (wireframe surface with contour level 
0.1542e/A^3 (3.50rmsd)); (B) Interactions of docked emetine (green) with Pf40S residues and comparison with 
previously modelled interactions of its enantiomer (maroon) (Wong et al., 2014) 
 
 
A 
B 
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In this U-shape, an intermolecular T-shaped -stacking interaction was observed between the 
two cyclic systems of emetine, ie. benzo[a]quinolizine rings A/B/C and isoquinoline rings 
D/E. The docked emetine also forges a number of comparable interactions with the Pf40S 
subunit as its modelled enantiomer, with a key -stacking interaction between the A/B/C 
rings of emetine with the purine ring of Gua973 of h23 (Wong et al., 2014). The location of 
the emetine secondary and tertiary amines are broadly similar (within 1 - 2 Å), allowing 
hydrogen bonding interactions with a backbone oxygen atom of Ura2061 (h45) and the 2’-
hydroxyl group of Ura1068 (h24) respectively (Figure 3.3.38 B). The tertiary amine also 
forms a salt bridge interaction with the carboxylate side chain of C-terminal residue Leu151 
of uS11 (Figure 3.3.38 B). This interaction was not highlighted in the cryo-EM study and is a 
consequence of modelling into the E-site the natural emetine geometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
96 
 
    
 
 
 
Figure 3.3.37 Overlay of docked poses. 
(A) Overlay of docked poses of (-)-R,S-dehydroemetine (red) and (-)-S,S-dehydroisoemetine (cyan) with 
emetine (blue). (B) Interactions of (-)-R,S-dehydroemetine (red) and (-)-S,S-dehydroisoemetine (cyan) with the 
Pf40S binding site. Distances (dotted lines) in Å. 
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Figure 3.3.38 Binding site residues for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine.  
(A) Docking through MOE showing the amino acid binding site residues for (-)-R,S-dehydroemetine molecule. 
(B) Docking through MOE showing the amino acid binding site residues for (-)-S,S-dehydroisoemetine 
molecule. 
 
A 
B 
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Subsequently, the two diastereomers of emetine, (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine, were docked in turn into the emetine-binding region of the Pf40S 
subunit. It was found that the preferred docked pose of the (-)-R,S-dehydroemetine adopts the 
familiar U-shaped conformation, superimposing rather closely onto the bound pose of 
emetine (Figure 3.3.38 A). The docking scores were correspondingly similar for emetine, 
with a London dG value of -7.2 kcal/mol, and (-)-R,S-dehydroemetine, which has a dG score 
of -7.3 kcal/mol. As observed for emetine, the (-)-R,S-dehydroemetine forms the  
stacking interaction with the Gua973 pyrimidine ring and polar interactions with Ura2061, 
Ura1068 and Leu151 (Figure 3.3.38 B).  
 
However, (-)-S,S-dehydroisoemetine docks into the binding site with a lower dG score of -6.5 
kcal/mol and does not overlay in conformation so readily with emetine or the (-)-R,S-
dehydroemetine. The particular stereochemical configuration of (-)-S,S-dehydroisoemetine 
appears to result in its secondary amine being more distant from the E-site residues of Pf40S. 
Consequently, this amine N…O Ura2061 distance extends by 0.8 Å in proceeding from R to 
S isomer. The tertiary amine interaction with Ura1068 is maintained, however, as is the 
interaction with the terminal carboxylate of Leu151 (Figure 3.3.38 B). The  stacking 
interaction with Gua973 is also present, but at a slightly larger distance between planes, 
increased by ~0.7 Å. Figure 3.3.39 (A) and (B) shows the predicted binding site residues for 
(-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine. 
 
3.4 Conclusion 
 
The study performed to replicate the binding conformation of emetine on 40S subunit of 80S 
ribosome shows the chirality of emetine molecule in the 3J7A cryo-EM model is incorrect 
and requires revision. Most docking software were unable to replicate the bound 
conformation of emetine. Poor resolution of ribosome and presence of magnesium ion in the 
vicinity of the binding pocket is another factor which complicates the docking. MOE was 
able to replicate the U-shaped binding conformation and predicted a better fit for (-)-R,S-
dehydroemetine in comparison with (-)-S,S-dehydroisoemetine. The prediction of binding 
site interactions suggests potentially better activity for (-)-R,S-dehydroemetine amongst the 
two diastereomers.  
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Chapter 4 Lead optimisation and drug interaction analysis of 
dehydroemetine 
 
4.1 Introduction: 
 
In the course of drug discovery, through a meticulous selection process, only a handful of 
drugs, from countless potential candidate molecules become successful (Baek et al., 2015). 
Drug repositioning offers a solution to the dilemma by reducing the research and 
development timelines. The emergence and spread of drug resistance in Plasmodium 
falciparum has prompted a renewed call to develop new antimalarials. The Malaria research 
group at the University of Salford has identified the anti-amoebic drug emetine 
dihydrochloride as a potent antimalarial option with IC50 of 47 + 2.17 nM against the K1 
strain (Matthews et al., 2013). Emetine is not currently used as an antiprotozoal drug due to 
its emetic and cardiotoxic side effects. 
 
Until the mid-20
th
 century, emetine was widely used as a treatment for amoebic dysentery. 
First brought to Europe by Piso, emetine was introduced in large doses in 1858 in Mauritius 
by E. S. Docker and helped reduce the death rate from dysentery from 10-18% to 2% 
(Thompson, 1913). Emetine with oral chloroquine, niridazole and metronidazole were given 
to three groups of 20 patients each in a controlled clinical trial. It was observed that while 
metronidazole was unable to effectively treat seven patients and niridazole showed toxic side-
effects, emetine with oral chloroquine was able to effectively treat all but one patient (Datta 
et al., 1974). Emetine and its derivatives have been tested in laboratories and have shown 
potent activity on prostate cancer, bladder cancer, ovarian cancer, pancreatic cancer and a few 
other cancer cell lines (S Akinboye and Bakare, 2011) (Foreman et al., 2013) (Sun et al., 
2015) (Han et al., 2014). 
 
A synthetic analogue of emetine, dehydroemetine could be given intramuscularly or orally as 
resinate for slow release. It was synthesised by Roche and Glaxo (Mebadin) (1967). In the 
second edition of WHO model prescribing information: Drugs used in parasitic diseases, 
WHO recommends the use of a 1 ml ampoule of 60 mg of dehydroemetine to be given 
intramuscularly as one of the most effective treatment for amoebic dysentery or amoebic 
abscesses (Appendix II). It is an irritant if taken orally but is less toxic than its parent 
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compound emetine. It could be used as an alternative to metronidazole or other 5-
nitroimidazoles if there is an inadequate response to the treatment. The drug is usually 
administered not more than 60 mg/day (1mg/kg/day) for 4 to 6 days in a hospital setting and 
could be repeated after 6 weeks in severe cases or relapses. A supplementary treatment with 
chloroquine or diloxanide is also usually recommended. It should be avoided in patients with 
renal, cardiac or neuromuscular diseases due to side-effects. It is contra-indicated in 
pregnancy but could be given to the mother in life-threatening cases of amoebic dysentery 
(Goessling and Chung, 2002). Weakness, muscular pain, hypotension, purpuric rashes, 
tachycardia, inversion of T-wave, prolongation of QT interval and dysrhythmias could 
manifest as side-effects (Folb and Trounce, 1970). 
 
Oral dehydroemetine was used in a study of 24 patients with intestinal amoebiasis, given 
post-prandial for 10 days in a dose of 1 mg/kg/day. Dehydroemetine resulted in a cure rate of 
71% and symptomatic relief by 85% without any severe side-effects. Most patients tolerated 
it well and it was proposed to be a safe and potent drug for intestinal amoebiasis (Salem, 
1967). In another study of 144 patients, the effect of injectable dehydroemetine, slow release 
oral dehydroemetine and niridazole were observed in mild, moderate and severe cases of 
dysentery. Oral dehydroemetine was found to be a well-tolerated, safe and an effective 
treatment in all cases of dysentery in a dose of 1 to 1.5 mg/kg /day for 10 days 
(Wolfensberger, 1968). 
 
The preference of combinatorial regimes over monotherapy for the treatment of malaria has 
affected the drug discovery pipeline in a crucial way (Bell, 2005). More often than not, 
instead of developing two new drugs for combination therapy, newer drug candidates are 
tested for synergistic activities with existing anti-malarial treatments (Kremsner and Krishna, 
2004). Combination therapy not only helps in dose reduction and better therapeutic efficacy, 
it is also useful in delaying the emergence of resistance and widens the shelf-life of the 
existing cohort of drugs (Harasym et al., 2010). The drugs used in combinatorial regimes 
should ideally be free of major side-effects and have matching pharmacokinetics besides 
showing synergistic activity against drug resistant strains (Kremsner and Krishna, 2004). 
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Similar to emetine, dehydroemetine also has emetic and cardiotoxic side-effects and 
combinatorial partner drugs showing synergistic activity could potentially decrease the dose-
dependent toxicity profile of this potent compound (Chou, 2006). 
 
Bliss independence and Loewe additivity methods form the basis of most methods (Matthews 
et al., 2017). Bliss independence (fractional product method) is based on the assumption that 
each drug acts independently whereas Loewe additivity assumes that a drug cannot interact 
with itself (Yeh et al., 2009). Additivity is thus defined if the inhibition is constant along a 
line of equal effective dose and uses an isobole (a line of constant inhibition). Antagonism is 
defined by deviations above the line (convex) and synergism by deviations below the line 
(concave). Fractional Inhibitory Concentration (FIC) is based on the isobologram and sum of 
the FIC (∑FIC) value where 1 is additivity, <1 is synergism and >1 is antagonism.  
 
Drugs could exhibit synergy by interacting physically or with a target at the molecular level 
(Zimmermann et al., 2007). Lack of clear definition has resulted in many unsubstantiated 
claims of potential synergistic drug candidates. Chou and Talalay developed a method based 
on the argument that the issue of synergy is more physiochemical rather than statistical in 
nature and employed the mass-action law principle to derive a median-effect equation where 
additivity could be defined using the resulting combination index (CI = 1) with antagonism 
and synergism defined as >1 and <1 respectively. CalcuSyn and Compusyn are two software 
programmes based on the complex algorithms for median-effect analysis to allow automation 
and eliminate subjectivity during data analysis (Chou, 2010). The Chou-Talalay method 
incorporates a unified theory which takes into consideration four existing physiochemical 
equations namely; Michaelis-Menten (enzyme kinetics), Henderson-Hasselbalch (pH 
ionization), Hill (higher order ligand binding saturation), and Scatchard (receptor binding). 
 
The median-effect principle of Chou and Talalay were used to determine the drug 
interactions with the help of the isobologram and combination index method (CalcuSyn 
software, Biosoft: Chou, 2010). The median effect principle formula fa/fu = [D/Dm]
m
  used in 
CalcuSyn assesses drug-drug interactions where fa is the fraction of affected cells, fu= 1-fa, 
the unaffected fraction of cells, D equals the drug concentration, Dm the drug dose needed for 
50% inhibition, and m the slope of the median effect curve. A straight line joining the 
Fa points against the fixed ratio combinations of Drug 1 and Drug 2 on the x and y axes, 
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represents the isobologram graphically depicting the pharmacological interaction (Matthews 
et al., 2017).  
 
The pharmacological interactivity is quantitatively represented by the combination index (CI) 
which accounts for both the shape of the dose response curve and the potency (Dm, ED50). 
The following formula is used to derive the CI for the classic isobologram (CI = 1); CI = 
(D)1/(Dx)1 + (D)2(Dx)2 + (D)1(D)2/(Dx)1(Dx)2 where (DX)1 and (DX)2 are the concentrations 
for Drug 1 and Drug 2 resulting in X% inhibition when acting singly and (D)1 and (D)2 the 
concentrations of the respective drugs when acting in combination to achieve the same (iso-
effective) percentage inhibition (Reynolds and Maurer, 2005). The CalcuSyn software 
generates the CI over a range of fa levels at different growth inhibition percentages. The 
interpretation of CI was done in accordance with Table 4.4.1. 
 
Use of CalcuSyn has been demonstrated as a reliable method to define interactivity in drug 
combination (Matthews et al., 2017). Atovaquone and proguanil were first evaluated to test 
the efficacy of the method as the two drugs are known to exhibit synergism (Radloff et al., 
1996). The methodology was then applied to evaluate combinatorial partner drugs for 
dehydroemetine. This chapter reports on a series of experiments carried out to define 
antimalarial potency and drug interactivity of the lead. The current antimalarial drugs, 
artemether, atovaquone, proguanil and doxycycline were investigated for their interaction 
with dehydroemetine using the optimised 72 hour treatment regimen. Predetermined 
IC50 values for each compound were used to select the constant-ratio for each combination. 
Atovaquone was selected as it is already known to be synergistic with emetine 
dihydrochloride hydrate (Matthews et al., 2013). Artemether, doxycycline and proguanil 
were selected as they are currently used in the treatment and prophylaxis of malaria.  
 
4.2 Methods: 
 
4.2.1 Culture of Plasmodium falciparum 
 
Erythrocytic stage, strain K1, P. falciparum parasites (gifted by Prof J. E. Hyde) were 
cultured in RPMI 1640 1x (+) L-Glutamine (+) 25 mM Hepes (Gibco, Life Technologies, 
UK) in accordance with Read and Hyde, 1993 as mentioned in General materials and 
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methods (Chapter 2). The parasites were routinely maintained in O+ human blood (NHS 
Blood Bank, Manchester, UK). Multi-drug resistant strain K1 of P. falciparum is resistant to 
chloroquine, pyrimethamine and sulphadoxin. 
 
4.2.2 Experimental determination of IC50: 
 
Experiments to test drug efficacy were performed following the protocol mentioned in 
Chapter 2. Briefly, 2-fold serial dilutions of (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine from 200 nM to 12.5 nM and 20 µM to 1.25 µM, respectively were tested 
against multi-drug resistant K1 strain of P. falciparum. 
 
4.2.3 Time-course analysis through IC50 speed assay for determination of speed of 
action of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine: 
 
In 2012, Tres Cantos developed a labour intensive low-throughput assay taking up to 28 days 
to determine in vitro parasite reduction ratio (PRR) and presence of lag phase in response to 
the drug (Sanz et al., 2012). Besides rapid relief of symptoms, a fast-acting drug also helps to 
curtail the mutations which lead to the development of new mechanisms of drug resistance. 
The method used in this study to differentiate between fast and slow acting compounds gives 
initial results in 4 to 7 days (Le Manach et al., 2013). 
 
Unsynchronised Plasmodium falciparum culture were used, and parasites were grown in 
presence of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine for three incubation 
periods of 24 hours, 48 hours and 72 hours. The assays were analysed by determining SYBR 
green fluorescence as described in Chapter 2. Error bars on the graphs represent the standard 
error on the experiments performed twice with each concentration of (-)-R,S-dehydroemetine 
and (-)-S,S-dehydroisoemetine tested in triplicates. 
 
4.2.4 Stage-specific profiling of (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine: 
 
Parasite cultures with ≥ 80% trophozoites and ≥ 80% rings were obtained by synchronisation 
with 5% Sorbitol (Le Manach et al., 2013). The cultures were synchronised twice, at 0 hours 
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and 31 hours to obtain young rings which were up to 3 hours old. To obtain early schizont 
stages, the culture was synchronised twice with the second synchronisation being 6 to 8 hours 
after the first.  Each synchronous stage was incubated for 24 hours at 37°C on a 96-well 
microtitre plate with two fold serial dilution of the drugs ranging from 1.6 to 100 times the 
IC50 of each drug. The plates were washed 4 times after the incubation in order to dilute the 
drug concentration by > 1000 fold. The plates were incubated for another 24 hours at 37°C 
following which SYBR green staining was used to read the plates as described in general 
materials and methods in Chapter 2. Error bars on the graphs represent the standard error on 
the experiments performed twice with each concentration of (-)-R,S-dehydroemetine and (-)-
S,S-dehydroisoemetine tested in triplicates 
 
4.2.5 MTT cell viability assay for determination of cell cytotoxicity: 
 
Human hepatoma (HepG2) cells were grown in Dulbecco’s modified eagle medium (DMEM) 
containing (+) 4.5 g/L D-glucose, L-glutamine and supplemented with 10% fetal calf serum 
(FCS), 1% non-essential amino acids, and 1% penicillin/streptomycin, in a 5% CO2  
atmosphere at 37
0
C. Media was changed where cells reached approximately 80% confluency. 
 
The MTT (3-(4,5-dimethyltrazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was 
performed using the protocol described by Mosmann (1983). The assay was carried out in a 
96 well plate. Media from the cell culture flask was removed and discarded. 3-5 ml of PBS 
was used to wash the cells and 0.75 ml of trypsin-EDTA reagent was added to the cells. Flask 
was incubated at 37
0 
C with 100% humidity and 5% CO2 for approximately 3 minutes. To 
detach the cells, the flask was tapped gently until the cells detached. Cells were re-suspended 
in 4-5 ml of media and centrifuged at 1500 rpm for 5 minutes and the supernatant was 
discarded. The cell pellet was re-suspended in 5 ml of media and 10 µl of this cell solution 
was used to count the cells on a haemocytometer. Cells were calculated to make a new ‘cell-
media’ solution to a concentration of 5000 cells/100 µl as mentioned below in cell count 
protocol. 100 µl of this new cell solution was added into each well of the 96 well plate and 
100 µl of the drug prepared in media was also added to each well. This was repeated in 
triplicate and the 96 wells plate was incubated for 3 days. After the 3 days incubation, 50 µl 
of MTT solution was added to each well and incubated for 3 hours. The liquid in each well 
was aspirated carefully making sure the purple formazan crystals formed at the bottom of the 
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well were not removed. 200 µl of DMSO was added to each well and the results were read on 
the Ascent plate reader. The optical density was determined spectrophotometrically with a 
570 nm filter and a back-ground at 630 nm. Absorbance from the appropriate background 
was subtracted and cell viability was expressed as a percentage of the control absorbance in 
the untreated sample. Graphpad Prism (GraphPad Prism 5.0) was used to construct dose-
response curves to obtain the IC50 values using. A 25-0.39 μM two-fold dilution dose series 
of cisplatin (Sigma-Aldrich) was included on each plate as a control drug. Selectivity index 
was calculated by dividing IC50 values by LD50 values. 
 
Table 4.2.1 Layout of a typical MTT plate assay 
 
 
 
 
Blank 
Control – Media Only  
 
 
Blank 
 
 
 
Blank 
1.56 µM Cisplatin Drug 1 Drug 2 
3.12 µM Cisplatin Drug 1 Drug 2 
6.25 µM Cisplatin Drug 1 Drug 2 
12.5 µM Cisplatin Drug 1 Drug 2 
25 µM Cisplatin Drug 1 Drug 2 
50 µM Cisplatin Drug 1 Drug 2 
100 µM Cisplatin Drug 1 Drug 2 
 
Cisplatin was used as the positive control drug. The stock solution of cisplatin used was 
3.33mM dissolved in 0.9% saline. Serial dilutions of the control and test drugs were prepared 
in working solutions for the experiment. 
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Figure 4.2.1  Examplar MTT assay plate.  
MTT assay performed on HepG2 cancer cell lines. Cells seeded at 5000 per well. Sample read after 72 hours 
incubation. 
 
4.2.6 Determination of cross-resistance in multidrug resistant Plasmodium falciparum 
strains: 
 
The experiment was carried out by GSK Tres Canto Laboratory in Madrid, Spain. The three 
strains used for the assay were 3D7A, Dd2 and W2 based on their resistance profiles. 3D7A 
is chloroquine–sensitive, Dd2 is resistant to chloroquine, mefloquin and pyrimethamine (Sun 
et al., 2014) and W2 is resistant to chloroquine, quinine, pyrimethamine, cycloguanil, and 
sulfadoxine (Rathod et al., 1997) (gifted from the Malaria Research and Reference Reagent 
Resource Centre MR4). A culture of infected red blood cells (RBC) of the corresponding 
strain, (0.5% parasitaemia, 2% haematocrit) in RPMI-1640, 5% albumax and 5 µM 
hypoxanthine was exposed to 9 dilutions (3-fold serial dilutions) of the compound starting at 
5 µM. 100 µl of culture volume was plated in 96-well flat bottom microtitre plates with 0.5 µl 
drug (stock x200 in DMSO). Plates were incubated for 24 h at 37 ºC, 5% CO2, 5% O2, 90% 
N2. Next, 3H-hypoxanthine was added, and plates were incubated for another 24 hours 
period. Following this, the parasites were harvested on a glass fiber filter using a TOMTEC 
Cell harvester 96. Filters were dried, and melt-on scintillator sheets were used to determine 
the incorporation of 3Hhypoxanthine. Radioactivity was measured using a microbeta counter. 
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Data was normalized using the incorporation of the positive control, (parasitized red blood 
cells without drug). IC50 values were determined using Grafit 7 program (Sanz et al., 2012). 
 
4.2.7 Determination of transmission blocking potential through in vitro inhibition of 
gamete activation 
 
The experiment was carried out by GSK Tres Canto Laboratory in Madrid, Spain. Asexual 
cultures of P. falciparum NF54 strain parasites were used to seed gametocyte cultures at 
0.5% parasitemia, 4% hematocrit in 50 ml total volume under 3% O2/5% CO2/92% N2 gas. 
Culture medium (RPMI 25 mM HEPES, 50 mg/l hypoxanthine, 2 g/l NaHCO3 without L-
glutamine + 5% human serum and 5% Albumax) was replaced daily for 14 days. At day 14, 
the concentration of non-purified cultures was adjusted to plate 700,000 total cells per well in 
each 384-well plate. The test drugs were then added in two-fold serial dilutions starting at 10 
µM (10 µM – 0.00976 µM) and incubated 48 h at 37 ºC (3% 02, 5% CO2, 92% N2). DMSO 
was used as the negative control and Thiostrepton as the positive control. Activation was 
performed with ookinete medium (same RPMI base used for culture but supplemented with 
xanthurenic acid 50 µM) supplemented with the antibody anti-Pfs25-Cy3 at a final 
concentration of 1/2000 (from 1 mg/ml stock). Plates were analysed to detect exflagellation 
centres. "Triggered" cultures were then incubated (protected from light) at 26 °C for 24 h (in 
a thermoregulated incubator). Following this the plates were analyzed to detect female 
activated gametes. Activation of male gametes was detected based on light changes provoked 
by flagella movements which caused movement of surrounding cells. A 10-frame video was 
taken and then analyzed to determine these changes in cell position based on pixels change. 
The exflagellation centres were located by the script, based on size and intensity of light 
changes. Activation of female gametes was based on detection of fluorescent Cy3-Anti Pfs25 
antibody (as the primary parameter) followed by a selection of events according to their size, 
roundness and the intensity of the fluorescence. Both measurements were performed using 
automated inverted microscope Ti-E Nikon using JOBS software. Analysis of images and 
videos was performed with the ICY program. The IC50 value was determined using Microsoft 
Excel and Graphpad. 
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4.2.8 Preparation of drugs for drug interaction analysis 
 
Primary stock solutions were prepared as mentioned in Chapter 2 Materials and methods. In 
brief, atovaquone (MW = 366.84) was dissolved at 5 mg/ml (13.63 nM) in DMSO. Proguanil 
was dissolved at 1 mg/ml in acetonitrile: water (60/40). All primary stock solutions were 
passed through a 0.22 μm porosity filter, aliquoted and stored at -20°C until further use. For 
experimental set up the primary stock solutions were further diluted with complete medium 
to give final test concentrations. 
 
A dose range of 0.125–8 x the IC50 was made by a two-fold serial dilution for artemether, 
atovaquone, proguanil, doxycycline and (-)-R,S-dehydroemetine. For artemether, the doses 
ranged from 1.875 to 120 nM. For atovaquone, the doses ranged from 0.25 nM to 16 nM for 
combination with proguanil, and 0.5 nM to 32 nM for combination with (-)-R,S-
dehydroemetine. For proguanil the doses ranged was from 1.75 µM to 112 µM. For (-)-R,S-
dehydroemetine the doses ranged was from 25 nM to 1600 nM for combination with 
doxycycline, and 12.5 nM to 800 nM for combination with atovaquone and proguanil. For 
doxycycline the doses ranged from 2.5 µM to 160 µM. For artemether the dose ranged from 
1.875 nM to 120 nM. At each level, the compounds were co-administered for example IC50 of 
atovaquone was combined with the IC50 of (-)-R,S-dehydroemetine and 2 x IC50 atovaquone 
was combined with 2 x IC50 (-)-R,S-dehydroemetine and so forth. Parasites were treated at 
ring stage and incubated for 72 hours in a 96 well plate format. The SYBR green plate reader 
method was used to determine drug susceptibility as described in general materials and 
methods in Chapter 2. The data was analysed for the median-effect using CalcuSyn software 
(Biosoft) by converting triplicate data to an averaged percentage. The Dm, m and r values are 
also reported for all sets of data. Dm depicts the median effect dose at the ED50 level of 
inhibition. The m value refers to the kinetic order and shape of the curve m = 1, > 1, and < 1 
indicates hyperbolic, sigmoidal, and negative sigmoidal shape, respectively. The r value 
represents the linear correlation coefficient for the median effect plot and indicates 
conformity to the mass action law. 
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4.2.9 Virtual screening of FDA approved drug library to identify compounds for drug-
interaction analysis with (-)-R,S-dehydroemetine: 
 
The orientation in which two molecules bind or interact with each other to make a stable 
complex could be predicted by docking (Shoichet et al., 1992) (Lengauer and Rarey, 1996). 
Scoring functions could be used to analyse the orientation of the molecules with respect to 
each other and help in the prediction of binding affinity or the strength of association (Berry 
et al., 2015). Drug designing could be aided by use of docking as it could quickly identify a 
potential hit by scanning through large databases of compounds. The potential lead could be 
optimised to design analogs which are more potent and selective (Jorgensen, 2009). 
 
Autodock vina was used in this study for performing the virtual screening of drugs on various 
P. falciparum target receptors. Cygwin was used to run Autodock vina virtual screening 
commands. Following script was used to perform virtual screening (Trott and Olson, 2010). 
 
#! /bin/bash 
for f in ligand_*.pdbqt; do 
    b=`basename $f .pdbqt` 
    echo Processing ligand $b 
    mkdir -p $b 
    vina --configure conf.txt --ligand $f --out $
10
/out.pdbqt --log $/log.txt 
done 
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4.3 Results: 
 
4.3.1 Experimental determination of IC50 values for (-)-R,S-dehydroemetine and (-)-
S,S-dehydroisoemetine: 
 
Synthesis of the analogues of emetine dihydrochloride, ((-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine) was outsourced to Chiroblock GMBH, Germany. Receptor-ligand 
docking predicted the activities of the two diastereomers with the possibility of (-)-R,S-
dehydroemetine being more active than (-)-S,S-dehydroisoemetine. 
  
(-)-R,S-dehydroemetine was tested in serial dilutions of 200nM, 100nM, 50nM, 25nM and 
12.5nM. Dose response experiment was set up to be read at 72 hours. Based on the drug 
efficacy experiments, IC50 of (-)-R,S-dehydroemetine was found to be 69.58 + 2.62 nM. 
Results are shown in the Figure 4.3.1. 
 
Figure 4.3.1: Dose response experiment for (-)-R,S-dehydroemetine. 
The effective dose of (-)-R,S-dehydroemetine (dose range tested in serial dilutions from 12.5 nM to 200 nM) on 
P. falciparum (K1) infection after an incubation period of 72 hours using SYBR Green-based plate-reader assay. 
Data were analysed using GraphPad prism. Each value is a mean ± SD of triplicate data values. 
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(-)-S,S-Dehydroisoemetine was tested in serial dilutions of 20 µM, 10 µM, 5 µM, 2.5 µM and 
1.25 µM. 50% reduction was observed at 1.85 + 0.2 µM concentration. Results are shown in 
the Figure 4.3.2. 
 
 
Figure 4.3.2: Dose response experiment for (-)-S,S-dehydroisoemetine. 
The effective dose of (-)-S,S-dehydroisoemetine (dose range tested in serial dilutions from 2.5 µM to 20 µM) on 
P. falciparum (K1) infection after an incubation period of 72 hours using SYBR Green-based plate-reader assay. 
Data were analysed using GraphPad prism. Each value is a mean ± SD of triplicate data values. 
 
4.3.2 Time-course analysis through IC50 speed assay for determination of speed of 
action of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine:  
 
The IC50 speed assay was performed for (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine (with concentrations of 25 nM, 125 nM, 625 nM, 3125 nM and 15625 nM 
and 0.5 µM, 2.5 µM, 12.5 µM, 62.5 µM and 312.5 µM, respectively) using unsynchronised 
cultures of P. falciparum (n = 3). The ratio of 24 hours IC50 values to 72 hours IC50 values for 
(-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine could not be determined as IC50 could 
not be reached within 24 hours. Both compounds exhibited onset of activity within 24 hours 
but achieved 50% inhibition at the previously defined IC50 values only after 48 hours of 
exposure, indicating that the isomers have delayed action against the multi-drug resistant K1 
strain of P. falciparum. Figures 4.3.3 and 4.3.4 show the results for IC50 speed assay for (-)-
R,S-dehydroemetine and (-)-S,S-dehydroisoemetine respectively (error bars represent the 
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standard error on the experiments performed twice with each concentration of (-)-R,S-
dehydroemetine and (-)-S,S-dehydroisoemetine tested in triplicates). 
 
 
 
 
Figure 4.3.3: Time course analysis of (-)-R,S-dehydroemetine against Plasmodium falciparum K1.  
Effect of (-)-R,S-dehydroemetine on unsynchronised cultures of P. falciparum at 24h, 48h and 72h. Dose range: 
25 nM, 125 nM, 625 nM, 3125 nM and 15625 nM. IC50 could not be reached within 24 hours. (-)-R,S-
Dehydroemetine reached the IC50 by 48 hours. Error bars represent the standard error on the experiments 
performed twice with each concentration of (-)-R,S-dehydroemetine tested in triplicates. 
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Figure 4.3.4: Time course analysis of (-)-S,S-dehydroisoemetine against Plasmodium falciparum K1.  
Effect of (-)-S,S-dehydroisoemetine on unsynchronised cultures of P. falciparum at 24h, 48h and 72h. Dose 
range 0.5 µM, 2.5 µM, 12.5 µM, 62.5 µM and 312.5 µM. IC50 could not be reached within 24 hours. (-)-S,S-
Dehydroisoemetine reached the IC50 by 48 hours. Error bars represent the standard error on the experiments 
performed twice with each concentration of (-)-S,S-dehydroisoemetine tested in triplicates.  
 
4.3.3 Stage-specific profiling of (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine: 
 
The two isomers of dehydroemetine were tested on synchronous cultures ((-)-R,S-
dehydroemetine was tested in two fold serial dilutions from 132.81 nM to 8500 nM and (-)-
S,S-dehydroisoemetine was tested in two fold serial dilutions from 3.13 µM to 200 µM) to 
determine the stage-specificity of the compounds by measuring the concentration dependent 
growth of trophozoites/schizonts and rings following incubation with the two compounds.  
 
It was observed that (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine affect both the 
ring and schizont stages of the parasite (Figures 4.3.5 and 4.3.6, error bars represent the 
standard error on the experiments performed twice with each concentration of (-)-R,S-
dehydroemetine and (-)-S,S-dehydroisoemetine tested in triplicates). The decrease in growth 
0 0.5 2.5 12.5 62.5 312.5
24 hours 100 93.10 72.19 59.01 58.49 55.50
48 hours 100.00 86.45 47.12 24.42 22.19 20.68
72 hours 100 102.25 41.54 26.76 17.54 27.34
0
20
40
60
80
100
120
%
 P
ar
as
it
ae
m
ia
 
(-)-S,S-dehydroisoemetine (µM) 
114 
 
of schizonts was observed to be more marked in comparison to rings. Both the isomers were 
thus found to be more active against the late trophozoite/schizont stages. 
 
 
 
Figure 4.3.5: Stage-specific effects of (-)-R,S-dehydroemetine on synchronous ring and trophozoite 
cultures of P. falciparum K1 strain.  
The decrease in growth of trophozoites/schizonts was observed to be more marked in comparison to rings. 
Cultures were exposed to a serial dilution of (-)-R,S-dehydroemetine (from 132.81 nM to 8500 nM) for 24 
hours. The drug effects are expressed as a percentage of growth of the rings relative to trophozoites/schizonts 
24h after post-exposure wash. Error bars represent the standard error on the experiments performed twice with 
each concentration of (-)-S,S-dehydroisoemetine tested in triplicates. 
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Figure 4.3.6: Stage-specific effects of (-)-S,S-dehydroisoemetine on synchronous ring and trophozoite 
cultures of P. falciparum K1 strain.  
The decrease in growth of trophozoites/schizonts was observed to be more marked in comparison to rings. 
Cultures were exposed to a serial dilution of (-)-S,S-dehydroisoemetine (from 3.13 µM to 200 µM) for 24 hours. 
The drug effects are expressed as a percentage of growth of the rings relative to trophozoites/schizonts 24h after 
post-exposure wash. Error bars represent the standard error on the experiments performed twice with each 
concentration of (-)-S,S-dehydroisoemetine tested in triplicates. 
 
4.3.4 MTT cell viability assay for determination of cell cytotoxicity: 
 
MTT assay for cell cytotoxicity was performed to determine the safety profile as mentioned 
in the methodology section for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine (n = 
3). Emetine and Cisplatin were used as control drugs. The plate was read at 48 hours. 
Emetine was tested in two-fold serial dilutions from 31.25 nM to 2000 nM with IC50 
observed to be 225.1 + 17.2 nM (Figure 4.3.7). (-)-R,S-Dehydroemetine was tested in two-
fold serial dilution from 11.72 nM to 750 nM with IC50 observed to be 196.4 + 11 nM (Figure 
4.3.8). (-)-S,S-Dehydroisoemetine was tested in two fold serial dilutions from 0.312 µM to 10 
µM with IC50 observed to be 1.429 + 0.18 µM (Figure 4.3.9). Cisplatin was tested in two fold 
serial dilutions from 0.78 µM to 25 µM and with IC50 observed to be 10.16 + 2.6 µM (Figure 
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4.3.10). Selectivity indices (ratio of LD50 by IC50) for emetine, (-)-R,S-dehydroemetine and 
(-)-S,S-dehydroisoemetine were calculated to be ~4.5, ~3 and ~1 respectively. 
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Figure 4.3.7: 48 hour MTT cytotoxicity assay for emetine in HepG2 Cell lines. 
Cells were seeded at 5000 cells per well. Cell viability was determined using standard MTT assay. Emetine 
hydrochloride was tested in two fold serial dilutions from 31.25 nM to 2000 nM. Data was analysed using 
GraphPad prism. Error bars represent triplicate data values (mean ± SD). 
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Figure 4.3.8: 48 hour MTT cytotoxicity assay for (-)-R,S-dehydroemetine in HepG2 Cell lines. 
Cells were seeded at 5000 cells per well. Cell viability was determined using standard MTT assay. (-)-R,S-
Dehydroemetine was tested in two fold serial dilutions from 11.72 nM to 750 nM. Data was analysed using 
GraphPad prism. Error bars represent triplicate data values (mean ± SD). 
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Figure 4.3.9: 48 hour MTT cytotoxicity assay for (-)-S,S-dehydroisoemetine in HepG2 Cell lines. 
Cells were seeded at 5000 cells per well. Cell viability was determined using standard MTT assay. (-)-S,S-
Dehydroisoemetine was tested in two fold serial dilutions from 0.312 µM to 10 µM. Data was analysed using 
GraphPad prism. Error bars represent triplicate data values (mean ± SD). 
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Figure 4.3.10: 48 hour MTT cytotoxicity assay for cisplatin in HepG2 Cell lines. 
Cells were seeded at 5000 cells per well. Cell viability was determined using standard MTT assay. Cisplatin was 
tested in two fold serial dilutions from 0.78 µM to 25 µM. Data was analysed using GraphPad prism. Error bars 
represent triplicate data values (mean ± SD). 
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4.3.5 Determination of cross-resistance by hypoxanthine incorporation assay 
 
This assay was carried out at GSK Tres Cantos, Madrid (Spain) and relies on the parasite 
incorporation of labelled hypoxanthine that is proportional to P. falciparum growth. In vitro 
cross-resistance of the compounds was measured as an IC50 ratio between the IC50 value for 
the corresponding P. falciparum strain versus the IC50 value for 3D7A. Every replicate from 
an MDR strain involved a simultaneous determination using a 3D7A replicate to avoid any 
artefact linked to experimental conditions. Table 4.3.1 shows the IC50 values of emetine 
dihydrochloride, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine in P. falciparum 
sensitive strain (3D7A) and two Pf resistant strains (Dd2 and W2). The ratios of in vitro 
cross-resistance of emetine dihydrochloride in both resistant strains (Dd2 and W2) using 
3D7A strain as reference was found 1.15 and 0.77, respectively. The ratios of in vitro cross-
resistance of (-)-R,S-dehydroemetine in both resistant strains (Dd2 and W2) using 3D7A 
strain as reference was found 1.21 and 1.15 respectively. The results showed that the 
inhibitory potency observed for emetine dihydrochloride and (-)-R,S-dehydroemetine in both 
multidrug resistant strains (Dd2 and W2) is similar to the sensitive strain 3D7A. These results 
suggest that there is no cross-resistance of emetine dihydrochloride and (-)-R,S-
dehydroemetine with any of the MDR strains tested. (-)-S,S-Dehydroisoemetine did not 
achieve 50% inhibitory values for Dd2 and W2, hence displayed cross-resistance against the 
strains tested. 
 
Table 4.3.1 Analysis of results to determine cross-resistance through hypoxanthine incorporation assay. 
Compounds 
3D7A Dd2 W2     
Pf 
IC50 
(µM) 
st dev 
Pf 
IC50 
(µM) 
st dev 
Pf 
IC50 
(µM) 
st 
dev 
ratio 
Dd2/3D7A 
ratio 
W2/3D7A 
Emetine 
dihydrochloride 
0.234 0.022 0.269 0.025 0.181 0 1.15 0.77 
(-)-R,S-
dehydroemetine 
0.146 0.003 0.177 0.014 0.168 0.005 1.21 1.15 
(-)-S,S-
dehydroisoemetine 
1.031 0.041 NA   NA       
 
In-vitro IC50 values of emetine dihydrochloride, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine in P. 
falciparum sensitive strain (3D7A) and Pf resistant strains (Dd2 and W2). It also shows the ratios of in vitro 
cross-resistance of emetine dihydrochloride and (-)-R,S-dehydroemetine in both resistant strains (Dd2 and W2) 
using 3D7A strain as reference. NA represents IC50 not achieved. Bioassay carried out at GSK Tres Cantos, 
Madrid (Spain). 
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4.3.6 In vitro IC50 against P. falciparum male and female activated gametes: 
 
This bioassay was carried out at GSK Tres Cantos, Madrid (Spain) to assesses the malaria 
transmission blocking potential of compounds by estimating their ability to prevent male 
mature gametocytes to progress to male microgametes or/and to inhibit female gamete 
activation, as indicators of gametocyte functionality. The activation of male gametocytes into 
mature microgametes is evaluated by the process of exflagellation (extrusion of rapidly 
waving flagellum-like microgametes from the infected erythrocyte). The activation of female 
gametocytes is evaluated based on the specific expression of the Pfs25 protein at the surface 
of the female activated gametes (Miguel-Blanco et al., 2015). Male P. falciparum 
gametocytes exflagellate when activated, causing the movement of the surrounding RBCs in 
the media. Detecting these changes in cells position, it was possible to detect activated male 
gametes. Female P. falciparum gametocytes round up when activated and the Pfs25 protein 
distributes widely in the membrane of the gamete. Using a monoclonal antibody against this 
protein it was possible to specifically detect activated female gametes. Dual gamete 
formation assay was performed and the results are shown in Table 4.3.2 (-)-R,S-
dehydroemetine was found to display gametocidal activity against both male and female 
gametes whereas (-)-S,S-dehydroisoemetine was found to be not gametocidal. 
 
Table 4.3.2 Activity against male and female activated gametes. 
 
  
P. falciparum Dual Gamete Formation Assay 
Male Female 
Compounds Average    Stdev Average    stdev 
(-)-R,S-dehydroemetine (µM) 0.43    0.02 1.04    0.02 
(-)-S,S-dehydroisoemetine (µM) >10   >10   
 
In-vitro IC50 values of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine against male and female 
gametocytes in P. falciparum NF54 strain. Bioassay carried out at GSK Tres Cantos, Madrid (Spain). 
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4.4 Results for in-vitro CalcuSyn-based drug interaction analysis of (-)-R,S-
dehydroemetine: 
 
Experimental results of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine showed (-)-
R,S-dehydroemetine to be highly potent against the K1 strain of P. falciparum whereas (-)-
S,S-dehydroisoemetine was found to be less potent. IC50 of (-)-R,S-dehydroemetine was 
found to be 69.58 + 2.62 nM and that of (-)-S,S-dehydroisoemetine  was found to be 1.85 + 
0.2 µM. As such only the more potent isomer of dehydroemetine, (-)-R,S-dehydroemetine 
was taken forward for drug interaction analysis. The Dm, m and r values are also reported for 
all sets of data. Dm depicts the median effect dose at the ED50 level of inhibition. The m 
value refers to the kinetic order and shape of the curve m = 1, > 1, and < 1 indicates 
hyperbolic, sigmoidal, and negative sigmoidal shape, respectively. The r value represents the 
linear correlation coefficient for the median effect plot and indicates conformity to the mass 
action law. 
 
4.4.1 Validation of the CalcuSyn assay for malaria 
 
CalcuSyn method has been previously validated in our laboratory as a useful tool for 
antimalarial drug interaction analysis (Matthews et al., 2017). To establish the robustness of 
the method, the known synergistic drug combination, atovaquone and proguanil, was used. 
The doses selected for the experiment were based on the respective IC50 values for 
atovaquone (0.25nM-16nM) and proguanil (1.75 µM to 112 µM). Triplicate samples were 
analysed by SG-plate-reader after 72 hours. Calclusyn predicted strong synergism between 
the two drugs which is in accordance with the published literature (Table 4.4.1). 
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Table 4.4.1 Combinatory Index values. 
 
Range of CI Symbol Description 
<0.1 +++++ Very strong synergism 
0.1-0..3 ++++ Strong synergism 
0.3-0.7 +++ Synergism 
0.7-0.85 ++ Moderate synergism 
0.85-0.90 + Slight synergism 
0.90-1.10 + Nearly additive 
1.10-1.20 - Slight antagonism 
1.20-1.45 -- Moderate antagonism 
1.45-3.3 --- Antagonism 
3.3-10 ---- Strong antagonism 
>10 ----- Very strong antagonism 
 
Classification of synergism or antagonism using CI (Combination Index) values generated by Chaou-Talalay 
method (Chou, 2010). 
 
4.4.2 CalcuSyn-based dranalysis of the atovaquone - proguanil combination 
 
The CalcuSyn based analysis of the drug interactivity between atovaquone and proguanil 
using a constant-ratio combination of 1:7000 dose was performed. The output includes a 
dose-effect curve and a median-effect plot in addition to the Combination Index (CI) and an 
isobologram plot, to figuratively depict the compound’s potency and conformity to the mass 
action law (Figure 4.4.1). Specifically, CI = 0.20, 0.34 and 0.57 at the IC50, IC75 and 
IC90 levels, respectively were obtained inferring strong synergism at IC50 and IC75, and 
synergism at IC90. Good correlation coefficients of the median-effect plot were reported for 
atovaquone (r = 0.99), proguanil (r = 0.89), and the combination (r = 0.93), inferring good 
conformity to the mass-action law (Table 4.4.2). 
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Table 4.4.2 CalcuSyn based drug interaction analysis of atovaquone and proguanil. 
Drug CI Values at  nM     
  IC50 IC75 IC90 Dm m r 
Atovaquone N/A N/A N/A 6.53 0.88 0.99 
Proguanil N/A N/A N/A 27771 1.06 0.89 
Combination (1:7000) 0.21 0.34 0.57 0.56 0.68 0.93 
 
Dm depicts the median effect dose at the ED50 level of inhibition. The m value refers to the kinetic order and 
shape of the curve m = 1, > 1, and < 1 indicates hyperbolic, sigmoidal, and negative sigmoidal shape, 
respectively. The r value represents the linear correlation coefficient for the median effect plot and indicates 
conformity to the mass action law. 
 
 
 
Figure 4.4.1: CalcuSyn drug interactivity analysis for atovaquone and proguanil.  
CalcuSyn based dose-effect curve (A), CalcuSyn based isobologram and CalcuSyn based median effect plot (C) 
for drug interactivity between atovaquone and proguanil. Atovaquone and proguanil (1:7000) combination was 
found to be strongly synergistic at IC50 (CI = 0.21), and synergistic at IC75 (CI = 0.34) and IC90 (CI = 0.57). 
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4.4.3 CalcuSyn analysis of (-)-R,S-dehydroemetine: 
 
Following validation of the CalcuSyn software employing Chou-Talalay method for drug 
interaction analysis using the atovaquone-proguanil combination, the interaction between (-)-
R,S-dehydroemetine – artemether, (-)-R,S-dehydroemetine - atovaquone, (-)-R,S-
dehydroemetine - proguanil and (-)-R,S-dehydroemetine – doxycycline were studied. The 
doses used for each compound were based on the known IC50 values which served as the 
midpoint for a two-fold, constant-ratio dose series as shown in Table 4.4.3. 
 
Table 4.4.3 The dose series used for the combination of existing antimalarials with (-)-R,S-
dehydroemetine 
 
Dose Dose (nM or  µM) 
Level (-)-R,S-
dehydroemet
ine (nM) (for 
doxycycline) 
(-)-R,S-
dehydroemet
ine (nM) for 
(artemether, 
atovaquone 
and 
proguanil) 
Artemeth
er (nM) 
Atovaquo
ne (nM) 
Progua
nil 
( µM) 
Doxycycli
ne ( µM) 
A 25 12.5 1.875 0.5 1.75 2.5 
B 50 25 3.75 1 3.5 5 
C 100 50 7.5 2 7 10 
D 200 100 15 4 14 20 
E 400 200 30 8 28 40 
F 800 400 60 16 56 80 
G 1600 800 120 32 112 160 
Combination 
ratio with (-)-
R,S-
dehydroemet
ine 
                     
 -- 
                       
-- 
 
 
6.667:1 
             
 
1:25 
       
 
140:1 
               
 
100:1 
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4.4.4 CalcuSyn-based analysis of the (-)-R,S-dehydroemetine - artemether 
combination 
 
The CalcuSyn based analysis of the drug interactivity between (-)-R,S-dehydroemetine and 
artemether using a constant-ratio combination of 6.667:1 dose was done (Figure 4.4.2). 
Specifically, CI = 1.615, 1.684 and 1.766 at the IC50, IC75 and IC90 levels, respectively were 
obtained inferring antagonism at all measurement points. Good correlation coefficients of the 
median-effect plot were reported for (-)-R,S-dehydroemetine (r = 0.93), artemether (r = 0.90), 
and the combination (r = 0.91), inferring good conformity to the mass-action law (Table 
4.4.4). 
 
Table 4.4.4 CalcuSyn based analysis of drug interaction between (-)-R,S-dehydroemetine and artemether 
 
Drug CI Values at nM   
 IC50 IC75 IC90 Dm M R 
(-)-R,S-
dehydroemetine 
N/A N/A N/A 89.56 1.49 0.93 
Artemether N/A N/A N/A 14.26 1.88 0.90 
Combination 
(6.667:1) 
1.62 1.68 1.77 74.49 1.57 0.91 
 
Dm depicts the median effect dose at the ED50 level of inhibition. The m value refers to the kinetic order and 
shape of the curve m = 1, > 1, and < 1 indicates hyperbolic, sigmoidal, and negative sigmoidal shape, 
respectively. The r value represents the linear correlation coefficient for the median effect plot and indicates 
conformity to the mass action law. 
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Figure 4.4.2: CalcuSyn drug interactivity analysis for (-)-R,S-dehydroemetine and artemether 
combination.  
CalcuSyn based dose-effect curve (A), CalcuSyn based isobologram and CalcuSyn based median effect plot (C) 
for drug interactivity between (-)-R,S-dehydroemetine and artemether. (-)-R,S-dehydroemetine and artemether 
(6.667:1) combination was found to be antagonistic at IC50 (CI = 1.62), IC75 (CI = 1.68) and IC90 (CI = 1.77). 
 
4.4.5 CalcuSyn-based analysis of the (-)-R,S-dehydroemetine - atovaquone 
combination: 
 
The CalcuSyn based analysis of the drug interactivity between (-)-R,S-dehydroemetine and 
atovaquone using a constant-ratio combination of 25:1 dose was done (Figure 4.4.3). 
Specifically, CI = 0.88, 0.88 and 0.89 at the IC50, IC75 and IC90 levels, respectively were 
obtained inferring mild synergism at all measurement points. Good correlation coefficients of 
the median-effect plot were reported for atovaquone (r = 0.94), (-)-R,S-dehydroemetine (r = 
0.95), and the combination (r = 0.97), inferring good conformity to the mass-action law 
(Table 4.4.5). 
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Table 4.4.5 CalcuSyn based analysis of drug interaction between atovaquone and (-)-R,S-dehydroemetine 
 
Drug CI Values at nM   
 IC50 IC75 IC90 Dm M R 
Atovaquone N/A N/A N/A 8.56 1.52 0.94 
(-)-R,S-dehydroemetine N/A N/A N/A 85.98 2.41 0.95 
Combination (1:25) 0.88 0.88 0.89 2.16 2.09 0.97 
 
Dm depicts the median effect dose at the ED50 level of inhibition. The m value refers to the kinetic order and 
shape of the curve m = 1, > 1, and < 1 indicates hyperbolic, sigmoidal, and negative sigmoidal shape, 
respectively. The r value represents the linear correlation coefficient for the median effect plot and indicates 
conformity to the mass action law. 
 
 
 
Figure 4.4.3: CalcuSyn drug interactivity analysis for atovaquone and (-)-R,S-dehydroemetine 
combination.  
CalcuSyn based dose-effect curve (A), CalcuSyn based isobologram and CalcuSyn based median effect plot (C) 
for drug interactivity between (-)-R,S-dehydroemetine and atovaquone. Atovaquone and (-)-R,S-dehydroemetine 
(1:25) combination was found to be synergistic at IC50 (CI = 0.88), IC75 (CI = 0.88) and IC90 (CI = 0.89). 
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4.4.6 CalcuSyn-based analysis of the (-)-R,S-dehydroemetine - doxycycline 
combination: 
 
The CalcuSyn based analysis of the drug interactivity between (-)-R,S-dehydroemetine and 
doxycycline using a constant-ratio combination of 1:100 dose was done (Figure 4.4.4) 
Specifically, CI = 1.55, 1.47 and 1.52 at the IC50, IC75 and IC90 levels, respectively were 
obtained inferring antagonism at all measurement points. Good correlation coefficients of the 
median-effect plot were reported for doxycycline (r = 0.97), (-)-R,S-dehydroemetine (r = 
0.84), and the combination (r = 0.81), inferring good conformity to the mass-action law 
(Table 4.4.6). 
 
Table 4.4.6 CalcuSyn based analysis of drug interaction between doxycycline and (-)-R,S-dehydroemetine 
 
Drug CI Values at µM   
 IC50 IC75 IC90 Dm M R 
Doxycycline N/A N/A N/A 39.46 1.50 0.97 
(-)-R,S-
dehydroemetine 
N/A N/A N/A 0.076 0.78 0.84 
Combination 
(100:1) 
1.55 1.47 1.52 9.84 0.91 0.81 
 
Dm depicts the median effect dose at the ED50 level of inhibition. The m value refers to the kinetic order and 
shape of the curve m = 1, > 1, and < 1 indicates hyperbolic, sigmoidal, and negative sigmoidal shape, 
respectively. The r value represents the linear correlation coefficient for the median effect plot and indicates 
conformity to the mass action law. 
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Figure 4.4.4: CalcuSyn drug interactivity analysis for doxycycline and (-)-R,S-dehydroemetine 
combination.  
CalcuSyn based dose-effect curve (A), CalcuSyn based isobologram and CalcuSyn based median effect plot (C) 
for drug interactivity between (-)-R,S-dehydroemetine and doxycycline. Doxycycline and (-)-R,S-
dehydroemetine (100:1) combination was found to be antagonistic at IC50 (CI = 1.55), IC75 (CI = 1.47) and IC90 
(CI = 1.52). 
 
4.4.7 CalcuSyn-based analysis of the (-)-R,S-dehydroemetine - proguanil combination: 
 
The CalcuSyn based analysis of the drug interactivity between (-)-R,S-dehydroemetine and 
proguanil using a constant-ratio combination of 140:1 dose was done (Figure 4.4.5). 
Specifically, CI = 0.67, 1.04 and 1.62 at the IC50, IC75 and IC90 levels, respectively, were 
obtained inferring synergism at IC50, nearly additive at IC75 and antagonism at IC90. Good 
correlation coefficients of the median-effect plot were reported for proguanil (r = 0.91), (-)-
R,S-dehydroemetine (r = 0.86), and the combination (r = 0.96), inferring good conformity to 
the mass-action law (Table 4.4.7). 
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Table 4.4.7 CalcuSyn based analysis of drug interaction between proguanil and (-)-R,S-dehydroemetine 
 
Drug CI Values at  µM     
  IC50 IC75 IC90 Dm M R 
Proguanil N/A N/A N/A 20.93 1.62 0.91 
(-)-R,S-dehydroemetine N/A N/A N/A 232.46 0.88 0.86 
Combination ratio (140:1) 0.67 1.04 1.62 14.17 0.98 0.96 
 
Dm depicts the median effect dose at the ED50 level of inhibition. The m value refers to the kinetic order and 
shape of the curve m = 1, > 1, and < 1 indicates hyperbolic, sigmoidal, and negative sigmoidal shape, 
respectively. The r value represents the linear correlation coefficient for the median effect plot and indicates 
conformity to the mass action law. 
 
 
Figure 4.4.5: CalcuSyn drug interactivity analysis for (-)-R,S-dehydroemetine-proguanil combination. 
CalcuSyn based dose-effect curve (A), CalcuSyn based isobologram and CalcuSyn based median effect plot (C) 
for drug interactivity between (-)-R,S-dehydroemetine and proguanil. (-)-R,S-Dehydroemetine and proguanil 
(1:140) combination was found to be synergistic at IC50 (CI = 0.67), additive at IC75 (CI = 1.04) and antagonistic 
at IC90 (CI = 1.62). 
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After 72 hours of incubation, the (-)-R,S-dehydroemetine and atovaquone interaction was 
classified as synergistic (25:1 ratio, CI = 0.88-0.89) at all inhibitory levels analysed. The 
interaction between (-)-R,S-dehydroemetine and artemether (1:6.667 ratio, CI = 1.6-1.7), and 
between (-)-R,S-dehydroemetine and doxycycline (1:100 ratio, CI = 1.5), at IC50, IC75 and 
IC90 levels of inhibition were classified as antagonism. For the (-)-R,S-dehydroemetine and 
proguanil (1:140) combination the IC50 level of inhibition was classified as synergism (CI = 
0.67), the IC75 as nearly additive (CI = 1.04) and IC90 as antagonism (CI = 1.62). 
 
4.5 Results for virtual screening of FDA approved drug library to identify 
compounds for drug-interaction analysis with (-)-R,S-dehydroemetine: 
 
Most docking software used in the study were unable to correctly predict the activity of the 
ligand molecules on 80S ribosome structure 3J7A. Due to lack of reliability of the cryo-EM 
structure, a virtual screen of FDA approved 1376 drugs was not performed against 3J7A 80S 
ribosome.  
 
Experiments conducted in this study to detect combinatorial partnership depicted synergistic 
activity between atovaquone and (-)-R,S-dehydroemetine. Atovaquone is known to bind on 
cytochrome bc1 causing its inhibition which leads to interruption of pyrimidine biosynthesis 
(Srivastava et al., 1999). A virtual screen of FDA approved 1376 drugs was performed 
against cytochrome bc1 (4PD4). FDA approved library of drugs was obtained from zinc 
database. This library of FDA approved drugs was docked on cytochrome bc1 (4PD4). The 
receptor PDB file (4PD4) was obtained from protein databank. 
 
4.5.1 Virtual screening on cytochrome bc1: 
 
Virtual screening of FDA approved library of drugs was performed on cytochrome bc1 
(4PD4) using autodock vina. 1376 drugs were docked on the atovaquone binding site of 
cytochrome bc1 using autodock vina (Figure 4.5.2. – Figure 4.5.4) 
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Figure 4.5.1: Atovaquone structure. 
3D structure of atovaquone downloaded from Pubchem database visualised through Discovery Studio. 
    
   
 
Figure 4.5.2: Pdb structure of cytochrome bc1. 
X-ray crystallographic structure of cytochrome bc1 downloaded from protein data bank (4PD4) visualised 
through Discovery Studio. 
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Figure 4.5.3: Atovaquone binding site residues. 
Amino acid residues involved in the atovaquone binding site on cytochrome bc1 visualised through Discovery 
Studio    
 
   
 
Figure 4.5.4: Atovaquone binding site. 
Focussed view of atovaquone in the binding cavity on cytochrome bc1 visualised through Discovery Studio.   
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Receptor based Virtual Screening of FDA approved drugs library on cytochrome bc1 helped 
reduce the number of potential candidate compounds from 1376 to 80 by eliminating the 
compound which scored a binding affinity lower than atovaquone on cytochrome bc1. This 
was further reduced to 45 by filtering out anti-tumour, anti-viral and anti-psychotic drugs. 
Top 25 drugs are shown in Table 4.5.1. Five of the 25 drugs identified are already reported on 
zinc database (database of chemical molecules) to display activity against P. falciparum. 
These drugs could serve as potential leads for synergistic partners for emetine and (-)-R,S-
dehydroemetine. 
 
 
 
Figure 4.5.5: Filtering of FDA approved library of drugs. 
Receptor based Virtual Screening of FDA approved drugs on cytochrome bc1 (4PD4) helped to narrow down 
the library from 1376 to 45 drugs as potential synergistic partners for emetine and (-)-R,S-dehydroemetine. 
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Table 4.5.1 FDA approved drugs identified through virtual screening. 
 
 
 
List of top 25 drugs based on the virtual screening of FDA library of 1376 drugs on cytochrome bc1 (4PD4). 
Activity against P. falciparum for 5 of the 25 drugs identified in the screen has been reported on Zinc database 
of chemical molecules. 
 
4.6 Conclusion 
 
Accurate determination of parasite killing rate in response to treatment is crucial in 
development of drugs against Plasmodium, as chemotherapy still remains the most essential 
element in control of malaria. Speed of action of compounds on viability of parasites is 
difficult to measure through traditional techniques (Burrows et al., 2011). Emergence of 
parasite resistance against artemisinin-based combination therapy could jeopardise the recent 
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advances made against the disease. It is important to identify new drugs with rapid parasite 
killing kinetics early in the drug development process. (-)-R,S-Dehydroemetine  was found to 
be potent against the multi-drug resistant K1 strain of P. falciparum with an IC50 of 69.58 + 
2.62 nM. It displayed gametocidal activity against male and females gametes, and on 3D7A, 
Dd2 and W2 strains showed no strain specific cross-resistance. (-)-S,S-Dehydroisoemetine, 
on the other hand displayed an IC50 value of 1.85 + 0.2 µM against the multi-drug resistant 
K1 strain of P. falciparum. It did not inhibit the male and female gametes. As it could not 
reach 50% inhibitory values against Dd2 and W2 strains, it was found to display cross-
resistance. Stage specificity experiment showed both diastereomers display more activity 
against the trophozoite stage of the parasite. Cell cytotoxicity experiments showed a low 
selectivity index against HepG2 liver cancer cell lines (SI= ~3 for (-)-R,S-dehydroemetine 
and SI= ~1 for (-)-S,S-dehydroisoemetine). Emetine shows good synergy with atovaquone 
(Matthews et al, 2013). Based on the same principle, drug interaction experiments were 
conducted between the more potent diastereomer, (-)-R,S-dehydroemetine and four known 
antimalarials atovaquone, proguanil, artemether and doxycycline. Artemether (CI= 1.6) and 
doxycycline (CI= 1.55) were found to be antagonistic while proguanil displayed mild synergy 
at IC50 (CI= 0.67) and nearly additive (CI= 1.04) to antagonistic (CI= 1.64) at IC75 and IC90, 
respectively. Atovaquone was found to display mild synergy (CI = 0.88) with (-)-R,S-
dehydroemetine. Following the experimental findings, a virtual screen of FDA approved 
library of drugs was conducted on atovaquone binding site and 45 drugs were identified 
which could potentially display synergy with emetine and (-)-R,S-dehydroemetine. 
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Chapter 5 Cellular basis for emetine and dehydroemetine cardiotoxicity: 
role of ATP, mitochondria and hERG K
+
 channels 
 
5.1 Introduction: 
 
Blood flow to a target site and the drug’s diffusion characteristics determine adequate 
delivery of the drug to the site. The pharmacological effect of a drug is dictated by its 
biochemical interactions in the body (Magee et al., 2007). Drugs could elicit their effect by 
binding to a receptor, such as atovaquone, or by changing the physical and chemical 
properties of the body like laxatives or antacids. It is important to know the mechanism of 
action of a drug. Microscopy, biochemical assays or computational methods could be used to 
identify a drug’s mechanism of action (Cushnie et al., 2016). Knowing how a drug produces 
its effect could help guide dosing, anticipate clinical safety, determine target susceptibility, 
develop a new drug, formulate combination therapy or reposition it for use in other diseases 
(Schenone et al., 2013) (Chang et al., 2017). There are many drugs with known mechanism of 
action, however there many others which are widely used but the mechanism of action is 
unknown. 
 
Cardiovascular side-effects were observed following treatment of amoebiasis with emetine 
which included ECG changes such as T-wave inversion, prolongation of QT interval and to 
some degree, increased width of QRS complex and PR interval. Hypotension, tachycardia 
and precordial pain were also observed (Yang and Dubick, 1980). Stoppage of treatment 
resulted in complete recovery of cardiovascular functions. Cardiac microscopic examination 
revealed separation of muscle fibres and destruction of myocardial fibres but absence of 
inflammatory cells led to the interpretation that myocarditis is toxic rather than inflammatory 
in origin. In a study conducted on thirty two patients treated with subcutaneous injections of 
emetine dihydrochloride in a dose range of 1 – 2 mg/kg/day, pain was noted at the injection 
site along with ECG abnormalities, myalgia, muscle weakness and increased levels of serum 
creatinine phosphatase (Mastrangelo et al., 1973).  
 
A synthetic analogue of emetine, dehydroemetine was introduced in 1959 which is less 
emetic, can be given orally as resinate and was found to be comparatively safer than emetine 
when given parenterally in similar doses, with similar electrocardiographic changes but less 
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marked and of shorter duration (Dempsey and Salem, 1966). In a study conducted on 58 
African adults with amoebic liver abscess (Powell et al., 1965), it was found that treatment 
with 80 to 120 mg daily of dehydroemetine plus chloroquine for 10 days followed by similar 
course for 6 days after 14 days interval was as effective as 65 mg daily of emetine plus 
chloroquine in a similar regimen.  
 
Experimental results have also shown that changes observed in heart conduction, 
contractility, automaticity and ECG abnormalities by emetine and dehydroemetine could be 
due to their effect on membrane permeability to Na
+
, K
+
 and Ca
2+
 ions (Yang and Dubick, 
1980). In another study, reversal of effects were observed by addition of ATP and NADH 
indicating nicotinamide adenine dinucleotide mediated (NAD) enzymatic oxidation of 
substrates to be potentially affected (Watkins and Guess, 1968). 
 
Cell membranes function as a diffusion barrier to ion movements and are made of lipid 
bilayers with embedded proteins. A concentration gradient is established across the 
membrane by active pumping of ions by transmembrane ion transporter proteins. Movement 
of ions down the concentration gradient across the membrane through ion channels leads to a 
voltage difference between the two sides of the membrane. Sodium (Na
+
), potassium (K
+
), 
calcium (Ca
++
) and chloride (Cl
-
) are the important ions regulating the action potential (Fry 
and Jabr, 2010). In this study, the possibility of inhibition of glycolysis and mitochondria 
(sources of ATP), along with the effect of emetine and dehydroemetine on K
+
 and Ca
++
 ion 
channels were analysed. 
 
5.1.1 Glycolysis: 
 
Glycolysis is a 10 step oxygen-independent metabolic pathway, with each step characterised 
by a different enzyme. It occurs in the cytosol and produces a net gain of two ATP molecules 
by anaerobic conversion of glucose to pyruvate while generating intermediate metabolites in 
the process which are used in other metabolic pathways (Li et al., 2015). The pathway has a 
preparatory or investment phase where there is consumption of ATP and the second phase is 
the ‘pay off’ phase where there is production of ATP. There are 3 rate-limiting steps in 
glycolysis. The first step is a rate-limiting step where glucose-6-phosphate (G6P) is generated 
by phosphorylation of glucose by hexokinase. It helps to transport glucose inside the cells by 
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converting it to G6P which cannot escape out as the cell membrane is impervious to it. The 
step catalyzed by phosphofructokinase-1 (PFK-1) for hydrolysis of ATP is also a rate-
limiting step and is irreversible (Boscá and Corredor, 1984). Pyruvate kinase is the third 
regulatory enzyme which catalyses the final step which results in the formation of ATP and 
pyruvate. NADH is oxidised back to NAD
+
 either aerobically or anaerobically. Lactic acid 
fermentation or ethanol fermentation converts pyruvate to lactate or ethanol respectively and 
NADH to NAD
+
 in anoxic or hypoxic conditions (Berg et al., 2002).  
 
 
 
Figure 5.1.1 Schematic representation of the glycolysis (Li et al., 2015). 
The enzymes (hexokinase (HK), phosphofructokinase (PFK) and pyruvate kinase (PK)) catalysing the rate-
limiting steps are depicted in red. Glycolysis results in the net gain of 2 ATP molecules. 
 
Emetine has been reported to inhibit glycolysis as addition of fructose-1,6-bisphosphate, a 
glycolysis intermediate, was found to reduce the adverse effects of emetine on isolated, 
perfused rat hearts (Pan and Combs, 2003). Studies have demonstrated high energy needs of 
the cells, such as muscle contraction, are met by oxidative metabolism whereas cellular 
membrane functions such as transmembrane electrical activity and ionic pumps are 
maintained through glycolysis derived ATP (Parker and Hoffman, 1967) (Paul, 1983) 
(MacLeod and Daniel, 1965) (Hasin and Barry, 1984). Disturbances in intracellular ionic 
concentrations and osmotic balance of the cell are observed when glycolysis is inhibited 
(Higgins et al., 1981) (Gebhard et al., 1977) (Bricknell et al., 1981). Rapidly multiplying 
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parasite cells could possibly have a higher dependency on glycolysis as observed in cancer 
cells exhibiting the ‘Warburg effect’, a phenomenon where glycolysis is up-regulated (Liberti 
and Locasale, 2016). 
 
5.1.2 hERG potassium channel: 
 
The human Ether- à -go-go-Related Gene (hERG) encodes the pore-forming alpha subunit of 
potassium ion channel of the rapidly activating delayed rectifier potassium (K+) channel (IKr). 
The repolarising current in the cardiac action potential is mediated by the hERG channel 
(Lamothe et al., 2016). The cardiac ‘rapid’ delayed rectifier current is responsible for the 
movement of potassium (K
+
) ions out of cardiac cells and bringing it back to resting 
membrane potential during repolarisation. Warmke and Ganetzky from University of 
Wisconsin-Madison were the first to describe the hERG gene which is a homolog of 
Drosophila fly’s Ether- à -go-go gene. Flies with mutation in Ether- à -go-go gene would 
begin to shake their legs when anaesthetised with ether, resembling dancing at a popular 
nightclub of the time ‘Whisky A Go Go’ in California, leading to the gene being named 
Ether- à -go-go (Warmke and Ganetzky, 1994). The hERG potassium channel is made of 4 
alpha subunits aligned to form the pore of the channel traversing through the plasma 
membrane. Inhibition of hERG channel by genetic mutations or by drugs could lead to 
shortening or prolongation of QT interval predisposing individuals to fatal ventricular 
arrhythmias such as torsades de pointes (Hedley et al., 2009) (Shah and Li, 2018). Decrease 
in serum potassium levels affects the hERG function. Many drugs which lengthen the QT 
interval, interact with hERG potassium channel (Milnes et al., 2003). Prolongation of QT 
interval is observed in unstable angina, ischemic cardiac disease and myocardial infarction 
thus making the extent of QT interval prolongation a strong predictor of sudden cardiac death 
(Shawl et al., 1990). The United States Food and Drug administration (FDA) recommends 
preclinical hERG studies during drug development to test the cardiac safety profile (Fermini 
et al., 2016). 
 
5.1.3 Role of mitochondria: 
 
The engulfment of an α-proteobacterium by a precursor of the modern eukaryotic cell 
resulted in the formation of mitochondria (Friedman and Nunnari, 2014). Mitochondria also 
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known as the powerhouse of the cell is a double-membrane bound organelle in most 
eukaryotic cells (Perier and Vila, 2012). Carl Benda in 1898 coined the term mitochondria 
(Mazzarello, 1999). In 1946, Albert Claude was able to isolate mitochondria through tissue 
fractionation and concluded the enzymes necessary for respiratory chain were from 
mitochondria. In 1948, Eugene Kennedy and Albert Lehninger concluded oxidative 
phosphorylation in eukaryotes occurred in the mitochondria (Ernster and Schatz, 1981). It is 
absent in certain cells such as mature mammalian red blood cells. Mitochondria supplies ATP 
to meet most of the energy needs of the cell and is involved in signalling, cellular 
differentiation and cell death (McBride et al., 2006). The ATP production occurs aerobically 
and requires the presence of oxygen. It produces more ATP than glycolysis. Mitochondria 
have its own genome which shows similarity to bacterial genome giving rise to the 
hypothesis of an endosymbiotic origin about 1.7 to 2 billion years ago (Gray, 2012). It 
replicates through binary division. Unlike the nuclear genes, the mitochondrial genes are 
inherited only from the egg cell. Mitochondria also have ribosomes (Martin et al., 2015). 
Mitochondria have five distinct parts which are an outer and inner phospholipid membrane 
with embedded proteins, inter-membrane space, cristae and the matrix. Mitochondria-
associated ER-membrane (MAM) formed with association with endoplasmic reticulum plays 
an important role in transfer of lipids as well as calcium signalling (Hayashi et al., 2009). 
Mitochondria play an important role in regulation of cell proliferation through ATP 
production. Cell cycle is arrested when oxidative phosphorylation is inhibited (Porporato et 
al., 2018). Proteins from the inter-membrane space leak out in the cytosol up on disruption of 
the outer membrane which could result in cell death. The inner mitochondrial membrane 
contains proteins which perform the redox reactions in oxidative phosphorylation. The 
enzymes of the electron transport chain leads to a membrane potential across the inner 
membrane (Jastroch et al., 2010). Matrix of the mitochondria has enzymes for citric acid 
cycle and, oxidation of pyruvate and fatty acids. Acetyl CoA is reduced to carbon dioxide and 
3 molecules of NADH, one molecule of FADH2 (reduced cofactors for electron transport 
chain) and GTP (readily converted to ATP) are produced during the citric acid cycle. Matrix 
also contains the mitochondrial ribosomes, mitochondrial DNA, 22 tRNA and 2 rRNA 
(Anderson et al., 1981). Mitochondria play a role in Ca
++
 signalling pathway as well through 
MAM. Calcium can be stored in mitochondria transiently making mitochondria a cytosolic 
buffer for Ca
++
 (Santulli et al., 2015). Low affinity calcium channels are present on the outer 
membrane of the mitochondria but an efficient transmission of Ca
++
 occurs between the ER 
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and mitochondria MAM contact points. Transient depolarisation in mitochondrial membrane 
is caused by mild influx of calcium from cytosol into the matrix. ATP production is 
stimulated by the uptake of calcium by MAM and this provides energy to SERCA to move 
Ca
++
 in the ER. The MAM Ca
++
 uptake is operated in a certain window threshold which if 
crossed collapses the mitochondrial membrane potential essential for metabolism and 
stimulates apoptosis through intrinsic pathway (Rizzuto et al., 2009). Decrease in the ER 
Ca
++
 filling decreases the efflux of Ca
++
 in mitochondria and prevents the mitochondrial 
membrane potential collapse (Rizzuto et al., 2009).  
 
Mitochondrial Ca uniporter (MCU) is a calcium channel situated on the inner mitochondrial 
membrane through which Ca
++
 enters the mitochondria (De Stefani et al., 2011). Influx of 
Calcium in the mitochondria activates many mitochondrial enzymes to increase the supply of 
ATP for increased demand during contraction. When compared to the Ca
++
 released from SR, 
only a small amount of calcium enters the mitochondria suggesting mitochondria does not 
play a major role in removing calcium from the cytoplasm (Lu et al., 2013) (Negretti et al., 
1993). 
 
In this chapter, to determine probable causes for the observed cardiotoxicity and a possible 
multi-modal mechanism of action, the effect of emetine and (-)-R,S-dehydroemetine was 
evaluated on ATP proliferation, mitochondrial membrane potential disruption and hERG K
+
 
channel. 
 
5.2 Methods: 
 
5.2.1 ATP bioluminescence assay (Luciferase assay) for detection of changes in ATP 
concentration: 
 
ATP, which is generated by cellular respiration, is the primary source of energy in all 
organisms. Targeted luciferase probes could be used to measure ATP concentration via 
luminescence techniques. Light is emitted (emission ~560 nm at pH 7.8) when the substrate 
luciferin is oxidised to oxyluciferin by the protein luciferase (Morciano et al., 2017). ATP is 
required as a source of energy for this reaction. Emitted light is proportional to the 
concentration of ATP which can be used to assess the cell viability. ViaLight
TM
 plus kit 
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(Lonza) was used to perform the experiments. Assay kit contained cell lysis reagent to extract 
ATP from the cells, ATP monitoring reagent plus (AMR plus) (reconstituted by adding assay 
buffer to the vial containing lyophilised ATP monitoring reagent pellet). Following 
reconstitution, unused AMR plus was stored at -20ºC. The experiment was performed at 
room temperature.  
 
Synchronised culture of P. falciparum K1 strain at trophozoite stage incubated at 2.5% 
haematocrit was used for the experiment. Positive control was devoid of the test compounds 
and contained only complete media.  Experiment was set on a 96 well plate with 2-fold serial 
dilutions of emetine and (-)-R,S-dehydroemetine from 0.5 µM to 2 µM with 100 µL in each 
well. The plate was incubated for two hours at 37ºC. Post-incubation, the culture plate was 
allowed to cool to room temperature and 50 µL of cell lysis reagent was added to control and 
test wells. After 10 minutes of incubation at room temperature, 100 µL of AMR plus was 
added to each well and further incubated for 5 minutes. The experiment was read using a 
microplate luminometer with luminescence set at 560 nm. Data was analysed using Microsoft 
excel. 
 
5.2.2 Staining with rhodamine123 and draq5 for fluorescence microscopy: 
 
Rhodamine123 and draq5 were used to observe the effect of emetine and its two synthetic 
analogues on mitochondrial membrane potential. Rhodamine123 is a mitochondrial specific 
dye which emits in FITC channel on flow-cytometry whereas draq5 stains the DNA and 
emits in APC-Cy7-A channel. The two dyes were chosen to perform the experiment as there 
is very minimal overlap in their emission signals. Synchronised cultures of P. falciparum K1 
strain at trophozoite stage was incubated with 1 ml of 200 nM Rhodamine123 for 1 hour, 
followed by a further incubation with 100 µl of 10 µM Draq5 for 20 mins. Smear was 
prepared after the incubation and slides were immediately viewed under fluorescence 
microscope at 100x magnification with oil emersion to visualise localisation of the dyes 
inside the parasite. 
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5.2.3 Staining with rhodamine123 and draq5 for flow-cytometry to detect 
mitochondrial membrane potential disruption: 
 
To test the effect of emetine and its analogues on mitochondria, synchronised cultures of P. 
falciparum K1 strain at trophozoite stage were incubated at 2.5% haematocrit (in a 96 well 
plate format, 200 µl final well volume) for 2 hours with IC50 concentrations of atovaquone, 
emetine hydrochloride and (-)-R,S-dehydroemetine. Atovaquone, a known mitochondrial 
inhibitor was used as a control. Compounds were then washed away by centrifuging the 
cultures and a pellet was prepared for each drug concentration. Pellets were then incubated 
with 1 ml of 200 nM rhodamine123 for 1 hour, followed by a further incubation with 100 µl 
of 5 µM of draq5 for 20 mins. After a wash with PBS, the experiment was read using a flow-
cytometer on the FITC channel. Loss of mitochondrial membrane potential was indicated by 
a decrease in fluorescent intensity. 
 
5.2.4 hERG Channel Inhibition (IC50 Determination) assay: 
 
hERG channel inhibition assay was performed by Cyprotex, UK in the presence of the 
author. Figure 5.2.1 shows a schematic representation of the hERG channel. Chinese Hamster 
Ovary cells expressing the hERG potassium channel were dispensed into 384-well planar 
arrays and hERG tail-currents was measured by whole-cell voltage-clamping. Emetine, (-)-
R,S-dehydroemetine and (-)-S,S-dehydroisoemetine in a range of concentrations were then 
added to the cells and a second recording of the hERG current was made.  The percentage 
change in hERG current was measured and used to calculate an IC50 value. 
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Figure 5.2.1 Schematic representation of the hERG channel. 
The hERG channel mediates the repolarising current in the cardiac action potential. The cardiac ‘rapid’ delayed 
rectifier current is responsible for the movement of potassium (K
+
) ions out of cardiac cells during 
repolarisation. Adapted from Cyprotex, UK 
 
The assay was performed to test emetine, (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine’s potential to inhibit the hERG channel. 100 µL in 20 mM concentration 
of emetine, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine in DMSO was provided to 
Cyprotex. The experiments were performed on an IonWorks
TM
 automated patch clamp 
instrument (Molecular Devices LLC), which simultaneously performs electrophysiology 
measurements for 48 single cells in a specialised 384-well plate (PatchPlate
TM
).  All buffers, 
cell suspensions and drug compound solutions were at room temperature. 
 
Chinese hamster ovary (CHO) cells stably transfected with hERG (cell-line obtained from 
Cytomyx, UK) were used for the experiment.  A single-cell suspension was prepared in 
extracellular solution (Dulbecco’s phosphate buffered saline with calcium and magnesium 
pH 7.2) and aliquots were added automatically to each well of a PatchPlate
TM
.  Vacuum was 
applied beneath the plate to form an electrical seal after positioning over a small hole at the 
bottom of each well.  The vacuum was applied through a single compartment common to all 
wells which were filled with intracellular solution (buffered to pH 7.2 with HEPES).  The 
resistance of each seal was measured via a common ground-electrode in the intracellular 
compartment and individual electrodes were placed into each of the upper wells. 
 
Amphotericin B was used as a perforating agent and circulated underneath the PatchPlate
TM
 
to gain electrical access to the cell.  The pre-compound hERG current was then measured.  
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An electrode was positioned in the extracellular compartment and a holding potential 
of -80 mV was applied for 15 sec.  The hERG channels were activated by applying a 
depolarising step to +40 mV for 5 sec and then clamped at -50 mV for 4 sec to elicit the 
hERG tail current, before returning to -80 mV for 0.3 sec. 
 
5.3 Results:  
 
5.3.1 ATP proliferation assay (luciferase assay) for detection of changes in ATP 
concentration: 
 
Experiments were performed using the ATP proliferation assay (n=3, standard error 
represented by error bars on Figure 5.3.1) with each concentration of emetine and (-)-R,S-
dehydroemetine (0.5, 1 and 2 µM for both compounds) tested in triplicates. Emetine and (-)-
R,S-dehydroemetine showed slight decrease in ATP concentration. Less than 10% decrease 
was observed at 0.5 µM and approximately 15% decrease was observed with higher 
concentrations of 1 µM and 2 µM for both emetine and (-)-R,S-dehydroemetine. 
 
 
 
Figure 5.3.1 ATP proliferation assay for detection of changes in ATP concentration 
Emetine and (-)-R,S-dehydroemetine tested at 0.5 µM, 1 µM and 2 µM concentration. Following 1-hour 
incubation, ~15% decrease in ATP concentration was observed with emetine and (-)-R,S-dehydroemetine. Error 
bars denote the standard error observed in experiments performed thrice in triplicates. 
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5.3.2 Staining with rhodamine123 and draq5 for fluorescence microscopy and 
flowcytometry for measurement of mitochondrial membrane potential: 
 
Changes in mitochondrial membrane potential was measured using rhodamine123, a cationic 
fluorescent dye (Tanabe, 1990). Fluorescence microscopy was used to visualise localisation 
of rhodamine123 within the cytoplasm of the parasites (Figure 5.3.2). Draq5 is a far-red 
fluorescent DNA dye which is cell permeable and was used to identify the parasites. SYBR 
green was not preferred for this experiment as it emits in the same channel as rhodamine123 
and would result in the overlap of emission signals. 
 
Changes in mitochondrial membrane potential can be observed using rhodamine123 
(excitation wavelength: 511 nm and emission wavelength: 534 nm), a membrane permeable 
fluorescent dye which accumulates by electrostatic attraction in the mitochondria because of 
its negative transmembrane potential. A change in the dye’s concentration in the 
mitochondria is caused by a depolarisation event and can be visualised as a shift in 
fluorescent intensity of rhodamine123 (Gaur et al., 2016). Draq5, (excitation wavelength: 647 
nm and emission wavelength: >665 nm) a DNA dye was used to distinguish the parasites on 
flow-cytometry in APC-Cy7-A channel. Atovaquone, a known mitochondrial inhibitor was 
used as a control. A decrease in fluorescent intensity measured in FITC-A channel indicates a 
loss of mitochondrial membrane potential. A shift in fluorescent intensity was observed after 
treatment with all three compounds. The compounds were tested at IC50 and 10 x IC50 values. 
Emetine and (-)-R,S-dehydroemetine showed a shift in fluorescent intensity of rhodamine123 
in a direction similar to atovaquone indicating a possible mitochondrial effect. Atovaquone 
produced a ~40 to 43% change in mean fluorescent intensity, emetine produced a change of 
approximately 30 to 35% in a direction similar to atovaquone and (-)-R,S-dehydroemetine 
produced a change of approximately 25 to 30% in a direction similar to atovaquone (Figure 
5.3.3). 
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Figure 5.3.2 Staining with rhodamine123 and draq5 for fluorescence microscopy and the merge with 
brightfield.  
P. falciparum K1 strain trophozoites stained with (A) Draq5 10 µM, (B) Rhodamine123 200 nM, (C) Draq5 and 
Rhodamine merge and (D) Draq5, rhodamine123 and brightfield merge. Visualised under fluorescence 
microscope at 100x magnification. 
 
 
 
 
 
 
 
C D 
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Figure 5.3.3 Disruption of mitochondrial membrane potential 
Changes in mitochondrial membrane potential observed on treatment with IC50 of atovaquone, emetine and (-)-
R,S-dehydroemetine. (A) Changes in fluorescent intensity on application of drugs, (B) Gating for the 
experiment, (C) Graphical representation of change in fluorescent intensity. 
Rhodamine and Draq5 Parasitemia FITC-A mean FITC-A mean (range gate) Change in fluorescense intensity
Blood no dye 0.00% N/A 0 N/A
Uninfected blood 0.16% 280 0 -94.21%
Infected blood w/o drugs 1.70% 4839 6026 0
Atovaquone (IC50) 1.69% 2809 3705 -41.95%
Atovaquone (IC50 x 10) 1.66% 2750 3821 -43.17%
Emetine (IC50) 1.73% 3333 4491 -31.12%
Emetine (IC50 x 10) 1.72% 3139 4301 -35.13%
(-)-R,S -dehydroemetine (IC50) 1.78% 3544 4894 -26.76%
(-)-R,S -dehydroemetine (IC50 x 10) 1.67% 3243 4390 -32.98%
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5.3.3 hERG Channel Inhibition (IC50 Determination) assay: 
 
Compound dilutions were prepared by diluting a DMSO solution (default 10 mM) of the test 
compound using a factor 5 dilution scheme into DMSO, followed by dilution into 
extracellular buffer such that the final concentrations tested were typically 0.008, 0.04, 0.2, 1, 
5, 25 µM (final DMSO concentration 0.25 %).  The IonWorks
TM
 instrument was used to 
automatically add (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine dilutions to the 
upper wells of the PatchPlate
TM
.  The compounds were left in contact with the cells for 
300 sec before recording currents using the same voltage-step protocol as in the 
pre-compound scan.  Quinidine, an established hERG inhibitor, was included as a positive 
control, and vehicle control (0.25 % DMSO) as negative control. Each concentration was 
tested in 4 replicate wells on the PatchPlate
TM 
(maximum of 24 data points).  It was ensured 
only acceptable cells which maintain a seal resistance of greater than 50 MOhm and a 
pre-compound current of at least 0.1 nA, were used to assess hERG inhibition by applying 
filters to ensure cell stability between pre- and post-compound measurements.  
 
Data Analysis: 
 
For each replicate the hERG response was calculated using the following equation: 
                 
                          
                         
       
 
The % hERG response was plotted against concentration for the test compound and, where 
concentration-dependent inhibition was observed, and an IC50 value was calculated (Table 
5.3.1). (-)-R,S-Dehydroemetine was found to have an IC50 value of 19.3 µM for hERG 
channel whereas (-)-S,S-dehydroisoemetine was found to have an IC50 value of 2.99 µM. The 
IC50 of quinidine which was used as a positive control is 1.99 µM. Thus, it was found that 
with a selectivity index (SI) of over 285, (-)-R,S-dehydroemetine is not a hERG channel 
inhibitor, but (-)-S,S-dehydroisoemetine is a potent inhibitor (selectivity index = 2). 
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Table 5.3.1 hERG channel inhibition assay results for (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine 
 
Cyprotex hERG channel inhibition (IC50 determination) 
Compounds 
% Mean inhibition 
0 
µM 
0.016 µM 
0.08 
µM 
0.4 
µM 
2 
µM 
10 
µM 
50 
µM 
IC50 (µM) 
(-)-R,S-dehydroemetine 0 7.79 6.34 12.7 7.21 39.4 61.4 19.3 
(-)-S,S-dehydroisoemetine 0 8.13 4.61 9.33 36 70.7 96.9 2.99 
 
Effect of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine determined using hERG channel inhibition 
assay. Each value is a mean ± SEM of triplicate values. 
 
5.4 Conclusion: 
 
Emetine and dehydroemetine have been known to produce cardiotoxic side-effects during 
anti-amoebic therapy. In a bid to resolve the cellular basis of cardiotoxicity and to identify 
other mechanisms of action besides the inhibition of protein translation, emetine and (-)-R,S-
dehydroemetine were tested for their effect on ATP proliferation and mitochondrial 
membrane potential disruption. Emetine has previously been identified as a non-inhibitor of 
hERG K
+ 
channel in previous work conducted at the University of Salford. In this study, (-)-
R,S-dehydroemetine and (-)-S,S-dehydroisoemetine were evaluated for their effect on hERG 
K
+ 
channel. It was observed that both emetine and (-)-R,S-dehydroemetine produce an 
approximate 10 to 15% reduction in ATP concentration in RBCs infected with multi-drug 
resistant K1 strain of P. falciparum following one hour exposure at 10 to 40 times IC50 values 
in 2 fold serial dilutions. Both emetine and (-)-R,S-dehydroemetine also produced a change in 
rhodamine123 fluorescent intensity in RBCs infected with multi-drug resistant K1 strain of P. 
falciparum following a 2 hour exposure with IC50 and 10 x IC50 values in a  manner similar to 
atovaquone (a known mitochondrial inhibitor). This is suggestive of a disruption in 
mitochondrial membrane potential. (-)-R,S-Dehydroemetine and (-)-S,S-dehydroisoemetine 
were tested to determine their activity on hERG K
+ 
channel. (-)-R,S-Dehydroemetine was 
found to be a non-inhibitor (SI < 285) whereas its isomer (-)-S,S-dehydroisoemetine was 
found to inhibit hERG K
+ 
channel (SI = ~2). The two diastereomers not only differ in their 
activity against the multi-drug resistant K1 strain of P. falciparum but also display 
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differential potencies against hERG K
+ 
channel. This suggests the (R) configuration at C-1´ is 
important for emetine and dehydroemetine’s biological activity. 
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Chapter 6 Cellular basis of emetine and dehydroemetine cardiotoxicity: a 
role for dysregulated Ca handling and contractility 
 
6.1 Introduction 
 
Heart contraction is dependent on cell contraction which is dependent on a cyclical rise and 
fall of intracellular calcium on each heartbeat. Levels of intracellular calcium are much lower 
than that in extracellular space. Intracellular calcium levels in cardiomyocytes increase from 
~100 nM to ~1 µM during systole on each heart beat (Marks, 2003). Most of the calcium 
required for contraction is released from the sarcoplasmic reticulum (SR); an intracellular 
calcium store. SR Ca is released during a process known as cardiac cellular excitation-
contraction coupling (ECC). 
 
ECC is initiated when a cardiac cellular action potential depolarises the sarcolemma which 
activates the voltage-gated L-type Ca channels. The L-type Ca channels are located on the 
surface membrane and transverse tubules. Activation allows a small influx of calcium which 
results in the opening of Ca release channels (ryanodine receptors (RyR)) on the sarcoplasmic 
reticulum (SR) membrane. This causes release of a large amount of Ca
++
 from the SR in a 
process called calcium-induced calcium release (CICR) (Eisner et al., 2017). Intracellular Ca 
levels are then sufficient to allow the binding of Ca
++
 to troponin and so produce myofilament 
sliding. Cell shortening occurs and the pressure generated leads to systole with ventricles 
ejecting the blood (Allen and Kurihara, 1980).
 
 
For diastole, the cell must relax requiring removal of systolic Ca and so restoration of 
diastolic Ca levels. This occurs by (1) closure of RyRs post-systole and so cessation of Ca 
release and (2) the active removal of Ca from the cytosol. The latter is primarily achieved by 
two proteins (A) the SR Ca-ATPase (SERCA), which pumps Ca back into the ST and (B) the 
sodium-calcium exchanger (NCX) which takes Ca outside the cell. NCX exchanges 3 Na
+
 
ions for one Ca
++
 ion (Greensmith et al., 2014) so is electrogenic. During each Ca
++
 transient 
only 50% of SR Ca
++
 is released (Picht et al., 2011) and it remains localised without affecting 
other release sites (Cheng et al., 1993). Surface membrane depolarisation results in activation 
of more L-type Ca channels leading to a more uniform Ca
++
 release (Cannell et al., 1995). 
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The specialised signalling nexus which initiates the contraction is called ‘cardiac dyad’ which 
is formed by L-type Ca
++
 channel clusters on the sarcolemma in close apposition with RyR 
clusters on SR membrane (Eisner et al., 2017).  Large RyR clusters increases the chances of 
Ca
++
 spark whereas large uniformly distributed clusters of RyR leads to a more synchronous 
rise of Ca
++
 during depolarisation. In the steady state, the influx of Ca
++
 is equal to the efflux 
of Ca
++ 
(Negretti et al., 1995). Any imbalances in the Ca
++
 flux are corrected by cells via 
autoregulation. For example, the potentiation of RyR by sub-millimolar concentrations of 
caffeine results in increased amplitude of systolic Ca
++
 transient as Ca
++
 efflux is increased 
(O'Neill and Eisner, 1990). This causes the SR to lose Ca
++
 decreasing the SR Ca
++
 content 
which offsets the RyR potentiation and brings the amplitude of Ca
++
 transient back to steady 
state level i.e. the Ca
++
 efflux is equal to Ca
++
 influx.  
 
The amplitude of the [Ca2+]i transient is proportional to the cube of SR Ca
++ content 
(Greensmith et al., 2010). Due to this relationship, any change to SR Ca
++
 has a profound 
effect on systolic Ca
++
. As such, in the steady state (i.e. for a given inotropic tone) SR Ca
++
 
must be tightly regulated. SR Ca
++
 content is usually 1 to 1.5 mmol/L at the end of diastole 
and it decreases in systole by 50% to 75% (Shannon et al., 2003). SR Ca
++
 content is 
determined by cytosolic Ca
++
 concentration, the release of Ca
++
 through RyR and uptake of 
Ca
++
 in SR via SERCA. SR Ca
++
 content is decreased by increasing NCX activity and 
increased by decreasing RyR opening or increasing SERCA activity. Ca-sensitive indicators 
could be used to measure Ca
++
 content in SR (Eisner et al., 2017). However, these indicators 
could get saturated at high Ca
++
 levels. Application of 10 mmol/L of caffeine empties the SR 
by releasing all Ca
++
 from SR and measurement of the amplitude of the resulting Ca
++
 
transient provides a simple way of measuring SR Ca
++
 content.  
 
6.2 General methodology 
 
6.2.1 Primary myocyte isolation and preparation: 
 
Freshly isolated primary myocytes were sourced from the University of Manchester on each 
day of experimentation. Myocyte storage, loading and experiment set-up was performed by 
Natasha Hadcraft (University of Salford) in the author’s presence and analysis of the data was 
done by the author. 
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6.2.2 Animals, tissue preparation and ethics: 
 
Young control sheep at approximately 18 months old and in good health were used to isolate 
ventricular myocytes and tissue at the University of Manchester. All procedures accord with 
the Animals (Scientific Procedures) Act, UK, 1986 and Directive 2010/63/EU of the 
European Parliament (Home Office, 1986). Heparin was administered to limit the loss of 
tissue due to ischemia by minimising clot formation. Cardiothoracic incision was made and 
excess blood was removed to prevent tissue deterioration by briefly storing the heart in Ca
2+
 
free isolation. 
 
6.2.3 Isolation of sheep left ventricular myocytes 
 
Left ventricle was cannulated via the coronary artery onto Langendorff apparatus and 
perfused with Ca
2+
 free isolation solution for 10 minutes. Tissue digestion was done by 
adding collagenase type II (Worthington) and protease (Sigma) to the perfusate to allow the 
dissociation of myocytes. Due to the narrow temperature window for digestive enzymes, 
solutions used were preheated to 37°C.  Following digestion and perfusion with low Ca
2+
 
taurine containing solution, left ventricle was dissected and the pericardium and endocardium 
were removed. Remaining tissue was minced and agitated in fresh taurine solution, then 
filtered through a net mesh (200 µm pores). The pH of the perfusion solutions was 
maintained to 7.34 at room temperature (~22°C). All components were sourced from Sigma-
Aldrich or Fisher. 
 
6.2.4 Myocyte storage and loading 
 
Freshly isolated cells were viewed at 40 x magnification with emersion oil. Good quality, 
viable cells identified by distinctive rod shape and striated structure were used. Dead or non-
viable cells were often identified by their round shape due to hyper-contracture (Kivisto et al., 
1995). Cells were stored at room temperature (~22°C) before the experiments and loaded in 
an intermediate solution. The desired Ca
2+
 was maintained at 1.8 mM, and cells were stored 
in a (1:1) taurine:tyrodes solution (approximately 0.95 mM Ca
2+
). An aliquot of cells 
suspended in a storage solution (3-4 ml) were loaded with 2 µg/µl Fura-2-AM 
(Thermofisher) in pluronic F-127 (20 % solution in DMSO), for 10 minutes. 
155 
 
6.2.5 Standard experimental solution 
 
Tyrodes solution was used for all experiments. Control solution, and emetine (50 nM) and (-
)-R,S-dehydroemetine (80 nM) were also dissolved in tyrodes solution (components: NaCl, 
HEPES, glucose, BSA, KCl, MgCl, CaCl2 and Probenecid). All components were sourced 
from Sigma-Aldrich, Fisher or Fluka. 
 
Cells were allowed to settle in a cell bath for ~10 minutes after the loading procedure and 
viewed again using an epi-fluorescent inverted microscope under x 40 magnification with 
emersion oil. The cells for the experiment were selected. 
 
With aid of the eyepiece, the viable cell was positioned into the centre of the window, and the 
imaging was provided by an Ion Optix MyoCam-S CCD camera. Isolation of single cells 
from nearby cells and debris was done by using blinds to separate them. In order for 
experiments to be physiologically relevant, temperature of solutions were kept at 37°C. 
 
6.2.6 Measurement of intracellular calcium and contractility: 
 
Epi-fluorescence photometry was used to detect changes in intracellular Ca
2+
 in real time. 
Fura-2-AM was used to measure the intracellular calcium. Contractility was measured via 
video detection using an Ion Optix MyoCam-S high speed digital camera with a charge-
coupled device (CCD). Quantification of relaxation was done by measuring the time taken for 
the cell to relax at 50% of maximal shortening. Length of myocyte was plotted against 
[Ca
2+
]i from the point of cell re-lengthening during systole, the range where myocyte length 
and [Ca
2+
]i are in equilibrium (Greensmith et al., 2010). 
 
6.2.7 Quantification of Ca2+ fluxes, the activity of the [Ca2+]i removal mechanisms and 
SR Ca
2+
 content: 
 
All fluxes were normalised to cell volume. Rapid emptying of the SR was used to measure 
the SR Ca
2+
 content during application of 10 mM caffeine (Sigma–Aldrich, UK). The 
descending phase of the systolic [Ca
2+
]i transient was fitted to a single exponential decay. The 
rate constant of decay (ksys) depends on the combined activity of SERCA and NCX whereas 
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that of the caffeine response (kcaff) predominantly depends on NCX. Subtracting these rate 
constants gives kSERCA and so a calculated indication of SERCA activity. In the paced 
experiments, the above parameters, and the SR Ca
2+
 content, global [Ca
2+
]i and contractility 
were measured simultaneously in each cell (Greensmith et al., 2010) (Greensmith et al., 
2014).  
 
6.2.8 Field stimulation of ventricular myocytes 
 
Two electrodes were used to a current of electricity across the cell bath for field stimulation. 
The voltage and direction of current was controlled by a Constant Voltage Isolated Stimulator 
(model DS2A, Digitimer ltd). The amplitude was increased until cells began to respond, the 
resulting pacing of myocytes usually occurred with field stimulation between 40 – 70 V. A 
Train/delay generator (model DG2A, Digitimer ltd) was controlled the frequency at which 
cells were paced. In the majority of experiments the pacing frequency was 0.5 Hz. 
(Greensmith et al., 2010) (Greensmith et al., 2014). 
 
6.2.9 Data analysis and statistics: 
 
Data were analysed with custom-written Excel routines (Greensmith, 2014). Statistical 
significance was determined using either an unpaired t-test (to compare two groups) or 
repeated-measures ANOVA (to compare multiple, sequentially recorded groups). 
 
6.3 Results: 
 
All figures illustrate the experiment performed on sheep ventricular myocyte (representative 
of data from 16 cells from 6 animals for (-)-R,S-dehydroemetine and data from 13 cells from 
4 animals for emetine). Field stimulation was used to stimulate the myocytes with a pacing 
frequency of 0.5 Hz. Specimen figures demonstrate a typical example and histograms depict 
the means. 
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6.3.1 The effects of (-)-R,S-dehydroemetine on contractility: 
 
The specimen record of Figure 6.3.1 shows an example of the effect of (-)-R,S-
dehydroemetine on contractility. Figure 6.3.1 A shows the myocytes stimulated by (-)-R,S-
dehydroemetine at IC50. On average, the new steady state sarcomere length, a measurement 
for myocyte contractility, after application of (-)-R,S-dehydroemetine showed a statistically 
significant decrease in the degree of shortening (p<0.005, mean: 0.722, SEM: 0.059) below 
the pre (-)-R,S-dehydroemetine steady state levels. On removal of (-)-R,S-dehydroemetine, 
the sarcomere length to recovered to the pre (-)-R,S-dehydroemetine levels. There was no 
significant difference between the pre and post (-)-R,S-dehydroemetine levels. Figure 6.3.1 B 
shows the amplified records of the sarcomere length in pre (-)-R,S-dehydroemetine, (-)-R,S-
dehydroemetine and post (-)-R,S-dehydroemetine steady state levels. Figure 6.3.1 
C outlines the mean data showing the reproducibility of the decrease in steady state 
sarcomere length on the application of (-)-R,S-dehydroemetine which is followed by a 
recovery to control steady state levels after removing (-)-R,S-dehydroemetine. Figure 6.3.1 D 
shows no significant effect on diastolic sacrcomere length up on application of (-)-R,S-
dehydroemetine. Figure 6.3.1 E relaxation was also impaired as the time taken by the 
myocyte to relax to 50% of maximal shortening showed a significant increase (p<0.005, 
mean: 1.352, SEM: 0.136) on application of (-)-R,S-dehydroemetine which was followed by 
a recovery to control steady state levels on removal of (-)-R,S-dehydroemetine. 
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Figure 6.3.1 The effects of (-)-R,S-dehydroemetine on contractility 
The effects of (-)-R,S-dehydroemetine (DHE) on sarcomere lengthi in sheep ventricular myocytes stimulated 
with current pulses. (A) Time course of changes in sarcomere length, (-)-R,S-dehydroemetine (80 nM) was 
applied for the period shown. (B) Specimen records of sarcomere length taken at the points indicated on A. (C) 
Average data for systolic sarcomere length and (D) Average data for diastolic sarcomere length (E) Average 
data for quantification of relaxation at 50% of maximal shortening (from left to right); steady state in control, 
steady state in (-)-R,S-dehydroemetine, steady-state wash. n = 16 cells from 6 animals. Asterisk represents a 
statistically significant difference. NS represents a statistically non-significant difference. 
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6.3.2 The effects of emetine on contractility: 
 
The specimen record of Figure 6.3.2 shows an example of the effect of emetine on 
contractility. Figure 6.3.2 A shows the myocytes stimulated by emetine at IC50. On average, 
the new steady state sarcomere length, a measurement for myocyte contractility, showed no 
statistically significant changes compared to the pre emetine steady state levels. On removal 
of emetine, the sarcomere length showed no significant difference compared to the pre 
emetine levels. Figure 6.3.2 B shows the amplified records of the sarcomere length in pre 
emetine, emetine and post-emetine steady state levels. Figure 6.3.2 C outlines the mean 
data showing the reproducibility lack of any change in steady state sarcomere length on the 
application of emetine. Figure 6.3.2 D shows no significant effect on diastolic sarcomere 
length up on application and removal of emetine. In Figure 6.3.2 E quantification of 
relaxation at 50% of maximal shortening showed no significant changes on application of 
emetine. 
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Figure 6.3.2  The effects of emetine on contractility 
The effects of emetine on sarcomere length in sheep ventricular myocytes stimulated with current pulses. (A) 
Time course of changes in sarcomere length, emetine (50 nM) was applied for the period shown. (B) Specimen 
records of sarcomere length taken at the points indicated on A. (C) Average data for systolic sarcomere length 
and (D) Average data for diastolic sarcomere length. (E) Average data for quantification of relaxation at 50% of 
maximal shortening (from left to right); steady state in control, steady state in emetine, steady-state wash. n = 13 
cells from 4 animals. Asterisk represents a statistically significant difference. NS represents a statistically non-
significant difference. 
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6.3.3 The effects of (-)-R,S-dehydroemetine on systolic calcium: 
 
The specimen record of Figure 6.3.3 shows an example of the effect of (-)-R,S-
dehydroemetine on systolic calcium. Figure 6.3.3 A shows the myocytes exposed to (-)-R,S-
dehydroemetine at IC50. On average, the new steady state systolic [Ca
2+]i amplitude showed 
a statistically significant decrease (p<0.005, mean: 0.859, SEM: 0.027) below the pre (-)-R,S-
dehydroemetine steady state levels. On removal of (-)-R,S-dehydroemetine, the amplitude of 
the Ca transient failed to recover to the pre (-)-R,S-dehydroemetine levels. Figure 6.3.3 B 
shows the amplified records of the Ca transient in pre (-)-R,S-dehydroemetine, (-)-R,S-
dehydroemetine and post (-)-R,S-dehydroemetine steady state levels. Figure 6.3.3 
C outlines the mean data showing the reproducibility of the decrease in steady state amplitude 
of the Ca transient on the application of (-)-R,S-dehydroemetine which is not followed by a 
recovery to control steady state levels after removing (-)-R,S-dehydroemetine. Figure 6.3.3 D 
shows no significant effect on diastolic calcium levels up on application of (-)-R,S-
dehydroemetine. 
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Figure 6.3.3 The effects of (-)-R,S-dehydroemetine on [Ca
2+
]i 
The effects of (-)-R,S-dehydroemetine on systolic [Ca
2+
]i in sheep ventricular myocytes stimulated with current 
pulses. (A) Time course of changes in cytoplasmic Ca measured with fura-2, (-)-R,S-dehydroemetine (80 nM) 
was applied for the period shown. (B) Specimen records of Ca taken at the points indicated on A. (C) Average 
data for systolic Ca transient amplitude and (D) Average data for diastolic Ca (from left to right); steady state in 
control, steady state in (-)-R,S-dehydroemetine, steady-state wash. n = 16 cells from 6 animals. Asterisk 
represents a statistically significant difference. NS represents a statistically non-significant difference. 
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6.3.4 The effects of emetine on systolic calcium: 
 
The specimen record of Figure 6.3.4 shows an example of the effect of emetine on systolic 
calcium. Figure 6.3.4 A shows the myocytes stimulated by emetine at IC50. On average, the 
new steady state systolic [Ca2+]i amplitude did not show any statistically significant 
difference from the pre emetine steady state levels. Removal of emetine also did not produce 
any change in the steady state levels of Ca transient compared to emetine and pre emetine 
levels. Figure 6.3.4 B shows the amplified records of the Ca transient in pre emetine, 
emetine and post-emetine steady state levels. Figure 6.3.4 C outlines the mean data 
showing the reproducibility of no change in steady state amplitude of the Ca transient on the 
application and then removal of emetine. Figure 6.3.4 D shows no significant effect on 
diastolic calcium levels up on application of emetine. 
 
Only (-)-R,S-dehydroemetine showed significant changes in global calcium levels and hence 
next further experiments were conducted only on (-)-R,S-dehydroemetine to measure SR 
Ca
2+
 content. 
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Figure 6.3.4 The effects of emetine on [Ca
2+
]i 
The effects of emetine on systolic [Ca
2+
]i in sheep ventricular myocytes stimulated with current pulses. (A) Time 
course of changes in cytoplasmic Ca measured with fura-2, emetine (50 nM) was applied for the period shown. 
(B) Specimen records of Ca taken at the points indicated on A. (C) Average data for systolic Ca transient 
amplitude and (D) Average data for diastolic Ca (from left to right); steady state in control, steady state in 
emetine, steady-state wash. n = 13 cells from 4 animals. Asterisk represents a statistically significant difference. 
NS represents a statistically non-significant difference. 
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6.3.5 The effects of (-)-R,S-dehydroemetine on SR Ca2+ content: 
 
The specimen record of Figure 6.3.5 shows an example of the effect of (-)-R,S-
dehydroemetine on SR Ca2+ content. Figure 6.3.5 A shows the SR Ca2+ content 
measurements estimated by the amplitude of the Ca transient following application of 10 mM 
caffeine. On average, an application of (-)-R,S-dehydroemetine at IC50 resulted in a 
significant decrease in the amplitude of the caffeine evoked Ca transient. On removal of (-)-
R,S-dehydroemetine, the amplitude of the caffeine evoked Ca transient failed to recover to 
the pre (-)-R,S-dehydroemetine levels. Figure 6.3.5 B outlines the mean data showing 
the reproducibility of the decrease in caffeine evoked Ca transient amplitude on the 
application of (-)-R,S-dehydroemetine which is not followed by a recovery to control levels 
of caffeine evoked Ca transient amplitude up on removal of (-)-R,S-dehydroemetine.  
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Figure 6.3.5 The effects of (-)-R,S-dehydroemetine on caffeine-evoked Ca transient amplitude 
The effects of caffeine (10 mM) on systolic [Ca
2+
]i in sheep ventricular myocytes stimulated with current pulses. 
(A) Changes in caffeine-evoked Ca transient amplitude measured with fura-2 observed on application of (-)-R,S-
dehydroemetine (80 nM). (B) Average data for caffeine-evoked Ca transient amplitude (from left to right); 
caffeine-evoked Ca transient amplitude in control, caffeine-evoked Ca transient amplitude in (-)-R,S-
dehydroemetine, caffeine-evoked Ca transient amplitude wash. n = 8 cells from 2 animals. Asterisk represents a 
statistically significant difference. NS represents a statistically non-significant difference. 
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6.3.6 The effects of (-)-R,S-dehydroemetine on the activity of the [Ca2+]i removal 
mechanisms: 
 
The cause of decrease in SR Ca
2+ 
was investigated by quantifying the rate of [Ca
2+
]i removal 
as shown in Figure 6.3.6. Figure 6.3.6 A shows normalised systolic [Ca
2+
]i transients. 
Reduction in the rate of systolic [Ca
2+
]i removal is indicated by slowing of descending phase. 
Figure 6.3.6 B shows a significant decrease (p<0.005, mean: 0.830, SEM: 0.035) in the rate 
constant of systolic calcium removal (ksys) on application of (-)-R,S-dehydroemetine at IC50 
which returned to control levels up on removal of (-)-R,S-dehydroemetine. The rate constant 
of decay of the caffeine evoked [Ca
2+
]i transient (kcaff) (Figure 6.3.6 C) did not show any 
significant changes, indicating no change in NCX activity. kSERCA = ksys − kcaff could be used 
to calculate activity of SERCA and (Figure 6.3.6 D) it showed a significant decrease on 
application of (-)-R,S-dehydroemetine at IC50 (p<0.005, mean: 0.82, SEM: 0.042) (n >3). 
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Figure 6.3.6 The effects of (-)-R,S-dehydroemetine on the activity of the [Ca
2+
]i removal mechanisms 
The effects of (-)-R,S-dehydroemetine (80 nM) on the activity of the [Ca
2+
]i removal mechanisms. (A) Specimen 
normalised caffeine induced [Ca
2+
]i transients. (B) Meanksys. (C) Meankcaff. (D) Mean calculated kSERCA. (n = 4–
10 cells). Asterisk represents a statistically significant difference. NS represents a statistically non-significant 
difference. 
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6.3.7 The effects of (-)-R,S-dehydroemetine and emetine on ryanodine receptor: 
 
The specimen records of Figure 6.3.7 shows an example of the effect of (-)-R,S-
dehydroemetine and emetine on systolic Ca2+ and myocyte contractility. Figures 6.3.7 A 
and 6.3.7 B shows the myocytes stimulated by (-)-R,S-dehydroemetine and emetine 
respectively at IC50. On average the systolic [Ca
2+
]i amplitude showed a statistically 
significant increase (p<0.05, mean: 1.28, SEM: 0.06) above the control steady state levels 
immediately up on application of (-)-R,S-dehydroemetine and emetine, respectively, before 
declining to control steady state levels. Figures 6.3.7 C and 6.3.7 D show the corresponding 
sarcomere length record which depicts a corresponding increase in degree of shortening up 
on application of (-)-R,S-dehydroemetine and emetine respectively, which returns to control 
steady state levels. Figures 6.3.7 E and 6.3.7 F depicts the mean data showing 
the reproducibility of the increase in amplitude of the Ca transient on application of (-)-R,S-
dehydroemetine and emetine respectively, followed by a recovery to control levels in the 
steady state. Figure 6.3.7 G shows the comparison between the increase in amplitude of the 
Ca transient on application of (-)-R,S-dehydroemetine and emetine.  
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Figure 6.3.7 The effects of (-)-R,S-dehydroemetine and emetine on ryanodine receptor potentiation 
The effects of (-)-R,S-dehydroemetine  and emetine on systolic [Ca
2+
]i in sheep ventricular myocytes stimulated 
with current pulses. (A and B) Time course of changes in cytoplasmic Ca measured with fura-2, (-)-R,S-
dehydroemetine and emetine  at IC50 were applied for the period shown. (C and D) Time course of changes in 
sarcomere length, (-)-R,S-dehydroemetine (80 nM) and emetine (50 nM) were applied for the period shown. (E 
and F) Average data for first Ca transient amplitude on application of (-)-R,S-dehydroemetine  and emetine and 
(G) Comparison between average data for first Ca transient amplitude on application of (-)-R,S-
dehydroemetine  and emetine. (p<0.05, n=13-16). Asterisk represents a statistically significant difference. NS 
represents a statistically non-significant difference. 
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6.4 Discussion: 
 
Studies conducted on emetine and dehydroemetine in amoebiasis have found dehydroemetine 
to be less toxic than emetine (Scragg and Powell, 1968). It was postulated that this effect 
however could be due to faster excretion of dehydroemetine from the body. In this study, 
experiments were conducted on sheep ventricular myocytes to determine the role of calcium 
imbalance in the cellular basis of cardiotoxicity observed in emetine and dehydroemetine. 
This study has attempted to comprehensively cover most major calcium handling 
mechanisms. The study found (-)-R,S-dehydroemetine decreased SERCA resulting in 
decreased SR Ca
2+
 content and decreased systolic calcium leading to decreased contractility. 
No effect was observed on diastolic calcium levels. Emetine on the other hand showed no 
significant effect on global [Ca2+] levels. It was also observed that both compounds, (-)-R,S-
dehydroemetine  and emetine, potentiated RyR. 
 
6.4.1 The effects of (-)-R,S-dehydroemetine  on global [Ca
2+]i and contractility 
 
In paced ventricular myocytes, (-)-R,S-dehydroemetine  decreased the [Ca2+]i transient 
amplitude (Figure 6.3.3.1). A reduced degree of systolic shortening accompanied the 
reduction in [Ca2+]i transient amplitude (Figure 6.3.1.1). Diastolic [Ca
2+]i did not show any 
changes. A decrease in the rate of systolic [Ca2+]i decay and myocyte relaxation was also 
observed. This decrease in contractility could be accounted for by the decrease in systolic 
[Ca2+]i. The lack of changes to diastolic [Ca
2+]i explains the lack of change in resting 
sarcomere length. The data is suggestive of a negative inotropic effect by (-)-R,S-
dehydroemetine as in the steady state during drug treatment, [Ca2+]i transient amplitude and 
sarcomere length stay lower than the control levels. 
 
6.4.2 The effects of emetine on global [Ca
2+]i and contractility 
 
In paced ventricular myocytes, emetine did not show any significant effect on the 
[Ca2+]i transient amplitude (Figure 6.3.4.1). No change was observed on the degree of systolic 
shortening accompanying the [Ca2+]i transient amplitude (Figure 6.3.2.1). There were no 
changes observed in diastolic [Ca2+]i. In these experiments, emetine did not show any 
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significant effect on global [Ca2+]i and contractility. This eliminated the need to study the 
effects of emetine on SR Ca
2+
 content. 
 
6.4.3 Does (-)-R,S-dehydroemetine affect SR Ca2+ content? 
 
Caffeine-evoked increase of [Ca2+]i qualitatively measures the SR Ca
2+
 content. This study 
observed a significant decrease in SR Ca2+ content following exposure to (-)-R,S-
dehydroemetine (Figure 6.3.5.1). The amplitude of the [Ca2+]i transient is proportional to the 
cube of SR Ca2+ content (Greensmith et al., 2010). A small decrease in SR Ca2+ content would 
therefore cause an observable decrease in amplitude of the [Ca2+]i transient. However, in these 
experiments, the SR Ca was not measured directly and the Ca buffering was not accounted 
for which might have been altered by (-)-R,S-dehydroemetine (Varro et al., 1993). However, 
the magnitude of change of the caffeine-evoked Ca trainset is far greater than could be 
produced by altered Ca buffering alone which gives confidence in the observed effect being 
real. 
 
6.4.4 Does (-)-R,S-dehydroemetine decrease SERCA activity? 
 
A significant decrease in the rate constant of systolic calcium removal (ksys) on application of 
(-)-R,S-dehydroemetine at IC50 was observed which returned to control levels on removal of 
(-)-R,S-dehydroemetine (Figure 6.3.6.1). The rate constant of decay of the caffeine-evoked 
[Ca
2+
]i transient (kcaff) did not show any significant changes, indicating no change in NCX 
activity. kSERCA = ksys − kcaff could be used to calculate activity of SERCA. It showed a 
significant decrease on application of (-)-R,S-dehydroemetine at IC50. Decreased SERCA 
activity seems to be the probable cause for observed decrease of SR Ca2+ content which 
ultimately leads to the decreased [Ca2+]i transient amplitude.  
 
6.4.5 The effects of (-)-R,S-dehydroemetine and emetine on RyR 
 
From the data (Figure 6.3.7.1), it was observed both (-)-R,S-dehydroemetine and emetine 
produce a transient increase in the amplitude of the systolic Ca transient. RyR activity was 
not measured directly but RyR potentiation produces a characteristic effect on the Ca 
transient (temporary increase in Ca
++
 transient amplitude which recovers due to 
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autoregulation) (Greensmith et al., 2014) (Eisner et al., 2017) (Eisner et al., 2000). (-)-R,S-
dehydroemetine  produces a similar characteristic effect highly suggestive of RyR 
potentiation. It seems RyR potentiation by (-)-R,S-dehydroemetine and emetine leads to an 
initial increase in systolic calcium observed as an initial increase in Ca amplitude by 
increasing the release of calcium from the SR. Autoregulation brings Ca levels back down. 
The increased Ca efflux returns the Ca transient amplitude to control levels by decreasing SR 
Ca content (probably through decreased SERCA activity) in case of emetine, but lower than 
control levels in case of (-)-R,S-dehydroemetine. 
 
6.4.6 Implications of RyR is potentiation 
 
RyR potentiation will contribute to the decreased SR Ca
++
 content thus contributing to the 
negative inotropic effects of (-)-R,S-dehydroemetine.  
 
RyR potentiation is proarrhythmogenic (Venetucci et al., 2012). It can lead to the formation 
of calcium waves and thus extra systole. This would make the heart susceptible to 
arrhythmias. RyR potentiation is observed in (-)-R,S-dehydroemetine and emetine indicating 
the compounds could be proarrhythmogenic. Arrythmia is indeed one of the toxic effects 
observed during use of emetine and dehydroemetine for amoebiasis. 
 
6.4.7 Arrhythmogenicity of (-)-R,S-dehydroemetine and emetine: 
 
The experimental data suggests (-)-R,S-dehydroemetine produces a decrease in SR Ca
++
 
content whereas emetine does not produce any significant change on SR Ca
++
 content. Both 
compounds, (-)-R,S-dehydroemetine and emetine, cause a similar increase in RyR 
potentiation. RyR potentiation will decrease the threshold for generation of calcium waves 
which may lead to arrhythmia as the RyR will open spontaneously at lower levels of calcium. 
(-)-R,S-dehydroemetine however also causes a significant reduction in SR Ca
++
 content 
possibly through decreased SERCA activity. While this makes (-)-R,S-dehydroemetine 
negatively inotropic, decrease in SR Ca content does offer (-)-R,S-dehydroemetine some 
degree of protection against arrhythmia (Figure 6.4.1). Thus, making it potentially less 
arrythmogenic than emetine.  
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Figure 6.4.1 Potential for arrhythmia in (-)-R,S-dehydroemetine  and emetine 
Similar decrease in threshold for calcium waves is observed on application of (-)-R,S-dehydroemetine  and 
emetine as observed by similar level of potentiation of RyR. SR Ca content is reduced by both (-)-R,S-
dehydroemetine  and emetine but significantly more so by (-)-R,S-dehydroemetine, which was also observed to 
be negatively inotropic.  
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Chapter 7 General Discussion and Conclusions: 
 
Malaria is a disease mainly of tropical and sub-tropical regions of the world. The impact of 
the morbidity and mortality burdens of the disease on the endemic population has contributed 
adversely to the wider socio-economic developments of these countries. The mainstay of 
disease control has been largely reliant on the availability of affordable and effective 
chemotherapies. Drug discovery however has failed to keep abreast of resistance acquisition. 
Novel therapeutic antimalarial leads are urgently needed to prevent a potentially catastrophic 
gap in the drug market. 
 
Recent reports of the emergence of resistance to the front-line drug artemisinin, has 
invigorated research efforts to define potential new drugs.  The cost and long timelines of 
rational and target-based drug discovery can be bypassed by using drug repositioning or re-
purposing. Emetine dihydrochloride hydrate has been identified as a potential candidate with 
antimalarial activity through drug repositioning screens conducted at the University of 
Salford (Matthews et al, 2013). Although widely used previously as an anti-amoebic drug, 
the usefulness of this compound is restricted by its dose-dependent side effects, namely, 
emesis and cardiotoxicity. Our previous work suggests an approximately 1000-fold 
difference in the drug’s in vitro antimalarial and anti-amoebic potencies (47 + 2.17 nM and 
26.8 + 1.27 µM, respectively) (Bansal et al., 2004) (Matthews et al., 2013), suggesting 
potentially different toxicity profiles for its repositioned used. The main objective of the work 
was to employ a chimeric approach to further optimise through rational design, a potent 
natural product drug discovered through repositioning. The research presented in this thesis 
focusses on its synthetic analogue dehydroemetine. The two diastereomers of 
dehydroemetine, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine were synthesised 
and molecular modelling tools were used in this study in a bid to predict their activity on the 
multi-drug resistant strain K1 of P. falciparum. Further characterisation of its in-vitro 
antimalarial activity, mechanism of action and mechanism of toxicity strongly support 
progression of research to in vivo study models.  
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7.1 Lead optimisation of dehydroemetine: 
 
The rational design of the dehydroemetine analogues was facilitated by the publication of the 
Wong et al., 2014 paper defining through cryo-EM studies, the target binding site for emetine 
on the 40S subunit of the 80S P. falciparum ribosome. However, due to poor temperature 
stability of the 3J7A cryo-EM structure (Wong et al, 2014), emetine possessed a high degree 
of freedom within the 3.2A distance of its predicted binding conformation. This was 
supported with our docking results of emetine on 3J7A, when none of the docking software 
were able to reproduce the binding pose as shown in 3J7A. Due to the large size of the 
ribosome, GOLD was unable to process the 3J7A structure. MOE, PyRx and Autodock vina 
were able to process the structure, but initially unable to replicate the predicted binding pose 
of emetine suggested in the Wong et al., 2014 publication. On closer inspection, emetine 
structure in 3J7A was found to have incorrect chirality, a likely reason for the inability of the 
software to reproduce the published binding pose. In addition, the presence of a magnesium 
ion in the vicinity of the binding pocket was another factor which complicated the docking. 
We present here data form new docking studies employing the emetine structure with correct 
chirality and removal of magnesium ion from the vicinity of the binding pocket. The results 
obtained through MOE software was able to replicate the U-shaped binding conformation and 
predicted a better fit for (-)-R,S-dehydroemetine in comparison with (-)-S,S-
dehydroisoemetine. Binding site interactions observed through the docking of two 
diastereomers suggested potentially better activity for (-)-R,S-dehydroemetine compared to (-
)-S,S-dehydroisoemetine.  
 
(-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine were synthesised by Chirobloc 
(Germany) and their activity was evaluated on multi-drug resistant K1 strain of Plasmodium 
falciparum. (-)-R,S-Dehydroemetine was found to show a similar potency as emetine against 
the K1 strain with an IC50 of 69.58 + 2.62 nM. The isomer (-)-S,S-dehydroisoemetine was 
found to be less potent with an IC50 of 1.85 + 0.2 µM. The IC50 speed assay showed that (-)-
R,S-dehydroemetine and (-)-S,S-dehydroisoemetine analogues reached their IC50 in 48 hours 
despite exhibiting an early onset of action within 24 hours. Results from stage specificity 
assays depicted that the two isomers show activity against both ring and trophozoite stages, 
but they are more potent against the trophozoite stage of the parasite.  
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Emetine has been investigated as an antiviral (poliovirus, human cytomegalovirus, Zika virus 
and Ebola virus) and as a treatment for intractable lymphoma. 10 mg/kg of emetine 
administered intraperitoneally was found to be effective in NOD/SCID mice for the treatment 
of lymphoma, which is equivalent to 0.8 mg/kg in humans. 16.2 mg/kg has been established 
as the 50% lethal dose of emetine in mice. In clinical settings, 1 mg/kg is the recommended 
dose for emetine in humans. Pharmacokinetic study of low dose emetine (0.1 mg/kg to 1 
mg/kg given orally) was found to be safe and highly efficacious in BALB/c mice with a half-
life of 35 hours (Aoki et al., 2017) (Mukhopadhyay et al., 2016) (Yang et al., 2018). MTT 
assays were conducted on the recommended gold standard HepG2 liver cancer cell lines to 
evaluate cytotoxicity and safety profiles for (-)-R,S-dehydroemetine and (-)-S,S-
dehydroisoemetine. 5000 cells per well were plated and incubated with serial dilutions of the 
two diastereomers of dehydroemetine for 48 hours. LD50 of (-)-R,S-dehydroemetine and (-)-
S,S-dehydroisoemetine was found to be 196.4 + 11 nM and 1.429 + 0.18 µM, respectively. 
Selectivity index for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine was found to be 
approximately 3 and 1, respectively. Selectivity index for emetine was found to be ~4. Low 
selectivity indices observed could be due to anti-cancer properties of emetine and 
dehydroemetine. HepG2 being a cancer cell line could explain the low LD50 observed. The 
data further adds to the ongoing debate whether as per recommendations, HepG2 is the best 
cell line for toxicity testing of antimalarial leads, given their propensity for anticancer 
activity.  
 
Synergistic combinatorial drug regimens could be used to achieve dose reduction and 
improve dose-dependent toxicity profiles of drugs. In order to define synergistic/additive 
combinatorial partner drugs among currently used antimalarials, a range of drug interactivity 
studies were carried out. CalcuSyn analysis methodology previously validated in our 
laboratory for drug interactivity studies was used to identify synergistic partners (Matthews et 
al., 2017). CalcuSyn employs the Chou-Talalay method for in vitro drug interactivity 
analysis. Emetine was found to display good synergy with atovaquone (Matthews et al, 
2013). Following this (-)-R,S-dehydroemetine was experimentally evaluated for in-vitro drug 
interactivity with four known antimalarials; artemether, atovaquone, proguanil and 
doxycycline. Artemether and doxycycline were found to be antagonistic (CI = 1.6 and 1.5, 
respectively) while proguanil displayed mild synergy at IC50 (CI = 0.67) and nearly additive 
to antagonistic activity at ED75 and ED90 (CI = 1.04 and 1.62, respectively). Mild synergy 
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was observed between atovaquone and (-)-R,S-dehydroemetine (CI = 0.88). In a bid to 
discover more compounds with activity similar to atovaquone, a virtual screen of an FDA 
approved library of drugs was conducted using the atovaquone binding site. Forty five drugs 
were found to show a positive hit for the atovaquone binding site on cytochrome bc1. These 
drugs should be tested for activity against Plasmodium falciparum and if positive, the drugs 
could potentially be synergistic with emetine and (-)-R,S-dehydroemetine. 
 
7.2 Cellular basis for cardiotoxicity: 
 
A study conducted (Turner, 1963) on 25 East African patients taking emetine for the 
treatment of amoebiasis detected ECG changes in all patients, with T-wave changes being the 
most frequent. This followed the recommendation that emetine should be given 
intramuscularly only to patients in a hospital setting and resting in bed. It was also reported 
(Grollman, 1966) that dehydroemetine and emetine were potent inhibitors of protein 
synthesis in HeLa cells. At a concentration of 5 x 10
-8
 M, emetine was able to effectively 
inhibit protein synthesis by 50% in HeLa cells. It was found that 1.4 x 10
-4
 M of emetine had 
no effect on the incorporation of amino acids into the mitochondrial fraction of HeLa cells 
(Perlman and Penman, 1970). The study observed that emetine was unable to inhibit 
mitochondrial protein synthesis at concentrations which resulted in complete inhibition of 
protein synthesis in cytoplasm. 
 
The effects of emetine on cultured chicken embryo cardiac cells was also studied (Watkins 
and Guess, 1968). It was observed that 10
-5
 M or higher concentrations of emetine lead to the 
immediate cessation of contraction in atrial and ventricular cells, followed by detachment and 
lysis. Lower concentrations (10
-8
 to 10
-6
 M) of emetine progressively but rapidly decreased 
the rate of beating. Washing did not reverse the effects, but addition of NADH (10
-5
 M) 
increased the strength of beating and synchrony. The reversal lasted for 30 to 45 minutes. 
Intense and brief reversal of effects was observed by addition of ATP (10
-6
 M). The results 
showing brief reversal of effects by ATP and prolonged reversal by NADH, suggesting that 
at higher concentrations, emetine causes physical disruption of plasma membrane of the cells 
and at lower concentrations, it suppresses the process of formation of high energy phosphate 
compounds. It was thought that the site of inhibition was at the enzymatic oxidation of 
substrates mediated by nicotinamide adenine dinucleotide (NAD) (Watkins and Guess, 1968). 
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Under hypoxic conditions there is a greater flux through glycolysis. Glycolysis is activated by 
MYC and HIF-1α (Kim et al., 2007). Emetine has been found to inhibit glycolysis by 
suppressing HIF-1α along with enzymes hexokinase2 and PDK1 leading to apoptosis by 
accumulation of reactive oxygen species (Aoki et al., 2017). The experiments conducted in 
this current study found emetine decreased the ATP concentration by ~15% and also caused 
disruption in the mitochondrial membrane potential. (-)-R,S-Dehydroemetine also displayed a 
similar change in ATP concentration, and showed a disruption of mitochondrial membrane 
potential albeit to a slightly lesser degree compared to emetine. 
 
Schwartz and Herrero, in 1965, observed the distribution and excretion of dehydroemetine 
and emetine in guinea pigs. The compounds were labelled at 
14
C at 3
1
 position. It was found 
that 91.5% of dehydroemetine compared to 67% of emetine was excreted 72 hours after 
stoppage of doses. Dehydroemetine was eliminated rapidly from heart rather than the liver 
and reverse was found to be true for emetine. This could be one of the reasons for reduced 
cardiotoxicity observed in treatment with dehydroemetine, as emetine binds more tightly to 
heart even though it is not specifically concentrated in cardiomyocytes (Schwartz and 
Herrero, 1965). 
 
This study aimed to establish the mechanism of action for cardiotoxicity in a bid to propose 
analogues of emetine with reduced side-effects. Since emetine is presumed to affect the 
movements of Na+, K+ and Ca++ ions, dehydroemetine is also likely to affect the ion 
permeability. In a resting cardiac cell, the concentration of K+ is high intracellularly, which 
creates a chemical gradient for K+ to diffuse out of the cells. Subunit of rapid delayed 
rectifier potassium ion channel is involved in the cardiac repolarisation (Sanguinetti and 
Tristani-Firouzi, 2006). It is encoded by the hERG gene (Human ether-a-go-go related gene). 
Drugs inhibiting the hERG channel can prolong the QT intervals and cause the dangerous 
cardiac arrhythmia, Torsades de pointes. The experiment to test the potential of emetine, (-)-
R,S-dehydroemetine and (-)-S,S-dehydroisoemetine to inhibit hERG K
+
 channel was 
outsourced to Cyprotex, UK as the equipment to carry out the experiment was not available 
in the university. Emetine and (-)-R,S-dehydroemetine (SI > 285) were found to show no 
inhibition of hERG K
+
 channel, whereas (-)-S,S-dehydroisoemetine was found to inhibit the 
hERG K
+
 channel with a selectivity index of ~2. 
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With normal hERG results for emetine and (-)-R,S-dehydroemetine, the role of the drugs on 
the cardiac Ca
++
 channels was investigated. Tight regulation of calcium levels in the cells 
maintains various cellular functions and activities such as metabolism, cell cycle, secretion 
and neuronal signalling (Clapham, 2007) (Pandey et al., 2016).  Interference with calcium 
levels could cause parasite death (Enomoto et al., 2012) as calcium and calcium channels 
play major roles in human cells as well as the Plasmodium parasite (Furuyama et al., 2014) 
(Bogdanova et al., 2013). Higher levels of calcium have been found in parasite-infected 
RBCs (between 289 nM and 352 nM) compared with non-infected RBCs (between 30 nM 
and 60 nM) (Desai et al., 1996) (Rohrbach et al., 2005) (Lourido and Moreno, 2015) 
(Gazarini et al., 2003) (Bogdanova et al., 2013). Merozoites shed surface proteins during 
RBC invasion along with antibodies attached by the host to their surface. This is presumably 
done to distract the host’s immune response (Farrow et al., 2011) (Harvey et al., 2012). 
Invasion of RBCs via endocytosis results in development of a membrane which forms a 
vacuole (the PV) around the parasite. This allows an exchange of proteins and lipids between 
the PV membrane (PVM) and the host plasma membrane (Ward et al., 1993) (Eksi and 
Williamson, 2011), facilitating the entry of calcium required for parasite survival from the 
RBC cytosol to the PV.  
 
In addition to its reported role in parasite survival, calcium regulation in the host is also 
linked to cardiotoxicity. The effect of emetine and its analogues on calcium handling was 
evaluated in this study in order to identify a potential basis for cardiotoxicity. 
 
Arrythmias have been reported as adverse effects observed during emetine and 
dehydroemetine therapy in amoebiasis in the mid-20
th
 century. Cardiac myocyte ryanodine 
receptors enable potentiation lowers the threshold for generation of calcium waves which can 
ultimately lead to arrhythmia. Experiments conducted on sheep ventricular myocytes found 
both emetine and (-)-R,S-dehydroemetine caused similar potentiation of ryanodine receptor 
and could thus be considered arrhythmogenic as they could lower the threshold for generation 
of calcium waves. However, emetine displayed no significant changes in the SR calcium 
content whereas (-)-R,S-dehydroemetine showed a significant decrease in systolic calcium 
amplitude, systolic contractility, SERCA activity and thus a decrease in SR calcium content. 
(-)-R,S-dehydroemetine was also found to be negatively inotropic. Although at a cellular 
level, (-)-R,S-dehydroemetine appears to have more toxic effects, the decrease in SR calcium 
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content in the presence of ryanodine receptor potentiation makes (-)-R,S-dehydroemetine 
comparatively less arrhythmogenic than emetine. Decreased calcium wave threshold with a 
fuller SR calcium is potentially the reason for increased likelihood of arrhythmias observed in 
clinical settings during treatment with emetine as compared to dehydroemetine. 
 
Emetine is a natural product derivative displaying potent nanomolar antimalarial efficacy. 
Despite its previous widespread use as an anti-amoebic drug, emetic and cardiotoxic side 
effects and stringent regulatory processes in the drug discovery pipeline, prevent 
consideration of the lead for repositioning as an antimalarial. However, emetine and 
dehydroemetine are approximately 1000-fold more potent against multi-drug resistant K1 
strain of P. falciparum than against amoebiasis. Since toxicity is dose dependent, it is highly 
likely the adverse effects observed in antimalarial therapy with emetine and dehydroemetine 
would be significantly lower compared to the treatment in amoebiasis. Dehydroemetine, a 
synthetic analogue of emetine has been used in the past as a safer alternative and this study 
shows dehydroemetine is indeed less arrhythmogenic than emetine. The experimental 
validation of (-)-R,S-dehydroemetine shows it to be approximately as potent as emetine 
against the multi-drug resistant K1 strain of Plasmodium falciparum. Its transmission 
blocking capacity, lack of strain-specific cross-resistance, its ability to concentrate in hepatic 
tissues and synergistic interactions with atovaquone, makes (-)-R,S-dehydroemetine  a 
valuable antimalarial candidate for complicated cerebral malaria. The recent availability of 
the target-binding site offers more opportunities for further modification of the lead with a 
view to achieving a safer toxicity profile. A role for such a drug in combating deaths due to 
cerebral malaria, where treatment would necessarily be carried out in a hospital setting with 
continuous cardiac monitoring, cannot be overlooked given the current state of early 
resistance to the front-line antimalarial drug.  Dehydroemetine, although not available for 
purchase, still remains a WHO recommendation for the treatment of amoebiasis and 
giardiasis, in the event of treatment failure due to metranidozole (Appendix II). Antimalarial 
chemotherapy throughout the ages has been predominantly sustained by affordable, natural 
product drugs including derivatives of quinine and artemisinin. The work reported in this 
thesis, presents a strong argument for the further investigation of yet another potent, 
affordable, natural product lead; (-)-R,S-dehydroemetine. 
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Figure 7.2.1 Activity-profile of emetine and dehydroemetine 
Plant-derived anti-amoebic drug emetine dihydrochloride and its synthetic analogue dehydroemetine ((-)-R,S-
dehydroemetine) are highly potent with nanomolar efficacy against multi-drug resistant K1 strain of P. 
falciparum. 
 
7.3 Future work: 
 
 To perform in-vitro cytotoxicity studies on non-cancer cell lines to determine the 
safety profile of emetine dihydrochloride and its synthetic analogue, dehydroemetine 
((-)-R,S-dehydroemetine) 
 To perform in-vivo cytotoxicity studies at low doses on animal models to determine 
the safety profile of emetine dihydrochloride and (-)-R,S-dehydroemetine 
 To test the compounds identified through virtual screening for activity against 
Plasmodium parasites. 
 To perform drug-interaction analysis on the compounds identified through virtual 
screening with emetine dihydrochloride and (-)-R,S-dehydroemetine to identify a 
synergistic partner drug for combination therapy. 
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 To perform further conclusive experiments to determine the effect of emetine 
dihydrochloride and (-)-R,S-dehydroemetine on ATP production through glycolysis. 
 To perform further conclusive experiments to determine the effect of emetine 
dihydrochloride and (-)-R,S-dehydroemetine on mitochondria and mitochondrial 
membrane potential.   
 To perform further conclusive experiments to determine the effect of emetine 
dihydrochloride and (-)-R,S-dehydroemetine on calcium waves and calcium sparks in 
cardiomyocytes. 
 To perform experiments to determine which proteins are affected due to the inhibition 
of protein translation by emetine dihydrochloride and (-)-R,S-dehydroemetine. 
 To perform experiments to determine any other target sites for emetine 
dihydrochloride and (-)-R,S-dehydroemetine. 
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Appendix I 
 
Synthesis of dehydroemetine: 
 
The synthesis began with Mannich reaction of ethyl 2-ethylacetoacetate 1 with 
dimethylamine and formaldehyde leading to Mannich base 2 isolated with 42% yield after 
distillation. The compound 2 was then transformed into quaternary ammonium salt after 
quaternization with slight excess of methyl iodide. The salts are known to readily eliminate 
trimethylammonium iodide thus generating corresponding active enones which further react 
with imines like 3 giving 4-piperidinone derivatives. The particular reaction between 2 and 3 
was conducted in one-pot manner furnishing piperidinone 4 with best yield of 72%. It should 
be noted that minor amounts (10-20%) of the second diastereomer 5 were observed during 
the reaction control, workup, and purification processes (
1
H-NMR, GC-MS). We did not 
especially try to completely separate diastereomer 5 because the second stereocenter vanished 
in the next steps. However, analytically pure sample could be obtained after recrystallization 
from ethanol. Knoevenagel condensation of ketone 4 with malononitrile under general basic 
conditions led to unsaturated dinitrile 6 with 69% yield. This was hydrolysed and 
decarboxylated in refluxing 20% hydrochloric acid, and exocyclic double C=C bond 
transformed into more favorable endocyclic one of the compound 7. Usual esterification of 
carboxylic acid 7 to racemic methyl ester 8 in MeOH/HCl was followed by resolution of the 
racemate with (+)-dibenzoyl-D-tartaric acid. The salt was recrystallized twice from methanol 
to achieve rotation values known for optically pure compounds, and then set free to ester 9, 
which was further hydrolyzed into dilute HCl to (S)-carboxylic acid 10. Thermal amidation of 
the 10 with homoveratrylamine in refluxing xylenes furnished amide 11 with 55% yield. 
Bischler–Napieralski cyclization under general conditions (benzene, POCl3) led to 
dihydroisoquinoline derivative 12, also known as 2-dehydro-O-methyl psychotine, with 54% 
yield. The cyclic imine 12 was reduced with sodium borohydride in methanol to a 1:1 mixture 
of target 2-dehydroemetine 13 and 2-dehydroisoemetine dihydrobromide 14. Attempts were 
made to separate both diastereomers chromatographically as BOC-derivatives or as free bases 
on aluminium oxide, all unsuccessful. Finally fractional crystallization allowed separating the 
products 13 and 14 as dihydrobromide salts. 
3-[(Dimethylamino)methyl]pentan-2-one 2 (Openshaw and Whittaker, 1963). 
 
185 
 
 
Commercially available ethyl 2-ethylacetoacetate 1 (200g, 1.3mol) was combined with ice-
cold solution of potassium hydroxide (78g, 1.4mol) in water (1500ml). The mixture was 
stirred for 4.5 hours at r. t. before pH was adjusted to 7 with conc. HCl (2ml), and 
dimethylamine hydrochloride (104g, 1.3mole) and formaldehyde (98ml, 1.3mol, as 37% 
aqueous solution stabilized with 10-15% methanol) were added. After stirring for 10 minutes, 
conc. HCl (121ml, 1.4mol) was added dropwise during 1 hour. The reaction mixture was 
stirred for 16 hours at r.t. The solution was washed with diethyl ether (500ml), saturated with 
NaCl (500g) under stirring and cooled to 5°C. Diethylether (500 ml) was added, and cold 
concentrated solution of potassium hydroxide (106g, 1.9mol) in water (200ml) was added 
dropwise under vigorous stirring for 15 minutes while keeping the internal temperature 
<20°C in ice bath. Organic phase was gathered, aqueous solution extracted additionally with 
diethyl ether (3×500 ml). Combined organic solutions were dried over Na2SO4, filtered and 
carefully concentrated in vacuo (400mbar) to give the crude product (250g) as colorless oil. 
The latter was fractionally distilled to give the main pure fraction (151g, 42% yield) at 
64°C/19mbar. Analytical data (
1
H-NMR, GC-MS) confirmed identity and purity of the 
product. 
 (3S*,11bS*)-3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one 4 
(Brossi et al., 1959).  
 
Mannich base 2 (110g, 0.77mol) was dissolved in absolute ethanol (220ml) cooled in ice bath 
and treated with methyl iodide (152.6g, 67ml, 1.1mol) keeping the internal temperature 
<20°C. After the exothermic reaction ceased, homogeneous solution turned into white 
suspension, which was allowed to stir for 24 hours, treated with toluene (200ml) and 
evaporated to dryness in vacuo to give crude iodomethylate (221g) as yellow solid (a sample 
was characterized with 
1
H-NMR). The intermediate was suspended in absolute ethanol 
186 
 
(1400ml) and commercially available 6,7-dimethoxy-3,4-dihydroisoquinoline hydrochloride 
3 (142g, 0.624mol) was added followed by anhydrous potassium acetate (61.2g, 0.624mol). 
The reaction was stirred at reflux for 3 hours until full conversion of 3 is achieved (>98%, 
GC-MS). The reaction was quenched with chloroform (1000ml), water (500ml), 1N NaOH 
(500ml). Organic phase was separated, aqueous solution extracted additionally with 
chloroform (500 ml). Combined organic solutions were dried over Na2SO4, filtered and 
concentrated in vacuo to give the crude product (390g) as orange solid. This was purified 
chromatographically (silica gel, ethyl acetate) to give the pure product 4 (159.85g, 72% yield) 
as pale-yellow solid. Analytical data (
1
H-NMR, GC-MS) confirmed identity and purity of the 
product. 
2-[(3R*,11bS*)-3-Ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-
ylidene]propanedinitrile 6 (Battersby et al., 1953).  
 
Ketone 4 (122.1g, 0.422mol), malononitrile (33.45g, 0.506mol), ammonium acetate (13.3g, 
0.173mol) and acetic acid (26.6g, 25.3ml, 0.443mol) were dissolved in toluene (1120ml), and 
the yellow homogeneous solution was stirred under reflux for 2.5hours. After cooling to r.t., 
the reaction was treated with ethyl acetate (900ml) and saturated NaHCO3 (1000ml). Organic 
phase was separated, aqueous phase additionally extracted with ethyl acetate (600ml). 
Combined organic solutions were dried with Na2SO4, filtered and concentrated in vacuo to 
give crude product 6 (121g). Recrystallization from ethyl acetate and chromatography of 
mother liquor on silica gel with ethyl acetate-hexane 1:1 gave combined yield of 109g (69%) 
of the title product 6. Analytical data (
1
H-NMR, GC-MS) confirmed identity and purity of the 
product. 
rac-2-(3-Ethyl-9,10-dimethoxy-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizin-2-yl)acetic acid 
7 (Brossi et al., 1959). 
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The Knoevenagel product 6 (40g, 119mmol) was dissolved in hydrochloric acid (720ml of 
20% aq. solution) under reflux, and the clear brown solution was stirred under reflux for 5 
hours before concentrated in vacuo to dryness. The yellow solid residue was dissolved in 
water (50ml), made alkaline with Na2CO3 (pH=8-9) and extracted with toluene (100ml). 
Aqueous phase was separated, saturated with NaCl, neutralized with acetic acid (pH=5.5-6) 
and extracted with chloroform (2x200ml). Organic phase was separated, concentrated in 
vacuo and coevaporated with acetone (2x200ml) to give the title product 7 (40.1g, 71% yield, 
70% purity) as orange solid. 
rac-Methyl 2-(3-ethyl-9,10-dimethoxy-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizin-2-
yl)acetate 8 (Brossi et al., 1959). 
 
Cold (5°C) methanol (1000ml) was treated dropwise within 15 minutes with acetyl chloride 
(220g, 200ml, 2.8mol) under vigorous stirring. Acid 7 (97g, 0.293mol) was then dissolved in 
the mixture, and the clear brown solution was stirrerd at r.t. for 18 hours. The reaction was 
concentrated to dryness, and brown-yellow rest partitioned between CH2Cl2 (1000ml) and 
saturated NaHCO3 (1000ml). Organic phase was separated, aqueous phase extracted with 
CH2Cl2 (2x250ml). Combined organic phases were dried with Na2SO4, filtered and 
evaporated in vacuo to give crude product (110g) as brown oil. Chromatographic purification 
(silica gel, ethyl acetate – methanol 9:1) furnished the title product (92.3g, 64% yield, 95% 
purity according to GC) as brown oil. Analytical data (
1
H-NMR, GC-MS) confirmed identity 
of the product. 
Methyl 2-[(11bS)-3-ethyl-9,10-dimethoxy-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizin-2-
yl]acetate 9 (Brossi et al., 1962). 
 
Ester 8 (32.3g, 93.5mmol) was dissolved in methanol (100ml) and treated with solution of 
(+)-dibenzoyl-D-tartaric acid monohydrate (35.2g, 93.5mmol). 10 Minutes later 
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crystallization appeared, and the mixture was stored for 16 hours at 5°C. Crude tartrate was 
filtered, washed with cold methanol (3x20ml) and dried to give 51.13g with optical rotation -
46,0° (c=1, MeOH, 24°C). Additional recrystallization from methanol (200ml) improved the 
optical rotation to the constant value of -49.2° (c=1, MeOH, 24°C) which is identical with the 
value [a]D = +49° described for the opposite enantiomer. Free base was set free by stirring the 
salt with diethyl ether (400ml), saturated NaHCO3 solution (500ml) and water (500ml). 
Organic phase was separated and aqueous layer additionally extracted with diethyl ether 
(2x200ml). Combined organic phases were dried (Na2SO4), filtered and evaporated to 
dryness to give the title compound 9 (21.2g, 25% yield) as pale yellow oil. Analytical data 
(
1
H-NMR, GC-MS) confirmed identity and purity of the product. 
2-[(11bS)-3-Ethyl-9,10-dimethoxy-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizin-2-yl]acetic 
acid 10 (Brossi et al., 1962). 
 
Ester 9 (21.2g, 61.4mmol) was refluxed with 3N HCl (340ml) under stirring for 1.5 hour. 
Reaction was concentrated to dryness and treated with diethyl ether (200ml) and saturated 
NaHCO3 (250ml). Aqueous phase was separated, neutralized with acetic acid (pH=7), 
saturated with NaCl and chloroform (4x150ml). Organic solutions were dried with Na2SO4, 
filtered, evaporated to dryness and coevaporated once with ethyl acetate (150ml). The title 
product was isolated as yellow foam (21.3g, 94%, 90% purity). Analytical data (
1
H-NMR, 
GC-MS) confirmed identity of the product. 
2-[(11bS)-3-ethyl-9,10-dimethoxy-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizin-2-yl]-N-[2-
(3,4-dimethoxyphenyl)ethyl]acetamide 11 (Brossi et al., 1962). 
 
Carboxylic acid 10 (21.3g, 64mmol) and 3,4-dimethoxy-phenylethylamine (12.23g, 11.4ml, 
67.5mmol) were dissolved in xylene (500ml, mixture of isomers) and refluxed under stirring 
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for 18hours with Dean-Stark trap. The reaction was concentrated to dryness to give crude 
product as brown oil. This was purified chromatographically (silica gel, ethyl acetate – 
methanol 9:1) to give the title product 11 (17.5g, 55% yield) as beige solid. Analytical data 
(
1
H-NMR, LC-MS) confirmed identity and purity of the product. Optical rotation of the 
sample (-181°, c=1, MeOH, 21°C) corresponds to the values reported in literature ([a]D = -
189°). 
(11bS)-2-[(6,7-Dimethoxy-3,4-dihydroisoquinolin-1-yl)methyl]-3-ethyl-9,10-dimethoxy-
4,6,7,11b-tetrahydro-1H-benzo[a]quinolizine 12 (Brossi et al., 1959). 
 
Amide 11 (2.2g, 4.4mmol) and phosphorus oxychloride (1.7g, 1ml, 11.1mmol) were 
dissolved in benzene (45ml) and stirred under reflux for 1 hour. After cooling to r.t., 
supernatant solution was decanted from dark oil. The latter was dissolved in warm methanol 
(30ml, 40°C) and treated with diethyl ether (60ml), which caused crystallization. The mixture 
was kept at 5°C for 18 hours. Hygroscopic beige dihydrochloride-monohydrate of the product 
12 was filtered, washed with diethyl ether (2x20ml) and dried in vacuo. The salt was 
dissolved in cold water (50ml), made alkaline with conc. NH4OH (pH=9) and extracted with 
diethyl ether (3x100ml). Combined organic phases were concentrated and dried in vacuo to 
give free base of the product 12 (1.28g, 54% yield, 90% purity) as yellow foam. 
(11bS)-2-[[(1R)-6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-
dimethoxy-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizine dihydrobromide (2-dehydroemetine 
dihydrobromide) 13 and (11bS)-2-[[(1S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-
yl]methyl]-3-ethyl-9,10-dimethoxy-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizine 
dihydrobromide (2-dehydroisoemetine dihydrobromide) 14 (Brossi et al., 1959). 
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Cyclic imine 12 (8.5g, 17.8 mmol) was dissolved in methanol (300ml). The yellow solution 
was cooled to 5°C, and sodium borohydride (1.9g, 50mmol) was added in one portion. 
Conversion was complete in 1 hour, and the reaction was evaporated in vacuo and partitioned 
between diethyl ether (500ml) and water (150ml). Organic phase was separated, aqueous 
phase additionally extracted with diethyl ether (150ml). Combined organic phase were dried 
(Na2SO4) filtered and evaporated to give crude mixture of diastereomers (8.5g) in ratio 1:1 
according to 
1
H-NMR as yellow foam. The mixture was suspended in water (60ml), and 
conc. HBr (4.1ml, 35.7mmol) was added to give clear solution. Yellow crystalline solid 
deposited after standing at 5°C for 3 days. The solid was filtered, washed with methanol 
(25ml) and dried to give 3.93g of product 13 as single diastereomer (>95%de) according to 
1
H-NMR. Mother liquor was concentrated and left to crystallize for 3 day to give additional 
amount of the product 13. Both fractions were combined, stirred with methanol (25ml), 
filtered and dried to give 4.5g (40% overall yield, at >99% purity according to HPLC) of the 
dihydrobromide 13 as yellow crystalline solid. Optical rotation of the pure product was -106° 
(c=1, MeOH, 24°C) which corresponds to literature value [a]D = -97°. 
2-Dehydroisoemetine dihydrobromide 14 could be isolated from mother liquor after second 
crystallization. Evaporation of the solution to dryness furnished the crude salt 14, which was 
then redissolved twice from MeOH with diethyl ether to give 4.7g (41% overall yield) of 
amorphous solid with 94% purity according to HPLC. Optical rotation of the product was -
92° (c=1, MeOH, 24°C) which corresponds to literature value [a]D = -107°. 
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 Synthesis of 2,3-dehydroemetine by Chiroblock GMBH, Germany. 
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Appendix II 
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Appendix III 
 
Example of a 72 hours dose response experiment read through plate-reader. 
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Appendix IV 
 
 Optimisation of rhodamine123 for mitochondrial membrane potential disruption 
experiment 
 
Rhodamine123    200nM 
  
Rhodamine123   500nM 
  
Rhodamine123     1µM 
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 Gating used for detecting changes in fluorescent intensity of rhodamine123 indicating 
disruption of mitochondrial membrane potential 
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Appendix V 
 
 Raw data showing increase in amplitude of 1st calcium transient after addition of (-)-
R,S-dehydroemetine (circled in blue outline).  
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 Long time base raw data showing control caffeine, addition of emetine with increase 
in amplitude of 1
st
 calcium transient, caffeine during treatment with emetine, wash 
steady state, and wash caffeine  
 
 
 
 Raw data showing control and wash caffeine and increase in amplitude of 1st calcium 
transient after addition of emetine (circled in blue outline). 
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 Example of exported data from the raw data: 
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 Example of data sheet used for calculating the effects of emetine and (-)-R,S-
dehydroemetine  on calcium regulatory mechanisms: 
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